

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)


PCT

(10) International Publication Number
WO 2004/057021 A2


- (51) International Patent Classification⁷: C12Q 1/68
- (21) International Application Number: PCT/CA2003/001994
- (22) International Filing Date: 19 December 2003 (19.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2,411,264 19 December 2002 (19.12.2002) CA
2,418,004 24 January 2003 (24.01.2003) CA
- (71) Applicant (for all designated States except US): UNIVERSITÉ LAVAL [CA/CA]; Danielle Allard, Pavillon des sciences de l'éducation, bureau 1474, Québec, Québec G1K 7P4 (CA).
- (72) Inventor; and
(75) Inventor/Applicant (for US only): BOIVIN, Guy [CA/CA]; 2531 Montbray, Sainte-Foy, Québec G1V 1E7 (CA).
- (74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: MOLECULAR METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING RESPIRATORY VIRUSES



(57) Abstract: There is provided compositions and methods for the detection and/or quantification of respiratory viruses using specific nucleic acid sequences. In particular methods and composition are provided to detect human Metapneumovirus (hMPV). The invention also provides with multiplex assays for detecting respiratory viruses in test samples.



WO 2004/057021 A2



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished upon receipt of that report*

- 1 -

**MOLECULAR METHODS AND COMPOSITIONS FOR DETECTING AND
QUANTIFYING RESPIRATORY VIRUSES**

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims priority on Canadian applications serial number 2,411,264 filed on December 19, 2002 entitled "Sequences for detection and identification of the human metapneumovirus" and serial number 2,418,004 filed on January 24, 2003 entitled "Multiplex assays for detection and identification of viral respiratory pathogens.

10

TECHNICAL FIELD

This application relates to the field of microorganisms detection and more particularly to the detection of respiratory tract viruses using virus specific nucleic acids.

15

BACKGROUND OF THE INVENTION

Respiratory tract infections are a significant cause of morbidity and mortality in all age groups but especially in young children, elderly subjects, and immunocompromised patients. Most of these infections are caused by viruses with influenza A and B and the human respiratory syncytial virus (hRSV) being associated with the most frequent and severe complications i.e. pneumonitis and death (Dowell et al., 1996, J. Infect. Dis. 174:456-462; Simonsen et al., 2000, J. Infect. Dis. 181:831-837; Han et al., 1999, J. Infect. Dis. 179:25-30; Neuzil et al., 2000, N. Engl. J. Med. 342:225-231; Simoes, 1999, Lancet 354:847-852.). Other viruses such as adenoviruses (> 50 serotypes), parainfluenza viruses (PIV) (4 serotypes), rhinoviruses (> 100 serotypes), and coronaviruses also contribute to acute respiratory tract infections (Trcanor, 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 7-26). Also, recent studies by the inventor and others have suggested that the new human metapneumovirus (hMPV) should be added to the list of human respiratory viral pathogens in all age groups (van den Hoogen et al., 2001, Nat. Med. 7:719-724;

30

Peret et al., 2002, J. Infect. Dis. 185:1660-1663; Boivin et al., 2002, J. Infect. Dis. 186:1330-1334).

The hMPV was initially isolated from nasopharyngeal aspirates recovered from 28 children suffering from respiratory tract infections. Based on partial nucleic acid sequences, gene organization, and electron microscopy (EM) findings, this virus was preliminary assigned to the *Paramyxoviridae* family, subfamily *Pneumovirinae*, genus *Metapneumovirus*. Since then, hMPV has been isolated in North America by our group (Peret et al., 2002, J. Infect. Dis. 185:1660-1663), in Australia (Nissen et al., 2002, Med. J. Aust. 176:188), and in England (Stockton et al., 2002, Emerg. Infect. Dis. 8:897-901).

Preliminary virological characteristics of hMPV.

The initial report by Van Den Hoogen *et al.* (van den Hoogen et al., 2001, Nat. Med. 7:719-724) indicated that the new virus replicated slowly in tertiary monkey kidney (TMK) cells with cytopathic effects (CPE) consisting of syncytium formation appearing 10-14 days post inoculation. Notably, the virus grew very poorly in Vero and A549 cells and could not be propagated in Madin Darby canine kidney (MDCK) cells. Virus-infected TMK cell-culture supernatants also did not display any hemagglutinating activity. The supernatants of infected TMK cells were used for EM studies, which revealed the presence of paramyxovirus-like pleomorphic particles in the range of 150-600 nm with short envelope projections in the range of 13-17 nm. However, RT-PCR studies with primer sets specific for known paramyxoviruses were initially all negative. Using a random PCR amplification procedure known as RAP-PCR (Welsh et al., 1990, Nucleic Acids Res. 18:7213-7218; Ralph et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:10710-10714), the Dutch investigators identified differentially displayed bands (compared to human parainfluenza-1 virus) which, upon sequencing, were found to be most closely related to the avian pneumovirus (APV).

APV, the agent of turkey rhinotracheitis, has been the sole member of the recently assigned *Metapneumovirus* genus within the *Pneumovirinae* subfamily (Taxonomy Virus, 2000, Seventh Report of the International Committee on Taxonomy of Viruses. San Diego. 551, 557, 559-560). The latter virus is a major respiratory pathogen of

5 turkeys and other domestic fowl worldwide (Yu et al., 1992, *Virology*. 186:426-434; Jones et al., 1987, *Vet. Rec.* 120:301-302; Jones, 1996, *Avian Pathol.* 25:639-648; Seal et al., 2000, *Virus Res.* 66:139-147). There are four serotypes of APV with serotype C (present in US) being the most closely related to hMPV (van den Hoogen et al., 2001, *Nat. Med.* 7:719-724). The metapneumoviruses (including APV and

10 hMPV) are structurally similar to the human respiratory syncytial virus (hRSV), which also belongs to the *Pneumovirinae* subfamily, except for two features: they lack the two non-structural proteins (NS1 and NS2) and they have a different genomic organization (Yu et al., 1992, *Virology*. 186:426-434). Recently, an almost complete hMPV sequence (13.4 kb) was reported in GenBank (accession number: AF371337)

15 (van den Hoogen et al., 2002, *Virology*. 295:119-132). The overall percentage of amino acid sequence identity for the N (nucleoprotein), P (phosphoprotein), M (matrix), F (fusion), M2 (membrane), and L (polymerase) proteins is in the range of 56-88% between hMPV and APV whereas it is 18-44% between hMPV and hRSV. However, the G (glycoprotein) and SH (small hydrophobic) proteins of hMPV do not

20 possess significant amino acid sequence identity with those of any other viruses. In contrast to APV, hMPV was shown to be unable to replicate in turkeys and chickens but the human virus replicated efficiently in the respiratory tract of cynomolgous macaques inducing upper respiratory tract symptoms that correlated with peak viral replication in throat samples between 2 to 8 days post infection (van den Hoogen et al., 2001, *Nat. Med.* 7:719-724). Thus, these preliminary data indicated that hMPV

25 was a primate pathogen associated with respiratory diseases.

Clinical importance of hMPV.

There is little information about the clinical presentation of hMPV infection. In the original report by Van Den Hoogen *et al.*, 27 of the 28 infected children from the Netherlands were below the age of five (van den Hoogen *et al.*, 2001, *Nat. Med.* 7:719-724). It was mentioned that those infected patients were diagnosed with a range of acute respiratory tract infections (ARTI) from mild to severe including bronchiolitis and pneumonia although no detailed clinical data were provided. In a limited study conducted in the winter of 2000, the same authors found that 7 ($\approx 10\%$) of 68 pediatric patients with unexplained ARTI had evidence of acute hMPV infection by RT-PCR (van den Hoogen *et al.*, 2001, *Nat. Med.* 7:719-724). In addition, Australian investigators reported the detection of hMPV by RT-PCR in 3/200 (1.5%) nasopharyngeal aspirates from children whose specimens were negative for the common respiratory viruses during the winter of 2001 (Nissen *et al.*, 2002, *Med. J. Aust.* 176:188). Recently, hMPV RNA was detected by RT-PCR in 9/405 (2.2%) of nasopharyngeal swabs from English patients who consulted for influenza-like illnesses and had negative tests for other pathogens (Stockton *et al.*, 2002, *Emerg. Infect. Dis.* 8:897-901). These studies, however, suffer from major limitations such as their small size (in most cases), the superficial description of clinical features, the lack of morbidity/mortality data, their retrospective nature, the exclusion of patients who tested positive for other viruses, and the absence of a control group.

Thus far, seroprevalence studies have been limited to the Dutch population. An indirect immunofluorescence assay (IFA) using infected TMK cells has revealed that 25% of the children aged between 6 and 12 months had hMPV antibodies and 70% had become seropositive by the age of 5 years ($n=60$) (van den Hoogen *et al.*, 2001, *Nat. Med.* 7:719-724). Retrospective serological testing also indicates that hMPV has been circulating in the Dutch population for at least half a century.

Diagnosis of hMPV infections

Our laboratory was the first to report the presence of hMPV in America and the second in the world following the initial report from the Netherlands (Peret et al., 2002, *J. Infect. Dis.* 185:1660-1663). Our first 11 hMPV strains were isolated on LLC-MK2 cells, a continuous cell line from rhesus monkey kidneys that is used in our center to recover parainfluenza viruses (PIV). Electron microscopy studies of these isolates revealed pleomorphic, spherical and filamentous particles with characteristics (nucleocapsid diameter and pitch spacing, length of projections) that were consistent with paramyxoviruses. RT-PCR and immunofluorescent assays for paramyxoviruses (PIV 1-3, hRSV) and other respiratory viruses (adenoviruses, coronaviruses, influenza viruses A and B, rhinoviruses) were negative for all 11 isolates. In contrast, amplification of the hMPV F (fusion) and M (matrix) genes based on published partial sequences (van den Hoogen et al., 2001, *Nat. Med.* 7:719-724; van den Hoogen et al., 2002, *Virology.* 295:119-132) was positive for all isolates (Peret et al., 2002, *J. Infect. Dis.* 185:1660-1663).

Subsequently, the virological features and clinical findings associated with a larger set of 38 hMPV strains from subjects hospitalized at our institution (CHUL, Québec City) since 1993 were examined in our laboratory (Boivin et al., 2002, *J. Infect. Dis.* 186:1330-1334). With all cell lines used in our laboratory, we were able to determine that the previously unidentified hMPV strains only consistently grew on LLC-MK2 cells after a mean incubation time of 17.3 days (range 3-23 days). Interestingly, most isolates recovered before 2002 produced only limited syncytia on LLC-MK2 cells, whereas some of the recent strains produced large syncytia typical of those induced by hRSV. Notably, we also observed a seroconversion for hMPV in two adult patients for whom acute and convalescent sera were available using an IFA test designed in our laboratory. Such seroconversion episodes (titers from < 1/10 to 1/80 and from < 1/10 to 1/160 over 2 and 4 weeks, respectively) occurred during the course of the patients' illness suggesting that hMPV was a true respiratory pathogen. A phylogenetic analysis of hMPV Canadian strains based on F gene sequences identified two major phylogenetic groups. At the nucleotide level, we found a similarity of 94.2-100% and 92.6-100% for isolates of groups 1 and 2, respectively, whereas the similarity at the amino acid level was higher i.e. 96.8-100% (group 1) and

97.2-100% (group 2) suggesting a functional/immunological conservation of the F protein. Interestingly, co-circulation of the two hMPV groups during some years was observed.

5 Over the past 9 years, most (86.7%) hMPV strains from our center were isolated during a 5-month period, from December to May. As an indication of the relative frequency of detection of hMPV compared to other respiratory viruses, we reviewed all respiratory samples (n = 862) sent to our virology laboratory for viral culture during the winter season (Dec. to May) of 2000-01. During this period, hMPV was
10 recovered in 2.3% of all respiratory samples tested by viral culture compared to 2.3% for PIV, 3.4% for adenoviruses, 4.8% for hRSV, and 19.8% for influenza A or B viruses. Overall, hMPV represented 7.1% of all positive cultures from respiratory samples during that winter season with percentages of 4.1%, 2.8%, and 29.3% for
15 patients aged 0-5, 5-65, and > 65 years, respectively. A retrospective review of the clinical charts from hMPV-infected subjects identified for the first time the role of this virus as a cause of severe lower respiratory tract infections in all age groups but especially in young children, elderly subjects, and immunocompromised patients. More specifically, the most frequent diagnoses associated with hMPV infection in hospitalized children were pneumonitis (66%) and bronchiolitis (58.3%) whereas
20 bronchitis/bronchospasm (60%) and pneumonitis (40%) were most commonly seen in elderly subjects (Boivin et al., 2002, *J. Infect. Dis.* 186:1330-1334). Although no histopathological studies were available, hMPV was the only pathogen identified in respiratory tract secretions of 3 subjects (including 2 with immunosuppressive conditions) who died of respiratory insufficiency.

25

We recently studied in greater details one of the cases associated with a fatal hMPV infection (Pelletier et al., 2002, *Emerg. Infect. Dis.* 8:976-978). Interestingly, this child with acute lymphoblastic leukemia was successively infected by two genetically-distinct hMPV strains on two consecutive winter seasons. On each
30 occasion, hMPV was the only pathogen isolated from a nasopharyngeal aspirate obtained during the course of lower respiratory tract infections (bronchiolitis in the

7

first year, bronchiolitis followed by fatal pneumonitis in the second year). Comparative sequence analysis of the amplified F gene products (759 bp) revealed that the two viral isolates differed by 114 nucleotides (10 amino acids) and belonged to two different hMPV groups. Overall, our data suggest that many hMPV strains may co-circulate in a specific population during a given period and such viral diversity coupled with a waning immunity (as found in elderly subjects and immunocompromised patients) may lead to multiple and sometimes fatal reinfections similar to those reported with hRSV (Hall, 2001, *N. Engl. J. Med.* 344:1917-1928; Couch et al., 1997, *Am. J. Med.* 102:2-9).

10

The role and relative contribution of hMPV were recently further expanded in a prospective case-control study performed at our institution during the winter of 2001-02 (Dec. 15-April 20). All children ≤ 3 years were eligible as cases if they were hospitalized for a lower respiratory tract infection (bronchiolitis, croup, pneumonitis) whereas controls consisted of children matched for age and hospitalized for an elective surgery during the same period with no respiratory symptoms. Nasopharyngeal aspirates were obtained from all participants for real-time PCR studies performed on a LightCycler (Roche). The latter included a multiplex RT-PCR for common respiratory viruses (influenza A, influenza B, hRSV) and a real-time RT-PCR assay for hMPV (analytical sensitivity of 100 copies per PCR reaction). No viruses were detected in samples from the 51 control patients. In contrast, at least one virus was identified in samples from 163 (78.4%) of the 208 cases (51% hRSV, 21.6% influenza A, 0% influenza B, 5.8% hMPV, and 5.9% co-infections). hRSV and influenza A infections occurred predominantly in the period between January and March 2002, whereas hMPV infections increased after February. In fact, 11/12 hMPV cases occurred within a 4-week period from mid-March to mid-April accounting for 18.9% of all ARTI in children during this period. Data collected from our virology laboratory indicated that the hMPV outbreak extended after the end of the study protocol (April 20) which suggests that hMPV seasonal pattern may differ from that of other respiratory viruses. A bronchiolitis was diagnosed in 67% of hMPV-infected children whereas 16.7% developed a pneumonia. In brief, there was no statistical

30

difference between the different viruses with regard to the symptomatology and reported diagnoses. Similarly, the median duration of hospitalization for the 3 viruses was identical (4-5 days).

- 5 In view of the above, it will be appreciated that diagnosis assay that can rapidly detect the presence of many respiratory viruses is needed.

Respiratory viruses have been classically identified by viral culture using a variety of permissive cell lines. However, viral culture is not convenient for clinical
10 management due to the need of specialized techniques (cell culture, immunofluorescence methods), the long turnaround time before appearance of typical cytopathic effects for many viruses (up to a few weeks), and the need for rapid inoculation of an infectious virus into multiple cell lines for optimal sensitivity (Specter et al., 2002, *Clinical Virology*, 2nd ed., ASM Press, Washington, D.C., 243-
15 272).

Antigenic detection kits for some respiratory viruses (influenza viruses and hRSV) have been developed by many companies. Most are immunoenzymatic assays (ELISA) based on the capture of a viral antigen by a specific monoclonal antibody.
20 Although such assays eliminate many of the problems inherent to viral cultures (no need for specialized equipment, rapid turnaround time in < 30 min, no need to recover an infectious virus), they have not been widely adopted due to poor sensitivity and/or specificity compared to viral culture. For instance, the sensitivity and specificity of some rapid antigenic tests for influenza has varied from 46 to 96 % and from 52 to 99
25 %, respectively, compared to viral culture. The performance of these tests is dependent on many variables such as the patient's age, the type of specimen and the duration of the disease (Hayden et al., 2002, *Clinical Virology*, 2nd ed., ASM Press, Washington, D.C., 891-920). The performance of the rapid antigenic tests for hRSV has been considered quite good in children with sensitivity and specificity varying
30 from 80 to 95 % (Piedra et al., 2002, *Clinical Virology*, 2nd ed., ASM Press, Washington, D.C., 763-790) but poor in adults (Englund et al., 1996, *J. Clin.*

Microbiol. 34:1649-1653). Detection of antibodies against viral pathogens (serology) has a limited value in the diagnosis of acute viral infections since two serums, collected at a 2 to 3 week interval, are required in order to document a significant rise in viral antibody titers.

5

More recently, PCR or RT-PCR assays have been developed for many respiratory viruses allowing detection of small amounts of viral DNA or RNA in a clinical sample. In the so-called "multiplex" format, PCR assays have been designed to amplify more than one viral target in the same PCR reaction (Ellis et al., 1997, J. Clin. Microbiol. 35:2076-2082; Fan et al., 1998, Clin. Infect. Dis. 26:1397-1402; Liolios et al., 2001, J. Clin. Microbiol. 39:2779-2783; Grondahl et al., 1999, J. Clin. Microbiol. 37:1-7). However, most multiplex PCR assays reported to date do not allow the simultaneous detection of all viruses involved in acute respiratory tract infections of humans and they require separate steps for the amplification and detection of viral genes, greatly increasing the assay's turnaround time and preventing reliable quantification of the amplicons. At present, only one multiplex PCR assay (the Hexaplex test from Prodesse, Waukesha, WI) is commercially-available. The Hexaplex detects 6 respiratory viruses (influenza A and B, PIV 1-3 and hRSV) using specific viral probes in a microplate format (Fan et al., 1998, Clin. Infect. Dis. 26:1397-1402; Kehl et al., 2001, J. Clin. Microbiol. 39:1696-1701). This assay does not use real-time amplification methodologies and has a turnaround time of about one full working day. Thus, there is a need for developing more rapid molecular assays that permit detection of a larger panel of respiratory viral pathogens.

25 Rapid and sensitive detection of respiratory viruses is an important clinical goal to help physicians select the most appropriate antiviral, reduce nosocomial transmission of pathogens, decrease the length of hospitalization, and reduce antibiotic use and bacterial resistance. The present invention relates to the development of multiplex assays based on nucleic acids detection for sensitive and rapid diagnosis of most viral
30 respiratory pathogens of humans.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a rapid and sensitive method using amplification primers and/or probes for determining the presence and/or the amount in a test sample of nucleic acids from clinically important respiratory viral pathogens including human metapneumovirus.

In another aspect there is provided multiplex assays aimed at detecting conserved genes of common respiratory viral pathogens such as influenza A and B, human respiratory syncytial virus (hRSV) A and B, human metapneumovirus (hMPV), parainfluenza viruses (PIV) types 1-4, adenoviruses, rhinoviruses, enteroviruses, and coronaviruses.

The nucleic acid amplification method is preferably but not exclusively PCR. In a preferred embodiment, identification of the amplicons produced by the amplification of nucleic acids from respiratory viruses is achieved by verifying the specific melting temperature of amplified viral products or by hybridization with specific viral probes. Other amplification technologies including target and probe amplification techniques as well as signal amplification techniques performed in liquid phase or onto solid supports may also be used.

It is an object of the present invention to provide a method using nucleic acid amplification and/or detection for determining the presence and/or the amount of nucleic acids of the human metapneumovirus (hMPV).

In a preferred embodiment, the nucleic acid amplification method is PCR. However, other amplification technologies including target and probe amplification techniques as well as signal amplification performed in liquid phase or onto solid support may also be used.

This invention provides a method to detect the presence of hMPV in a test sample based on the detection of a nucleotide sequence from either the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G), and small hydrophobic (SH) genes. In a particularly preferred
5 embodiment, the method to detect the presence of hMPV in a test sample is based on the detection of a nucleotide sequence from the nucleoprotein (N) or polymerase (L) genes.

In another embodiment, identification of amplified hMPV products is achieved by
10 verifying the specific melting temperature of amplified viral products or by hybridization with hMPV-specific probes.

It is another object of this invention to provide a method for typing hMPV strains which comprises the steps of reproducing the above amplification method followed
15 by either hybridization using type-specific probes, DNA sequencing or restriction enzyme analysis. Typing is done preferentially, but not exclusively, on the most variable hMPV genes i.e. the fusion (F) and glycoprotein (G) genes.

All the proprietary DNA fragments and oligonucleolides useful in the detection or
20 identification of a hMPV strain are further objects of this invention as well as any composition of matters that include them (recombinant vectors, hosts, diagnostic kits...).

25 BRIEF DESCRIPTION OF THE DRAWINGS

Further features and advantages of the present invention will become apparent from the following detailed description, taken in combination with the appended drawings, in which:

12

Figure 1 represents a melting curve analysis of amplified hMPV strains using specific nucleoprotein primers (Sequence ID Nos. 92 and 94) ;

Figure 2 shows an ethidium bromide-stained agarose gel showing restriction fragment
5 length polymorphism of amplified hMPV fusion (F) gene sequences digested with
enzymes ApaL I and Avr II. PCR products of the hMPV F gene (amplified with
primers sequence ID Nos. 97 and 98) were digested with ApaL I and Avr II. Strains
belonging to hMPV genotype F-1 were digested only by ApaL I resulting in two
fragments of 532 bp and 227 bp whereas strains belonging to hMPV genotype F-2
10 were digested only by Avr II resulting in fragments of 447 and 312 bp.;

Figure 3 shows the age at admission of children hospitalized for acute respiratory tract
infections (ARTI) caused by hMPV (A), hRSV (B), and influenza A (C) as well as for
the whole study population (D) described in example 4;

15

Figure 4 represents the biweekly distribution of virologically cases with acute
respiratory tract infections and their controls in the study reported in example 4;

Figure 5 represents the biweekly distribution of hMPV isolates in the study group
20 (hospitalized children) described in example 4 and in respiratory specimens tested at
the regional virology laboratory (RVL);

Figure 6 illustrates a phylogenetic tree of hMPV strains recovered as part of the study
described in example 4 also including the prototype strain from the Netherlands
25 (GenBank af371367) and a Canadian isolate from season 2000-01 (hMPV35-2001).
The dates of sample collection are in parentheses;

Figure 7 is a melting curve analysis of viral strains amplified using the respiratory-1
multiplex real-time PCR assay. A- Multiplex real-time PCR assay using hMPV N
30 primers (SEQ ID NOS. 95 and 96). B- Multiplex real-time PCR assay using hMPV L

13

primers (SEQ ID NOS. 112 and 114). Note: the internal control is apparent (T_m : 91°C) in the absence of amplification of specific viral products.;

5 Figure 8 is a melting curve analysis of viral strains amplified using the respiratory-2 multiplex real-time PCR assay. Note: The internal control is apparent (T_m : 91°C) in the absence of amplification of specific viral products;

10 Figure 9A is a fluorescence signal as a function of elongation step for the determination of the hMPV load in clinical samples using quantitative real-time PCR;

Figure 9B is a standard curve for determination of the hMPV using quantitative real-time PCR;

15 Figure 10A is a phylogenetic tree for the F gene of hMPV;

Figure 10B is a phylogenetic tree for the G gene of hMPV;

20 Figure 11 is a melting curve analysis of amplified viral genes and of an internal control as determined by the LightCycler instrument. Note that high amounts of amplified viral products may preclude detection of the internal control in some PCR runs; and

Figure 12 is a melting curve analysis SARS-coronavirus using a real time PCR assay.

25 It will be noted that throughout the appended drawings, like features are identified by like reference numerals.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention provides nucleic acid based diagnostic methods and compositions to detect and quantify respiratory viruses.

5

In a preferred embodiment respiratory viral pathogens targeted by the diagnostic assays include all genotypes of influenza A and B viruses, hRSV, hMPV, PIV, adenoviruses, rhinoviruses, and enteroviruses. Other less common (coronaviruses, reoviruses) and yet to be discovered respiratory viruses are also targets under the scope of the present invention.

10

In the description of this invention, the terms «nucleic acids» and «sequences» might be used interchangeably. However, «nucleic acids» are chemical entities while «sequences» are the pieces of information encoded by these «nucleic acids». Both nucleic acids and sequences are equivalently valuable sources of information for the matter pertaining to this invention.

15

In one embodiment the method targets conserved hMPV nucleotide sequences for diagnostic purposes and variable hMPV sequences for epidemiological typing purposes. Nucleotide sequences were selected either from a number of hMPV viral sequences obtained in the inventor's laboratory or from public databases (GenBank accession number AF371337).

20

Our proprietary DNA fragments and oligonucleotides (a non-restrictive list of primers and probes) are listed in the following tables.

25

It will be understood by those skilled in the art that sequences that can selectively hybridize to the sequences of the present invention are also comprised in the scope of the invention. By selectively hybridizing it is meant that a nucleic acid molecule binds to a given target in a manner that is detectable in a different manner from non-target

15

sequence under moderate, or more preferably under high, stringency conditions of *hybridization*. "Complementary" or "target" nucleic acid sequences refer to those nucleic acid sequences which selectively hybridize to a nucleic acid molecule. Proper annealing conditions depend, for example, upon a nucleic acid molecule's length, base composition, and the number of mismatches and their position on the molecule, and must often be determined empirically. For discussions of nucleic acid molecule (probe) design and annealing conditions, see, for example, Sambrook et al. 1989 (Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)) or Ausubel et al. 1987 (Ausubel, F., et al., *Current Protocols in Molecular Biology*, New York (1987)).

The detection of the viruses including the hMPV is conducted through compositions of matters such as diagnostic kits comprising the amplification primers or probes of this invention.

15

In the methods and kits of the present invention, probes and primers are not limited to nucleic acids and may include, but are not restricted to, analogs of nucleotides. The diagnostic reagents constituted by the probes and the primers may be present in any suitable form (bound to a solid support, liquid, lyophilized, etc.) for detection and/or amplification of nucleic acid sequences of the viruses.

In the methods and kits of the present invention, amplification reactions may include but are not restricted to: a) polymerase chain reaction (PCR), b) ligase chain reaction (LCR), c) nucleic acid sequence-based amplification (NASBA), d) self-sustained sequence replication (3SR), e) strand displacement amplification (SDA), f) branched DNA signal amplification (bDNA), g) transcription-mediated amplification (TMA), h) cycling probe technology (CPT), i) nested PCR, j) multiplex PCR, k) solid phase amplification (SPA), l) nuclease dependent signal amplification (NDSA), m) rolling circle amplification technology (RCA), n) anchored strand displacement amplification, o) solid-phase (immobilized) rolling circle amplification.

In the methods and kits of the present invention, detection of the nucleic acids of target genes may include real-time or post-amplification technologies. These detection technologies can include, but are not limited to, the use of intercalating agents such as SYBR green, fluorescence resonance energy transfer (FRET)-based methods such as adjacent hybridization of probes (including probe-probe and probe-primer methods), *TaqMan* probe, molecular beacon probe, Scorpion probe, nanoparticle probe and Amplifluor probe. Other detection methods include target gene nucleic acids detection via immunological methods, solid phase hybridization methods on filters, chips or any other solid support. In these systems, the hybridization can be monitored by fluorescence, chemiluminescence, potentiometry, mass spectrometry, plasmon resonance, polarimetry, colorimetry, flow cytometry or scanometry. Nucleotide sequencing, including sequencing by dideoxy termination or sequencing by hybridization (e.g. sequencing using a DNA chip) represents another method to detect and characterize the nucleic acids of target genes.

Amplification of hMPV sequences

In one aspect of the invention there is provided methods and compositions for detecting hMPV in a sample.

In a preferred embodiment, a reverse-transcription (RT)-PCR protocol is used for nucleic acid amplification. The single-stranded viral RNA is converted to complementary DNA using an enzyme possessing a reverse transcriptase activity and a specific hMPV primer. Alternatively, random hexamer primers can be substituted to the specific hMPV primer. In a preferred embodiment, viral RNA was prealably extracted from 200 μ l of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN). Complementary DNA was synthesized using 10 μ l of eluted RNA, 0.75 μ M of a specific hMPV primer (Table 2, sequences ID Nos. 91, 97, 100, 102, 109, 112), and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's recommendations.

For DNA amplification by the widely used PCR method, primer pairs were derived from our proprietary DNA fragments or from public database sequences (Table 1). During DNA amplification by PCR, two oligonucleotide primers binding respectively to each strand of the heat-denatured target DNA from the microbial genome are used to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109).

10 In a preferred embodiment, complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation (Sigma-Aldrich, Oakville, ON) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 μ l including 2
15 μ l of RT mixture and 18 μ l of a reaction mixture containing 4 mM MgCl₂, 2 μ l of Faststart DNA SYBR Green Master Mix or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation, 3% DMSO, and 0.5 μ M of each hMPV primer (see Tables 2 and 4 for sequence ID Nos. and specific combinations of primers for amplification, respectively). Cycling conditions typically included an initial
20 denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. However, the cycling conditions could slightly vary according to the hMPV gene to amplify.

The person skilled in the art of nucleic acid and/or signal amplification knows the
25 existence of other rapid amplification procedures such as ligase chain reaction (LCR), reverse transcriptase PCR (RT-PCR), transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bDNA), cycling probe technology (CPT), solid phase amplification (SPA), rolling circle
30 amplification technology (RCA), solid phase RCA, anchored SDA and nuclease dependent signal amplification (NDSA) (Persing, 1993, Diagnostic Molecular

Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109; Lee, 1997, Nucleic Acid Amplification Technologies: Applications to Disease Diagnosis, Eaton Publishing, Boston, MA. 61-125; Westin et al., 2000, Nat. Biotechnol. 18:199-204). The scope of this invention is not limited to
5 the use of amplification by PCR, but rather includes the use of any nucleic acid amplification method or any other procedure which may be used to increase the sensitivity and/or the rapidity of nucleic acid-based diagnostic tests. The scope of the present invention also covers the use of any nucleic acid and/or signal amplification and detection technology including real-time or post-amplification detection
10 technologies, any amplification technology combined with detection, any hybridization nucleic acid chips or array technologies, any amplification chips or combination of amplification and hybridization chip technologies. Detection and identification by any nucleotide sequencing method is also under the scope of the present invention.

15

Any oligonucleotide, useful for diagnosis, and which are derived from hMPV sequences and used with any nucleic acid amplification and/or hybridization technologies are also under the scope of this invention.

20 Detection of amplification products

Classically, the detection of PCR amplification products is performed by standard ethidium bromide-stained agarose gel electrophoresis. Using this approach, primers specific for a nucleotide sequence from either the nucleocapsid (N), phosphoprotein
25 (P), matrix (M), fusion (F), polymerase (L), glycoprotein (G), genes generated amplicons of various lengths depending on the selected primers pairs (Table 4). It is however clear that other detection methods of amplified products may be faster, more sensitive, and more practical. Amplicon detection may also be performed by solid support or liquid hybridization using strain-specific internal DNA probes hybridizing
30 to an amplification product. Such probes may be generated from sequences from our repertory (Table 1) and designed to specifically hybridize to DNA amplification

products which are objects of the present invention. Amplicons can also be characterized by DNA sequencing. Alternatively, a rapid detection method developed with real-time PCR assays consists of determining the specific melting temperature of amplicons at the end of the amplification reaction.

5

In a preferred embodiment, detection of hMPV amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a LightCycler instrument, the internal temperature was rapidly increased to 94°C then decreased to 60°C for 30 seconds, followed by slowly
10 increasing to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture. Using this procedure, the specific melting temperature obtained with the specific amplicons produced by the pairs of primers specific for the N (SEQ ID No 92+94), M (SEQ ID No 100+101), F (SEQ ID 97+98), P (SEQ ID No 102 +103) and L (SEQ ID No 112 + 113) gene sequences was found to be 82.63°C ± 0.87°C, 82.75°C ± 0.80°C,
15 83.29°C ± 0.45°C, 80.48°C ± 0.46°C, and 77.99 ± 0.33°C, respectively (Table 5 and see also Figure 1 for example of the melting temperature obtained for different hMPV strains with the N primers). Alternatively, we also designed specific adjacent and TaqMan fluorescent probes for the various hMPV gene products (N, M, F, G, P and L) that can be used for real-time detection and quantification of amplicons (Table 3).
20 Here, quantification of hMPV gene products is achieved through fluorescence resonance energy transfer (FRET) when the two probes hybridize nearby on a complementary DNA sequence. Other types of detection methods including the use of TaqMan or molecular beacon probes specific for the hMPV sequences described above are also under the scope of this invention.

25

Typing of hMPV

Previous studies have shown that two major genotypes of hMPV circulate in North America and Europe (van den Hoogen et al., 2001, Nat. Med. 7:719-724; Boivin et
30 al., 2002, J. Infect. Dis. 186:1330-1334). We also designed a rapid molecular typing method for epidemiologic studies based on amplification of a portion of the F (fusion)

glycoprotein (primer sequence ID Nos. 97 and 98, Tables 2 and 4) followed by DNA sequencing or digestion with restriction enzymes (ApaI I and Avr II). Table 6 summarizes the size of the F fragments obtained for different hMPV isolates following enzymatic digestion and the corresponding genotype (see also Figure 2 for an example of the band pattern following electrophoresis on an agarose gel). Alternative typing methods based on the use of type-specific hMPV F primers and/or probes as well as DNA sequencing of amplified products are also within the scope of this invention. hMPV subtyping using similar methodologies for the other surface glycoprotein (i.e. the G gene) may also be used.

10

A method for detection of a plurality of potential hMPV strains having different genotypes may be conducted in separate reactions and physical enclosures, one type at the time. Alternatively, it could be conducted simultaneously for different types in separate physical enclosures, or in the same physical enclosures. In the latter scenario a multiplex PCR reaction could be conducted which would require that the oligonucleotides are all capable of annealing with a target region under common conditions. Since many probes or primers are specific for a determined genotype, typing an hMPV strain is under the scope of the present invention. When a mixture of oligonucleotides annealing together with more than one type of hMPV is used in a single physical enclosure or container, different detection labels would be used to distinguish one type from another.

15

The diagnostic kits, primers and/or probes mentioned above can be used to detect and/or identify hMPV, whether said diagnostic kits, primers and probes are used for *in vitro* or *in situ* applications. The said samples may include but are not limited to: any clinical sample, any environmental sample, any viral culture, any tissue, or any cell line.

20

It is also an object of the present invention that said diagnostic kits, primers and/or probes can be used alone or in combination with any other assay suitable to detect and/or identify other microorganisms (i.e. viruses, bacteria, fungi, and parasites) including but not limited to: any assay based on nucleic acids detection, any

25

30

immunoassay, any enzymatic assay, any biochemical assay, any lysotypic assay, any serological assay, any culture on specific cell lines, and any infectivity assay on animals.

- 5 In the methods and kits described herein below, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). All DNA sequences have been obtained either from our proprietary sequences (Table 1) or from SEQ ID No. 1 from public databases.
- 10 It is clear to the individual skilled in the art that oligonucleotide sequences other than those described in the present invention and which are appropriate for detection and/or identification of hMPV may also be derived from the proprietary fragment sequences or selected public database sequences. For example, the oligonucleotide primers or probes may be shorter but of a length of at least 10 nucleotides or longer
- 15 than the ones chosen; they may also be selected anywhere else in the proprietary DNA fragments or in the sequences selected from public databases; they may also be variants of the same oligonucleotide. If the target DNA or a variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true : a given target
- 20 DNA may hybridize to a variant oligonucleotide probe or be amplified by a variant oligonucleotide PCR primer. Alternatively, the oligonucleotides may be designed from said DNA fragment sequences for use in amplification methods other than PCR. Consequently, the core of this invention is the detection and/or identification of hMPV by targeting DNA sequences which are used as a source of specific and
- 25 ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes require much effort, it is quite possible for the individual skilled in the art to derive, from the selected DNA fragments, oligonucleotides other than the ones listed in Tables 2 and 3 which are suitable for diagnostic purposes. When a proprietary fragment or a public
- 30 database sequence is selected for its specificity and ubiquity (i.e. ability to detect all

hMPV strains), it increases the probability that subsets thereof will also be specific and ubiquitous.

5 The proprietary DNA fragments have been obtained as a repertory of sequences created by amplifying hMPV nucleic acids with proprietary primers. These primers and the repertory of nucleic acids as well as the repertory of nucleotide sequences are further objects of this invention (Tables 1-3).

10 As part of the design rules, all oligonucleotides were evaluated for their suitability for hybridization or PCR amplification by computer analysis using standard programs (i.e. the GCG Wisconsin package programs, the primer analysis software Oligo™ 6 and MFOLD 3.0). The potential suitability of the PCR primer pairs was also evaluated prior to their synthesis by verifying the absence of unwanted features such
15 as long stretches of the same nucleotide and a high proportion of G or C residues at the 3' end (Persing, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109). Oligonucleotide amplification primers were synthesized using an automated DNA synthesizer (Applied Biosystems).

20 The oligonucleotide sequence of primers or probes may be derived from either strand of the duplex DNA. The primers or probes may consist of the bases A, G, C, or T or analogs and they may be degenerated at one or more chosen nucleotide position(s) (Nichols et al., 1994, Nature. 369:492-493). Primers and probes may also consist of nucleotide analogs such as Locked Nucleic Acids (LNA) (Koskhin et al., 1998,
25 Tetrahedron Lett. 54:3607-3630), and Peptide Nucleic Acids (PNA) (Egholm et al., 1993, Nature. 365:566-568). The primers or probes may be of any suitable length and may be selected anywhere within the DNA sequences from proprietary fragments, or from selected database sequences which are suitable for the detection of hMPV.

30 Variants for a given target microbial gene are naturally occurring and are attributable to sequence variation within that gene. For example, different strains of the same viral

species may have a single or more nucleotide variation(s) at the oligonucleotide hybridization site. The person skilled in the art is well aware of the existence of variant nucleic acids and/or sequences for a specific gene and that the frequency of sequence variations depends on the selective pressure during evolution on a given gene product. The detection of a variant sequence for a region between two PCR primers may be demonstrated by sequencing the amplification product. In order to show the presence of sequence variations at the primer hybridization site, one has to amplify a larger DNA target with PCR primers outside that hybridization site. Sequencing of this larger fragment will allow the detection of sequence variation at this primer hybridization site. A similar strategy may be applied to show variations at the hybridization site of a probe. Insofar as the divergence of the target nucleic acids and/or sequences or a part thereof does not affect significantly the sensitivity and/or specificity and/or ubiquity of the amplification primers or probes, variant microbial DNA is under the scope of this invention. Variants of the selected primers or probes may also be used to amplify or hybridize to a variant target DNA.

In an other aspect of the invention there is also provided newly isolated human metapneumoviruses deposited with International Depository Authority of Canada on December 11 2003 and bearing IDAC numbers 111203-01 and 111203-02 (also referred herein as CAN 97-83 and CAN 98-75 respectively).

In a further aspect of the invention the diagnostic method is designed at performing simultaneous detection of nucleic acids from a variety of respiratory viruses using specific primers and/or probes. The method is aimed at detecting and/or quantifying conserved viral sequences from respiratory viruses for diagnostic purposes. Target nucleotide sequences were selected public databases and from viral strain sequences obtained in the inventor's laboratory.

The specific respiratory viral pathogens targeted by the diagnostic assays include all genotypes of influenza A and B viruses, hRSV, hMPV, PIV, adenoviruses, rhinoviruses, and enteroviruses. Other less common (coronaviruses, reoviruses) and

yet to discover respiratory viruses are also targets under the scope of the present invention.

The specific combination of oligonucleotides (primers and/or probes) in a multiplex
5 format is also another object of this invention.

Composition of matters such as diagnostic kits comprising amplification primers and/or probes for the detection of respiratory viruses are also objects of the present invention.

10

Amplification of viral sequences

In a preferred embodiment, a PCR protocol is used for nucleic acid amplification. Multiplex assay, aimed at amplifying a plurality of respiratory viruses in the same
15 physical enclosure, is an object of the present invention.

We aim at developing DNA-based tests or diagnostic kits to detect and identify most respiratory viruses in a limited number of amplification reactions using specific primers (Table 10) and/or probes (Table 11). Although some of the primer sequences
20 used for amplification of the various respiratory viruses, with the exception of hMPV (SEQ. ID. Nos. 95 and 96 or 112 and 114), PIV-1 (SEQ. ID. Nos. 147 and 148), PIV-3 (SEQ. ID. Nos. 151 and 152), and adenovirus (SEQ. ID. Nos. 153), have been described previously by others (Fouchier et al., 2000, J. Clin. Microbiol. 38:4096-4101 for influenza A virus / SEQ. ID. Nos. 139 and 140; Li et al., 2001, J. Clin.
25 Microbiol. 39:696-704 for influenza B virus / SEQ. ID. Nos. 141 and 142; Mazulli et al., 1999, J. Infect. Dis. 180:1686-1689 for hRSV / SEQ. ID. Nos. 143 and 144; Osiowy et al., 1998, J. Clin. Microbiol. 36: 3149-3154 for PIV-1, PIV-3, and adenovirus / SEQ. ID. Nos. 145 and 146, 149 and 150, and 154 and 155, respectively; Atmar et al., 1993, J. Clin. Microbiol. 31: 2544-2546 for rhinovirus and enterovirus /
30 SEQ. ID. Nos. 160 and 161) and that one influenza A primer (SEQ. ID. No. 139) is

25

almost identical to the one described in another patent (U.S. patent number 6,015,664), the object of the present invention is to combine many sets of primers and/or probes in the same physical enclosure (multiplex format).

5 Briefly, viral RNA was extracted from 200 μ l of naso-pharyngeal aspirates or other respiratory tract samples using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). Complementary DNA (cDNA) was then synthesized using 10 μ l of the RNA preparation, 0.75 μ M of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), 300 copies of an internal control
10 template, and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's instructions. The internal control template consisted of a 554 or 558 bp (depending on the multiplex assay) transcribed region of an herpes simplex virus type 2 DNA polymerase region flanked by either influenza B or rhinovirus/enterovirus complementary primer sequences (depending on the
15 multiplex assay) cloned in the pDrive plasmid (QIAGEN).

For DNA amplification by the widely used PCR method, primer pairs were mostly derived from public database sequences (Table 10). During DNA amplification by
20 PCR, two oligonucleotide primers binding respectively to each strand of the heat-denatured target DNA from the viral genome are used to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing, 1993, Diagnosis Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C., 88-109).

25

In a preferred embodiment, cDNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation (Sigma-Aldrich, Oakville, ON) in a LightCycler instrument (Roche
30 Diagnostics). Each reaction had a total volume of 20 μ l including 2 μ l of cDNA and 18 μ l of a reaction mixture containing 4 mM $MgCl_2$, 2 μ l of LC Faststart DNA SYBR

Green 1 Master Mix or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation, 3% DMSO, and 0.3-1.0 μ M of each viral primer (see Tables 10, 12, and 13 for primer sequence ID NOs., length of amplicons, and specific combination of primers, respectively). Cycling conditions typically included an initial
5 denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. However, the cycling conditions could vary slightly according to the multiplex PCR assay.

In a preferred embodiment, two real-time multiplex PCR assays were used to amplify
10 and detect the panel of common respiratory viruses (Table 13). The respiratory-1 multiplex assay combines 4 sets of primers for amplification of influenza A and B viruses, hRSV, hMPV, and an internal control template. The respiratory-2 multiplex assay comprises 4 other sets of primers for amplification of PIV-1, PIV-3, adenoviruses, rhinoviruses/enteroviruses, and an internal control template. The use of
15 any other combinations of the same or similar primer sequences in two or more than two multiplex assays for detection of common respiratory viral pathogens is also under the scope of this invention.

The person skilled in the art of nucleic acid amplification knows the existence of other
20 rapid amplification procedures such as ligase chain reaction (LCR), reverse transcriptase PCR (RT-PCR), solid phase PCR, transcription-mediated amplification (TMA), self-sustained sequence replication (SSR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bdNA), cycling probe technology (CPT), solid phase amplification (SPA), rolling
25 circle amplification technology (RCA), solid phase RCA, anchored SDA, and nuclease dependent signal amplification (NDSA) (Persing, 1993, *Diagnosis Molecular Microbiology: Principles and Applications*, American Society for Microbiology, Washington, D.C., 88-109; Lee, 1997, *Nucleic Acid Amplification Technologies: Application to Disease Diagnosis*, Eaton Publishing, Boston, MA., 61-125; Westin et al., 2000, *Nat. Biotechnol.*18:199-204). The scope of this invention is not limited to
30 the use of amplification by PCR, but rather includes the use of any nucleic acid

amplification method or any other procedure which may be used to increase the sensitivity and/or the rapidity of nucleic acid-based diagnostic tests. The scope of the present invention also covers the use of any nucleic acids amplification and detection technology including real-time or post-amplification detection technologies, any
5 amplification technology combined with detection, any hybridization nucleic acid chips or array technologies, any amplification chips or combination of amplification and hybridization chip technologies. Detection and identification by any nucleotide sequencing method is also under the scope of the present invention.

10 Detection of amplification products

Classically, the detection of PCR amplification products is performed by standard ethidium bromide-stained agarose gel electrophoresis. Using this approach, the amplicons may be discriminated based on their size. In the present invention, the
15 length of the different amplicons varies from 84 to 929 bp (Table 12). It is however clear that other detection methods of amplified products may be faster, more sensitive, and more practical. Amplicon detection may also be performed by solid support or liquid hybridization using strain-specific internal DNA probes hybridizing to an amplification product. Such probes may be generated from sequences designed to
20 specifically hybridize to DNA amplification products which are objects of the present invention. Amplicons can be also characterized by DNA sequencing. Alternatively, a rapid detection method developed with real-time PCR assays consist of determining the specific melting temperature of amplicons at the end of the amplification reaction.

25 The detection of viral amplicons was first characterized using the melting curve analysis feature of a real-time PCR instrument. Using this procedure, the different viral targets amplified in each of the multiplex PCR assays could be differentiated by their specific melting temperature (Table 13 and Fig. 7 and 8). Alternatively, specific fluorescent probes (Table 11) for each viral target can be used for real-time detection
30 and quantification of amplicons in a single amplification/detection assay. Real-time quantification of viral products can be performed through a variety of fluorescence-

based technologies such as adjacent probes, Taqman probes, and molecular beacons. Alternatively, these probes may be used in a separate post-amplification step.

5 The diagnostic kits, primers and probes mentioned above can be used to detect and/or identify respiratory viruses, whether said diagnostic kits, primers and/or probes are used for *in vitro* or *in situ* applications. The said samples may include but are not limited to: any clinical sample, any environmental sample, any viral culture, any tissue, and any cell line.

10 It is also an object of the present invention that said diagnostic kits, primers and/or probes can be used alone or in combination with any other assay suitable to detect and/or identify and /or quantify microorganisms, including but not limited to: any assay based on nucleic acids detection, any immunoassay, any enzymatic assay, any biochemical assay, any serological assay, any culture on specific cell lines, and any
15 infectivity assay on animals.

In the methods and kits described herein, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). It is clear to the individual skilled in the art that oligonucleotide sequences
20 other than those described in the present invention and which are appropriate for detection and/or identification of any respiratory viruses may also be derived from those selected in the present invention. For example, the oligonucleotide primers or probes may be shorter but of a length of at least 10 nucleotides or longer than the ones chosen; they may also be variants of the same oligonucleotide. If the target DNA or a
25 variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true; a given target DNA may hybridize to a variant oligonucleotide probe or be amplified by variant oligonucleotide PCR primers. Alternatively, the oligonucleotides may be designed for use in amplification methods other than PCR. Consequently, one
30 aspect of the present invention is the simultaneous detection and/or identification of various respiratory viruses by targeting nucleic acid sequences which are used as a

source of specific and ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes require much effort, it is quite possible for the individual skilled in the art to derive, from the selected oligonucleotides (listed in Tables 10 and 11), other
5 oligonucleotides which are suitable for diagnostic purposes.

Thus, the specific primers and/or probes selected for amplification and detection of respiratory viruses and their specific combination in multiplex assays are objects of this invention (Tables 10-13).

10

EXAMPLES:

Example 1: Evaluation of different primers for hMPV detection

15

An evaluation of the sensitivity of different hMPV primer sets in a real-time PCR assay was performed using 20 positive hMPV cultures grown in LLC-MK2 cells and 10 naso-pharyngeal aspirate specimens. These samples were collected in the Québec City area (QC, Canada) over a period of 3 years (2000-2002). Viral RNA was
20 preably extracted from 200 µl of viral culture supernatants or naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN). Complementary DNA was synthesized using 10 µl of eluted RNA, 0.75 µM of a specific hMPV primer (Table 2, sequences ID Nos. 91, 97, 100, 102, 112), and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's
25 recommendations. Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of RT mixture and 18 µl of a reaction mixture containing 4 mM MgCl₂, 2 µl of Faststart DNA SYBR Green Master Mix,
30 3% DMSO, and 0.5 µM of each hMPV primer (Table 4: sequence ID Nos.: 92 and 94; 100 and 101; 97 and 98; 102 and 103; and 112 and 113, for the nucleoprotein (N),

matrix (M), fusion (F), phosphoprotein (P), and polymerase (L) genes respectively). Cycling conditions typically included an initial denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. However, the cycling conditions could slightly vary according to the hMPV gene to amplify.

5 Detection of hMPV amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a LightCycler instrument, the internal temperature was rapidly increased to 94°C then decreased to 60°C for 30 seconds, followed by slowly increasing to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture.

10

Using this procedure, the specific melting temperature obtained with the hMPV amplicons produced by the primers specific for target genes coding for N, M, F, P and L proteins was found to be 82.63°C ± 0.87°C, 82.75°C ± 0.80°C, 83.29°C ± 0.45°C, 80.48°C ± 0.46°C, and 77.99 ± 0.33°C, respectively. As shown in Table 5, a real-time

15 PCR assay using primers complementary to the N gene successfully amplified RNA from all 20 cultures and 10 clinical specimens. In contrast, hMPV primers specific for the M, F, P, and L genes had sensitivities of only 70%, 63.3%, 50%, and 89.7% respectively. Thus, primers aimed at amplifying the hMPV N gene appear to target more conserved regions of the hMPV genome and, consequently, were selected for

20 further detailed evaluation (see example 2).

Example 2: Validation of a real-time PCR assay for the hMPV nucleoprotein (N) gene in a pediatric population

25 An hMPV N plasmid was constructed by subcloning the amplified hMPV N region in the plasmid pDrive (QIAGEN, Mississauga, ON, Canada). The new plasmid was transcribed using the RNA Transcription Kit (Stratagene, Vancouver, BC, Canada) for sensitivity analysis. Using the previously described RT procedure (N primer, sequence ID No. 91) and real-time PCR protocol (N primers, sequence ID Nos. 92

30 and 94) reported in example 1, the sensitivity of the assay was estimated at 100 copies per reaction with a specific melting temperature of 82 °C. The assay was found to be

specific with no amplification signal observed when viral cultures positive for the human respiratory syncytial virus, the parainfluenza viruses, the influenza viruses A and B, and the adenoviruses were tested. The real-time PCR assay for the hMPV N gene was subsequently validated in a prospective case-control study in children below the age of 3 years hospitalized at Laval University Hospital Center (CHUQ-CHUL) in Québec City, Canada, during the winter season of 2001-02. Cases consisted of children hospitalized for a respiratory syndrome whereas controls consisted of children hospitalized during the same period for a surgery with no respiratory symptoms. At admission, a nasopharyngeal aspirate was collected for viral antigen tests, viral cultures, and RT-PCR studies for influenza A and B viruses, the human respiratory syncytial virus (hRSV), and the hMPV N gene.

No virus was detected in any of the samples from the 51 control children. Among the 208 cases tested by real-time PCR for hMPV, hRSV, influenza A and B viruses, the positivity rates were 5.8%, 51.0%, 21.6%, and 0%, respectively. Viral culture was positive for hMPV in only 2 cases whereas the real-time hMPV PCR assay for the N gene was positive for 12 cases including the 2 positive by viral culture. All positive hMPV PCR results for the N gene were confirmed by a second PCR assay targeting the hMPV fusion (F) gene and by the use of DNA sequencing which indicated the presence of multiple hMPV strains clustering in the two previously-reported F genotypes. Thus, the real-time PCR assay described in this invention appears to be much more sensitive than conventional viral culture for the detection of hMPV in clinical samples.

Example 3: Typing of hMPV clinical strains using restriction enzyme analysis

We designed a rapid molecular typing method for hMPV epidemiological studies based on amplification of a portion of the fusion (F) gene which is then digested with specific restriction enzymes. Briefly, a 759-bp fragment of the hMPV F gene was amplified by a real-time PCR procedure as described in example 1 using specific primers (sequence ID Nos. 97 and 98). After PCR amplification, two aliquots (10 uL) of the PCR product were digested during 2 hours at 37°C with 10 units of ApaI and 4 units of Avr II (New England Biolabs, Mississauga, ON, Canada) according to the manufacturer's recommendations. Digested products were then loaded on an 1% agarose gel for electrophoresis.

Table 6 summarizes the size of the F fragments obtained for different hMPV isolates following enzymatic digestion and the corresponding genotype as defined by DNA sequencing and phylogenetic studies. In brief, all hMPV isolates belonging to the genotype F-I were digested by ApaI (fragments of 532 and 227 bp) but not by Avr II whereas those belonging to the genotype F-II were digested by Avr II (fragments of 447 and 312 bp) but not by ApaI (see Figure 2 for an example of the band pattern following electrophoresis on an agarose gel).

Example 4 : A prospective case-control study for defining the role of respiratory viruses in children hospitalized for acute respiratory tract infectionsSummary

The human metapneumovirus (hMPV) is a new paramyxovirus recently isolated from young children with respiratory syndromes. The objectives of this study were to estimate the relative contribution of hMPV in children's hospitalization for acute respiratory tract infections (ARTI) and to define its clinical presentation and seasonal pattern.

We evaluated the percentage of hospitalizations for ARTI in children aged 0-3 years attribute to hMPV and other respiratory viruses in a prospective case-control study during the winter/spring seasons of 2002. We used multiplex real-time PCR assays and other conventional diagnostic methods to detect hMPV, the human respiratory syncytial virus (hRSV), and the influenza viruses in nasopharyngeal aspirates of children.

hMPV was detected in 12 (5.8%) of the 208 children hospitalized for ARTI as compared to 118 (56.7%) for hRSV and 49 (23.6%) for influenza A. In contrast, none of the 51 controls harbored any of the respiratory viruses. Most hRSV and influenza infections occurred in January and February whereas the peak hMPV activity was in March and April. The peak age for hospitalizations for hRSV and hMPV infections was < 3 months and 3-5 months, respectively. Diagnoses of bronchiolitis and pneumonitis were made in respectively 67% and 17% of hMPV-infected children compared to 84% and 25% for those with hRSV infection. None of the hMPV-infected children was admitted to the intensive care unit compared to 15% for those with hRSV or influenza A infections.

hMPV causes significant morbidity in young children and its clinical presentation is similar although less severe than that of hRSV.

Introduction

The human metapneumovirus (hMPV) is the first human member of the new *Metapneumovirus* genus within the *Paramyxoviridae* family (van den Hoogen BG, de Jong JC, Groen J, et al. Nat Med 2001;7:719-24; van den Hoogen BG et al. Virology 2002;295:119-32.) The human respiratory syncytial virus (hRSV) belongs to a separate genus within the same family (Taxonomy V. Seventh Report of the International Committee on Taxonomy of Viruses. Academic, San Diego, 2000.).

hMPV has been recently identified in nasopharyngeal aspirates of children and adults suffering from a range of respiratory tract infections in various parts of the world (van

den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Nissen MD, et al. *Med J Aust* 2002;176:188; Peret TC, Boivin G, Li Y, et al. *J Infect Dis* 2002;185:1660-3; Stockton J, et al. *Emerg Infect Dis* 2002;8:897-901). The clinical syndrome of the infected children encompasses mild respiratory problems to bronchiolitis and pneumonitis (van den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Pelletier G, et al. *Emerg Infect Dis* 2002;8:976-8; Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4).

Using reverse-transcription polymerase chain reaction (RT-PCR), the rate of hMPV detection in nasopharyngeal aspirates (NPA) of pediatric patients with unexplained ARTI varied between 1.5 and 10% (van den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Nissen MD, et al. *Med J Aust* 2002;176:188). These retrospective studies are small, excluded patients who tested positive for other viruses, only superficially describe the clinical features of the disease and lack morbidity/mortality data. In absence of a control group, these studies cannot differentiate if hMPV is a colonizing or a pathogenic virus. More recently, Stockton et al. identified hMPV RNA in 2.2% of 405 specimens from patients with influenza-like illnesses who consulted general practitioners in England although few swabs were collected from children < 5 years (Stockton J, et al. *Emerg Infect Dis* 2002;8:897-901).

The objectives of this study were to estimate the relative contribution of hMPV in children's hospitalization for acute respiratory tract infections (ARTI) and to define its clinical presentation and seasonal pattern.

Materials and Methods

Study design. Participants were children aged ≤ 3 years hospitalized between December 15, 2001 and April 20, 2002 at Laval University Hospital Center (CHUQ-CHUL) in Québec City, Canada. Cases were admitted for an ARTI (bronchiolitis, pneumonitis, laryngotracheobronchitis, etc...) whereas controls were hospitalized for an elective surgery and had no respiratory symptoms or fever. Children hospitalized twice were counted as two cases. At admission, after signed consent was obtained from their parents, all children had an NPA (1-2 ml) collected and tested for hRSV antigen (TestPack, Abbott Laboratories, Abbott Park, IL). The specimen was frozen at -80°C until subsequent RT-PCR studies. Additionally, viral cultures, direct immunofluorescence staining, and microbiological testing were performed according to the treating physician. A standardized questionnaire was completed at admission by a single research nurse with the parents. At the end of the hospitalization, the children's charts were reviewed to collect clinical and laboratory data. The study was approved by the CHUQ-CHUL research ethics board.

RNA extraction and cDNA synthesis. Viral RNA was extracted from 200 μl of NPA specimens using the QIAamp viral RNA Mini Kit (QIAGEN, Mississauga, ON, Canada). Complementary cDNA was synthesized using 10 μl of eluted RNA and the Omniscript Reverse Transcriptase kit (QIAGEN). Random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada) were used in the RT step of the multiplex respiratory PCR assay whereas a specific primer (5'-TGGGACAAGTGAAAATGTC-3') serves to synthesize hMPV cDNA in a separate PCR assay. An internal control (300 copies) consisting of a 534-bp transcribed region of the pDrive plasmid (QIAGEN) flanked by influenza B complementary primer sequences (see below) was spiked in the RT reaction of the multiplex respiratory PCR assay to verify the presence of PCR inhibitors.

RT-PCR assays and phylogenetic studies. The multiplex respiratory PCR assay was designed to amplify conserved regions of the influenza A (SEQ. ID Nos.139-140) (Fouchier RA, et al. J Clin Microbiol 2000;38:4096-101) and B (SEQ. ID Nos. 141-

142) (Li J, Chen S, Evans DH. *J Clin Microbiol* 2001;39:696-704) matrix genes as well as the fusion gene of hRSV (SEQ. ID Nos. 143-144) (Mazzulli T, Peret TC, McGeer A, et al. *J Infect Dis* 1999;180:1686-9).

- 5 Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, Québec, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 μ l including 2 μ l of cDNA and 18 μ l of a reaction mixture containing 2.4 mM MgCl₂, 2 μ l of Faststart DNA SYBR Green Master Mix, 3% DMSO, 0.3 mM
- 10 each of influenza A and B primers, and 0.8 mM of hRSV primers. The thermal cycling incubations consisted of an initial denaturation step at 94°C for 10 min, followed by 50 cycles of 15 s at 94°, 5 s at 58°C, and 25 s at 72°C. At the end of each cycle, the fluorescent signal was measured at a wavelength of 530 nm using the LightCycler Fluorimeter. The melting curve analysis program of the LightCycler was
- 15 used to identify specific PCR products of influenza A (T_m: 85°C), influenza B (T_m: 83°C), hRSV (T_m: 79°C), and the internal control (T_m: 92°C). The sensitivity of the multiplex respiratory PCR assay was estimated at 50 copies for each viral target when mixed with 300 copies of the internal control.
- 20 A specific PCR assay was designed for amplification of the hMPV Nucleoprotein (N) gene in the LightCycler instrument. The sequences of the forward (MPV-NCS) and reverse (MPV-NCA) primers were respectively 5'-GAGTCTCAGTACACAATTAA-3' (SEQ ID NO 92) and 5'-GCATTTCCGAGAACAACAC-3' (SEQ ID NO 94). The specific cDNA was amplified using conditions similar to those of the multiplex
- 25 respiratory PCR assay except that 0.5 mM of each primer was added to the master mix. Cycling conditions included an initial denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. The melting temperature of the amplified hMPV N fragment was 82°C and the sensitivity of the PCR assay was 100 copies. For phylogenetic studies, nucleotide sequences were
- 30 determined from amplified hMPV F (fusion) gene products then analyzed using the

neighbor joining algorithm and Kimura-2 parameters. (Boivin G, Abed Y, Pelletier G, et al. J Infect Dis 2002;186:1330-4).

- 5 **hMPV in the general population.** To further assess the seasonal distribution, affected age groups and frequency of hMPV, we compared data from the study to those of the general population derived from the viral cultures found positive for hMPV in our regional virology diagnostic laboratory, the only one performing viral cultures for the Québec City area (population approximately 600 000). Respiratory specimens were inoculated in 96-well plates containing ten cell lines (MDCK, LLC-10 MK2, Hep-2, human foreskin fibroblast, Vero, mink lung, A-549, rhabdomyosarcoma, 293, and HT-29) then incubated for a period of 21 days. A positive cytopathic effect was confirmed by immunofluorescence testing using monoclonal antibodies or by RT-PCR (hMPV).
- 15 Statistical analyses. Proportions were compared by the χ^2 test.

Results

The study population included a total of 208 hospitalized cases with ARTI (including 8 children who were admitted twice) and 51 children who served as controls.

20

Description of the study population and viral etiologies. The age distribution of children with ARTI is presented in Fig. 3: 56% (116) were male and 44% (92) were female. Hospitalization was the highest in infants ≤ 3 months of age and steadily decreased thereafter. Most (90%) children had no underlying medical conditions at admission.

25

All 208 cases had an NPA. The mean delay between the onset of symptoms and collection of NPA was 6 days (median 4 days). This delay did not differ for the different viruses detected. All 208 cases were tested by PCR, 204 had an hRSV

antigen detection test, 100 had a direct examination procedure for other viruses, and 100 had a viral culture. At least one respiratory virus was detected in 164 (79%) cases whereas none was detected in 44. Twelve children (5.8%) were positive for hMPV, 118 (56.7%) for hRSV, 49 (23.6%) for influenza A, and none for influenza B (Table 7). There was no PCR testing for adenoviruses and PIV type 2 but these two viruses were found in 6% and 2%, respectively, of the 100 viral cultures or antigenic assays. Single virus infections occurred in 141 (86%) of the 164 positive cases and mixed infection was present in 23 (14%). Two of the 12 hMPV infections were mixed (hMPV-influenza and hMPV-hRSV). The other combinations were hRSV-influenza A (18 cases), hRSV-adenovirus (2), and influenza A-adenovirus (1).

Among the 208 cases tested by PCR for hMPV, hRSV, influenza A and B viruses, the positivity rates were 5.8%, 51.0%, 21.6%, and 0%, respectively (Table 7). In addition, 16 other cases had one of the four latter respiratory viruses identified only by culture (3 influenza A and one hRSV), only by an antigen detection test (10 hRSV and one influenza A) or by both culture and antigen detection test (1 hRSV). Among the 8 children hospitalized twice, none had the same viral infection at both admissions. The combinations observed were hMPV – hRSV (2), hMPV – no virus (1), hRSV – no virus (2), hRSV – influenza (2), no virus – no virus (1).

The biweekly distribution of cases with respiratory tract viruses is shown in Fig. 4. hRSV and influenza A infections occurred predominantly between January and March, whereas hMPV infections occurred mostly in March and April. The proportion of children with virologically-confirmed respiratory tract infection decreased after February.

Clinical features of cases. The distribution of the age distribution by different viral infections is shown in Fig. 3. While the peak age for hMPV infection was 3-5 months, it was before 3 months for hRSV infection. For influenza A, it spread evenly during the first year of life. The peak age for mixed infection was 6-11 months and decreased thereafter. Gender was distributed evenly with each virus group but more males

(70%) had mixed viral infections. The majority (75% with hMPV, 93% with hRSV, 90% with influenza A virus infection) of the children in different etiological groups had no medical underlying conditions. Three (25%) children with hMPV infection had a cardiac disorder, one having concomitant cardiac, pulmonary, and neurological
5 problems.

Signs and symptoms recorded with the different respiratory viruses were generally similar except for the vomiting which occurs more frequently with hMPV infections ($p = 0.05$) (Table 8). The mean and median duration of hospitalization was similar for
10 hMPV, hRSV and influenza A viruses being respectively 5.5 and 4.5, 5.8 and 5.0, and 4.9 and 4.0 days. Of note, one third of hMPV-infected children were hospitalized more than 7 days. None of the children with hMPV infection was admitted to the intensive care unit (ICU) contrasting with 15% and 16% of children with hRSV and influenza A, respectively. There was no death as part of this study. The duration of the
15 hospitalization in children with no detectable virus was shorter than that in children with single or mixed infection (Kruskal-Wallis Test, $p < .0001$). Two-thirds of the children were given antibiotics during their hospitalization, independently of the etiology of their respiratory disease.

20 At hospital discharge, a final diagnosis of bronchiolitis was given to 67% of children with hMPV, 84% with hRSV, and 51% with influenza A ($p < 0.001$) (Table 9). Otitis occurred in about half of children with hMPV, hRSV, and influenza A infections. Pneumonitis was less frequently diagnosed in children with hMPV compared to those with hRSV or influenza A (17%, 25%, and 37%, $p=0.22$). Final diagnoses were
25 similar with single and mixed infections.

Controls. There were 51 children in the control group, 29 (56.9%) males and 22 (43.1%) females. The age distribution of the controls was similar to that of the cases (Fig. 3) as was the period of hospital admission (Fig. 4). None of the controls had a
30 virus detected by PCR.

hMPV in the general population. The regional virology laboratory received 1505 respiratory specimens for viral culture between January 1 and June 30, 2002. In total, 36 (including two study participants) or 2.9% were positive for hMPV: 24 (66.6%) in children < 2 years of age, 5 in those 2 to 4 years, 4 in adults 30-49 years, and 3 in those 70 years or older. Most cases (81%) were isolated over a two-month period (from March 23 to May 18) (Fig. 5). When comparing the seasonal distribution of hMPV in hospitalized children (study population) and in the general population, it appears that the study in hospitalized children did not cover the entire hMPV season as it was stopped just after the peak time of hMPV transmission (April 6-20).

10

Phylogenetic analyses of hMPV strains. The 12 hMPV strains isolated in the prospective study clearly clustered into two F lineages with nine strains belonging to group 1 and three to group 2 (Fig. 6). Seven of the 9 group 1 strains had identical F gene sequences. At the nucleotide level, there was 84-85% similarity between groups versus 98-100% (group 1) and 93-99% (group 2) similarity within groups. There were fewer differences at the amino acid level i.e. 94-96% similarity between groups versus 99-100% (group 1) and 98-99% (group 2) among strains within the same group. Although there was a trend for more recent strains to cluster in group 2, the correlation between genotypes and date of hospitalization was not perfect as two strains detected on the same day (No. 216 and 217) belonged to two different F lineages.

15
20

Discussion

Our prospective study has revealed important clinical and epidemiological features related to hMPV. First, our data indicate that hMPV is really a respiratory pathogen. Second, we found that it contributes to ARTI leading to children's hospitalization in proportion similar to adenoviruses or PIV but significantly less than hRSV and influenza viruses. Third, the symptoms and complications associated with hMPV were indistinguishable from those caused by hRSV. Finally, our results suggest that the epidemiology of hMPV infection in children may differ from that of hRSV and

25
30

influenza viruses both in terms of the age of first acquisition and in the timing of the seasonal epidemics.

Recent studies by our group (Pelletier G, et al. *Emerg Infect Dis* 2002;8:976-8; Boivin
5 G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4) and others (van den
Hoogen BG, de Jong JC, Groen J, et al *Nat Med* 2001;7:719-24.; Nissen MD et al.
Med J Aust 2002;176:188; Stockton J, et al. *Emerg Infect Dis* 2002;8:897-901) had
suggested that hMPV should be added to the list of human respiratory viral pathogens
(Dowell SF, Anderson LJ, Gary HE, Jr., et al. *J Infect Dis* 1996;174:456-62; Treanor
10 JJ. *Respiratory Infections*. In: Richman DD, Whitley, R.J., Hayden, F.G., ed. *Clinical
Virology*. Vol. 1. Washington: ASM Press, 2002:7-26).

The absence of hMPV in respiratory tract of our 51 control children, the absence of
other respiratory viruses in 83% of the 12 hMPV-infected children and the severity of
15 their symptoms (bronchiolitis and/or pneumonitis) provide further evidence that
hMPV is really a pathogenic respiratory virus. The absence of underlying medical
conditions in 75% of the hMPV-infected children further demonstrates its
pathogenicity. The use of PCR assays was particularly advantageous for hMPV
because its growth in culture is fastidious and limited to a few permissive cell lines
20 (Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4) and because
rapid antigenic detection tests are currently unavailable.

Our study provides for the first an estimate of the proportion of ARTI hospitalizations
attributable to hMPV in a pediatric population. During the period ranging from
25 December 15 to April 20 2002, hMPV accounted for 5.8% of all hospitalizations for
respiratory tract infections in children aged 0-3 years. This underestimates the real
proportion as our hospitalization study stopped before the end of the hMPV season
prevailing in the community (Fig. 5). Although we did not perform PCR testing for
adenoviruses and PIV, the percentage of hospitalizations caused by hMPV seems
30 similar to that attributable to these two viruses and much smaller than that of hRSV or
influenza A.

One of the most important conclusion of our study is that hMPV disease cannot be distinguished on clinical findings from that caused by hRSV and influenza A (Tables 8 and 9) but tended to be somewhat less severe with fewer pneumonia and no admission in the ICU. Nevertheless, hMPV infection was associated with a significant clinical and economical burden as shown by a mean hospital stay of 5.5 days and one-third of hMPV-infected cases being hospitalized for > 7 days.

A small serological study from the Netherlands showed that all children over the age of 5 years had hMPV antibodies suggesting a high level of transmission.¹ Data from our study suggest that morbidity caused by hMPV is greatest in children < 2 years of age as they represented 83% (10/12) of our hospitalized cases and two-thirds of the hMPV isolates recovered in our diagnostic virology laboratory. This suggests that similar to other paramyxoviruses such as hRSV, the morbidity of hMPV in children occurs through primo-infection. In contrast to hRSV which peaked during the first three months of life, hMPV infections peaked at a slightly older age i.e. between the third and fifth month of life. Whether this difference depends on a longer persistence of maternal antibodies or a less efficient transmission mode in the case of hMPV would require additional studies.

20

During the 4-week period from mid-March to mid-April, hMPV infections clustered (11/12 detected) and accounted for 18.9% of all hospitalizations for ARTI in children. This contrasts with hRSV and influenza A which occurred mostly in January and February (Figure 4). Based on passive surveillance data from our regional virology laboratory, the peak time of hMPV transmission in the community occurred between April 6-20, 2002, and continued beyond the end of our study in hospitalized children (Fig. 5). Year-long active surveillance studies will be required to better assess the seasonal patterns of hMPV transmission.

25

As described for hRSV (Mazzulli T, Peret TC, McGeer A, et al J Infect Dis 1999;180:1686-9), several strains of hMPV circulated during a very short period of

time (one month) in our study area. The hMPV strains segregated into two F subgroups in agreement with previous studies although one strain clearly predominated accounting for 58.3% of all isolates (van den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Peret TC, Boivin G, Li Y, et al. *J Infect Dis* 2002;185:1660-3; Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4).

Due to the small number of hMPV strains belonging to one of the F subgroup, we did not attempt to correlate hMPV genotype with clinical outcome. Such viral heterogeneity may allow multiple reinfections throughout life especially in elderly subjects and immunocompromised patients (Pelletier G, Dery P, Abed Y, Boivin G *Emerg Infect Dis* 2002;8:976-8).

In conclusion, our study supports the concept of the epidemic nature of hMPV infection and establishes its role as a significant pathogen in severe ARTI of children.

Example 5: Determination of the hMPV Load in Clinical Samples Using Quantitative Real-time PCR

An evaluation of a quantitative real-time PCR hMPV assay using a TaqMan probe was performed using naso-pharyngeal aspirate specimens collected from children and adults in Québec City during the winter seasons of 2001-02 and 2002-03. Viral RNA was first extracted from 200 µl of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN) and eluted in a volume of 40 µl. Serial concentrations (5X10² to 1X10⁹ copies) of a transcribed hMPV plasmid were used to construct the standard curve of the assay. Complementary DNA was synthesized using 10 µl of eluted RNA from clinical samples or hMPV plasmid dilutions, 50 ng (0.75 µM) of random hexamer primers (Amersham Pharmacia Biotech), 0.5 mM of dNTPs, 1X Omniscript buffer and 4 units of the Omniscript reverse transcriptase (QIAGEN) in a final volume of 20 µl. The reverse transcription (RT) mixture was incubated during 1.5 hr, at 37°C and inactivated at 70°C during 10 min. Complementary DNA was amplified by real-time PCR with a TaqMan probe for the hMPV L gene and the LC

Master Hybridization Probe Mix (Roche Diagnostics) in a LightCycler instrument (Roche Diagnostics). Each reaction had a volume of 20 μ l including 2 μ l of RT mixture, 4 mM MgCl₂, 0.3 μ M of specific hMPV L primers (sequence ID Nos. 112 and 114), 0.6 μ M of a specific hMPV L probe (SEQ. ID. No. 127), and 2 μ l of the LC Master Hybridization Probe Mix (Roche Diagnostics). Cycling conditions included an initial denaturation step of 30 s at 94°C, followed by 60 cycles of 5 s at 94°C, 5 s at 56°C, and 25 s at 72°C. A fluorescence lecture was taken after each elongation step (Fig. 9A). A standard curve for the PCR reaction was constructed by plotting cycle threshold values against log concentrations of each hMPV plasmid dilution. The number of hMPV copies present in clinical samples was calculated by interpolating cycle threshold values into the assay's standard curve (Fig. 9B).

Example 6: Determination of hMPV genotypes based on amplification and sequencing of the viral F and G genes.

Determination of hMPV genotypes was achieved by PCR amplification of the F or G genes followed by DNA sequencing of the viral amplified products. Different sets of primers were used for PCR amplification and DNA sequencing of the F (SEQ. ID. Nos. 97 and 98) and G (SEQ. ID. Nos. 104 and 107 or 108 and 109) genes. Alignment of viral DNA sequences was done with the CLUSTAL W software version 1.7 for Unix and phylogenetic trees were computed by maximum parsimony, distance and maximum likelihood-based criteria analysis using PAUP version 4.0.d8. Phylogenetic trees for both the F (Fig. 10A) and G (Fig. 10B) genes from Canadian and non-Canadian viral isolates revealed the existence of two hMPV groups (genotypes A and B) with two subgroups (subtypes 1 and 2) within each group.

Example 7: Comparison of viral culture and multiplex PCR assay for detection of influenza A virus.

A multiplex PCR assay (including PCR primers defined in SEQ. ID. Nos. 139, 140, 141, 142, 143, and 144) aimed at detecting influenza A and B viruses and the respiratory syncytial virus was used to assess the etiology of severe acute respiratory

tract infections (ARTI) necessitating hospitalization in children aged 0-3 years during the winter season 2001-02 at the CHUL, an university-based hospital, in Québec City (Canada). Nasopharyngeal (NPA) samples from all 208 children with ARTI were tested by multiplex PCR whereas a subset of 100 NPA specimens was inoculated on

5 Madin Darby Canine Kidney (MDCK) cells for influenza culture. Briefly, viral RNA was prealably extracted from 200 µl of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). cDNA was then synthesized using 10 µl of the RNA preparation, 0.75 µM of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), 300 copies of an internal

10 control template, and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's instructions. The internal control template consisted of a 558-bp transcribed region of an herpes simplex virus type 2 DNA polymerase region flanked by influenza B complementary primer sequences cloned into the pDrive plasmid (QIAGEN). cDNA was amplified using a

15 real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of complementary DNA and 18 µl of a reaction mixture containing 4 mM MgCl₂, 2 µl of LC Faststart DNA SYBR Green Master 1 Mix, 3% DMSO, 0.3 µM of influenza A

20 and influenza B primers, and 0.8 µM of human respiratory syncytial virus primers (Table 10). Cycling conditions included an initial denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. Detection of viral amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a

25 LightCycler, the reaction temperature was rapidly increased to 94°C and was then decreased to 60°C for 30 seconds followed by a slow increase to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture. Using this procedure, the amplified products of influenza A, influenza B, hRSV, and the internal control could be differentiated by virtue of their specific T_m values i.e. 85, 83, 79, and 91°C,

30 respectively (Table 13 and Fig. 11).

Influenza A virus was detected by multiplex PCR (specific T_m value of 85°C) in 45/208 (21.6%) of the samples tested whereas the culture was positive for this virus in 14/100 (14%) tested NPA samples from children. For the subset of 100 NPA specimens tested by both methods, 88 (88%) had concordant results (11 positive, 77
5 negative) whereas discordant results were obtained for 12 (12%) samples (3 culture⁺/PCR⁻, 9 culture⁻/PCR⁺). Assuming that all positive results (by either culture or PCR) were true positive, the sensitivity values of the culture and the multiplex PCR for influenza A virus were 60.9% and 87.0%, respectively. There was no positive result for influenza B virus by any detection method as part of this study.

10

Example 8: Comparison of antigen detection and multiplex PCR assay for detection of the human respiratory syncytial virus.

Same as example 1, except that the multiplex PCR assay was used to detect hRSV
15 from NPA samples obtained from 211 children with ARTI and compared with an antigen detection test for hRSV (TestPack, Abbott Laboratories, Abbott Park, IL).

hRSV was detected by the multiplex PCR (specific T_m value of 79°C) in 109/211 (51.7%) of the tested samples whereas the hRSV antigen detection test was positive in
20 93/211 (44.1%) tested NPA samples from children. Concordant results were found in 183 (86.7%) samples (87 positive, 96 negative) whereas discordant results were obtained for 28 (13.3%) samples (6 antigen⁺/PCR⁻, 22 antigen⁻/PCR⁺). A second RT-PCR assay for detection of another hRSV gene (glycoprotein G) was used to resolve the discrepancies (Peret et al., 1998, J Gen Virol.79:2221-2229). After the resolution
25 of the discrepant results, the sensitivity values of the antigen detection test and the multiplex PCR for hRSV were 80.5% and 96.5%, respectively.

Example 9: Evaluation of multiplex real time PCR assay for Influenza and human respiratory syncytial viruses.

We developed a real-time multiplex PCR assay for influenza viruses and HRSV using the melting curve analysis feature of the LightCycler instrument to rapidly distinguish viral products.

Materials and methods

Study population and antigenic test. Nasopharyngeal aspirates (NPA) were prospectively collected from children aged 0-3 years hospitalized for ARTI during the winter season 2001-02 at a single, university-based hospital, in Québec City (Canada) (Boivin, G., et al. 2003. *Emerg. Infect. Dis.* 9:634-640). The study was approved by the institutional review board of the Centre Hospitalier Universitaire de Québec. All samples were tested by the multiplex real-time PCR assay whereas antigen detection tests were performed on a subset of samples upon request by the treating physician. An aliquot (750 µl) of fresh NPA was first tested for the presence of HRSV and influenza A/B antigens using respectively the RSV TestPack (Abbott Laboratories, Abbott Park, IL) and the Directigen Flu A+B test (Becton Dickinson, Sparks, MD). The rest of the specimen was frozen at -80°C for a maximum of 3 months before nucleic acid extraction and PCR testing.

RNA extraction and cDNA synthesis. Viral RNA was extracted from 200 µl of NPA samples using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). Complementary DNA was then synthesized using 10 µl of the RNA preparation, 0.75 µM of random hexamer primers (Amersham Pharmacia Biotech, Bale d'Urfé, QC, Canada), and the Omniscript Reverse Transcriptase kit (QIAGEN) in presence of 300 copies of an internal control. The internal control template consisted of a 558-bp transcribed region of the herpes simplex virus type 2 DNA polymerase gene flanked by influenza B complementary primer sequences (see below) cloned into the pDrive plasmid (QIAGEN).

Real-time multiplex and conventional PCR assays. The multiplex PCR respiratory assay was designed to amplify conserved regions of the influenza A (Fouchier, R. A., et al. . 2000.. *J. Clin. Microbiol.* 38:4096-4101) and B (Li, J., S. Chen, and D. H. Evans. 2001.. *J. Clin. Microbiol.* 39:696-704) matrix genes as well as the fusion gene of HRSV (Mazzulli, T., et al, 1999. *J. Infect. Dis.* 180:1686-1689). Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of cDNA and 18 µl of a reaction mixture containing 2.4 mM MgCl₂, 2 µl of Faststart DNA SYBR Green 1 Master Mix, 3% DMSO, 0.3 mM of influenza A and B primers (SEQ. ID Nos. 139-140 and 141-142), and 0.8 mM of HRSV primers (SEQ. ID Nos. 143-144). Cycling conditions included an initial denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. At the end of each cycle, the fluorescent signal was measured at a wavelength of 530 nm using the LightCycler Fluorimeter. The melting curve analysis program of the LightCycler was used to identify specific PCR products. Briefly, following the last amplification cycle, the reaction temperature was rapidly increased to 94°C and was then decreased to 60°C for 30 s followed by a slow increase to 94°C at a rate of 0.1°C per s, with continuous fluorescence monitoring. For resolution of discrepant results between the multiplex PCR assay and antigenic tests, conventional RT-PCR assays for detection of the glycoprotein G gene of HRSV (Peret, T. C., et al. 1998. *J. Gen. Virol.* 79:2221-2229) and the M2 gene of influenza A viruses (Klimov, A. I., et al. . 1995. *J. Infect. Dis.* 172:1352-1355) were performed retrospectively.

25 Results

Assay's characteristics. The sensitivity of each individual real-time PCR assay and of the multiplex PCR respiratory assay was determined for each target by testing serial dilutions of transcribed plasmids containing specific viral sequences. The lower limit of detection for influenza A, influenza B, and HRSV was found to be 10, 50 and 30 50 copies, respectively, in individual PCR assays whereas it was 50 copies for each target (10 out of 10 times for influenza A and 9 out of 10 times for influenza B and

HRSV) in the multiplex PCR test. No amplification signal was detected in the real-time multiplex assay when testing viral DNA or RNA from adenoviruses, rhinoviruses, enteroviruses (echo 11), parainfluenza viruses 1-3, human metapneumovirus, and herpesviruses (herpes simplex virus type 1 and 2, cytomegalovirus, and varicella-zoster virus). Specific melting temperature (T_m) values were first determined by testing a set of clinical isolates and vaccine strains (11 influenza A/H1, 10 influenza A/H3, 10 influenza B, and 17 HRSV) from different years (Table 14). A representative set of results is shown in Fig.11. The mean T_m values were 85.27 ± 0.22 , 83.47 ± 0.46 , and 79.51 ± 0.30 °C for influenza A, influenza B, and HRSV corresponding to fragments of 245, 524, and 380 bp, respectively, after gel electrophoresis (Table 14). We found no influence of influenza A subtype (H1 and H3) and HRSV genotype (A and B) on the T_m values (Table 14). The addition of 300 copies of the internal control in the assay's master mix resulted in a specific amplification peak with a T_m value of 91°C (558 bp) in the absence of amplified viral products.

Evaluation of the multiplex PCR respiratory assay in a pediatric population. The multiplex PCR assay was evaluated using extracted RNA from 208 NPA samples collected during a prospective pediatric study aimed at assessing the role of the human metapneumovirus in hospitalized children (0-3 years) with ARTI (Boivin, G., et al. 2003. *Emerg. Infect. Dis.* 9:634-640). The number of positive samples by multiplex PCR for influenza A, influenza B, and HRSV was found to be 45 (21.6%), 0 (0%), and 106 (51.0%), respectively. Overall, the rate of positivity for any of the 3 viruses was 66.8% (139/208) including 5.8% (12/208) of co-infections with influenza A and HRSV. None of the samples was considered to contain PCR-inhibitory samples as verified by the amplification of the internal control in all PCR-negative samples. The ranges of T_m values for influenza A- and HRSV-positive samples were 85.10 ± 0.39 and 79.60 ± 0.42 °C, respectively. All amplified products with one of the latter T_m values were confirmed as specific viral targets by visualizing the appropriate band on agarose gel. As none of the samples contained influenza B virus sequences (which correlates with the very occasional isolation of influenza B viruses in the Québec City

area during the 2001-2002 season), a clinical evaluation of the multiplex PCR assay was conducted for influenza A and HRSV only.

Evaluation of the multiplex PCR respiratory assay for detecting influenza A virus. From the 208 NPA evaluated by multiplex PCR, a subset of 172 samples were also tested for the presence of influenza antigens using the Directigen Flu A+B test (Table 15). Concordant results were obtained for 145 (84.3%) samples including 17 positive and 128 negative results by the two tests. A total of 27 (15.7%) samples showed discordant results with 25 being positive by the multiplex PCR assay only and two positive by the antigenic test only. In order to resolve the discrepant results, a second RT-PCR test targeting a conserved gene (M2) of influenza A viruses was performed as reported (Klimov, A. I., et al. . 1995. *J. Infect. Dis.* 172:1352-1355). As shown in Table 15, influenza A virus M2 sequences were detected by the conventional RT-PCR assay in 22 (81.5%) of the 27 discordant samples. Using the M2 RT-PCR assay as the reference test, the sensitivity, specificity, positive predictive and negative predictive values of the multiplex real-time PCR assay and the antigenic test for influenza A virus were 100%, 97.7%, 92.8%, 100% and 43.6%, 98.5%, 89.5%, 85.6%, respectively. The multiplex PCR respiratory assay was positive for HRSV in 12 (44.4%) of the 27 discordant influenza A samples with 10 of these samples showing dual HRSV/influenza A infections by the multiplex PCR assay (Table 16). The mean cycle threshold (C_T) values, which are inversely correlated with the amounts of viral RNA, were 28.1 and 33.0 for PCR-positive/antigen-positive and PCR-positive/antigen-negative samples, respectively (Table 16). These values correspond to approximately 5000 and 50 copies, respectively, when a specific influenza A plasmid was tested in the multiplex PCR assay.

Evaluation of the multiplex PCR respiratory assay for detecting HRSV. A total of 204 NPA samples could be evaluated by both the multiplex real-time PCR assay and the presence of HRSV antigens using the RSV TestPack (Table 17). Concordant results were found in 172 (84.3%) samples including 83 positive and 89 negative results by the two tests. Thirty-two (15.7%) samples had discordant results with 21

being positive by the multiplex PCR assay only and 11 by the antigenic test only. Conventional RT-PCR tests for the HRSV glycoprotein G (A and B subtypes) were performed as previously described (Peret, T. C., et al. 1998. *J. Gen. Virol.* 79:2221-2229) to resolve discrepant results. Specific sequences were detected by RT-PCR assays for the HRSV glycoprotein G gene in 26 (81.2%) of the 32 discordant samples including 11 A and 15 B strains (Table 18). Using the latter test as "gold standard", the sensitivity, specificity, positive predictive and negative predictive values of the multiplex real-time PCR assay and the antigenic test for HRSV were 94.5%, 98.9%, 99.0%, 94.0% and 81.6%, 94.7%, 94.7%, 81.8%, respectively. Four (66.7%) of the six false-negative HRSV results by multiplex PCR were positive for influenza A (Table 18). The mean C_T values of the PCR-positive/antigen-positive and PCR-positive/antigen-negative samples were 28.6 and 32.7, respectively (Table 18). These values correspond to approximately 1000 and 100 copies, respectively, when a specific HRSV plasmid was tested in the multiplex PCR assay.

15

Discussion

In this report, we describe a new multiplex real-time PCR assay for the most commonly detected respiratory viral pathogens, namely influenza viruses (A and B) and HRSV. The key features of this novel assay include its rapidity (turnaround time of approximately 2h30 including 30 min for sample preparation, 60 min for RT and 60 min for real-time PCR including viral identification), and its sensitivity (50 copies per assay for each viral target). Our results clearly demonstrate that our multiplex real-time PCR assay is more sensitive than commercially-available antigenic detection tests for both influenza A and HRSV with the greatest difference in sensitivity noted for influenza viruses.

25

Multiplex RT-PCR assays targeting up to nine different respiratory pathogens have been previously reported (Fan, J., K. J. Henrickson, and L. L. Savatski. 1998. *Clin. Infect. Dis.* 26:1397-1402, Grondahl, B., et al. 1999. *J. Clin. Microbiol.* 37:1-7, Kehl, S. C., et al. 2001. 39:1696-1701, Osiowy, C. 1998. *J. Clin. Microbiol.* 36:3149-3154, Stockton, J., et al. . 1998. *M J. Clin. Microbiol.* 36:2990-2995, Valassina, M., A. M.

30

Cippone, M. G. Cusi, and P. E. Valensin. 1996. *Clin. Diag. Virol.* 8:227-232). More recently, a TaqMan-based real-time PCR assay for simultaneous detection of influenza A and B viruses has also been described (van Elden, L. J., et al. 2001. *J. Clin. Microbiol.* 39:196-200). Compared to conventional multiplex PCR assays, our
5 real-time PCR test is much more rapid because it avoids additional nested amplification and/or hybridization steps required for identification of viral products. Furthermore, the real-time amplification procedure minimizes the chances of contamination because there is no post-PCR processing of the samples. Although our multiplex real-time PCR assay based on melting curve analysis of amplicons does not
10 permit absolute quantification of the viral targets as in the TaqMan PCR procedure (van Elden, L. J., et al. 2001. *J. Clin. Microbiol.* 39:196-200), it allows for a larger number of viral targets to be simultaneously detected since there is no limitation related to the capability of the system to detect multiple dyes linked to detection probes with distinct emission wavelengths. Eventually, more than three viral targets
15 could be simultaneously detected in the LightCycler assay assuming the absence of interaction between PCR primers and a reproducible and discriminative T_m value for each viral amplicon.

Evaluation of our multiplex real-time PCR assay in a pediatric population with severe
20 ARTI clearly illustrated its clinical potential. Indeed, our assay identified a viral pathogen (influenza or HRSV) in two-thirds of the hospitalized children. These numbers are similar to the ones previously reported by our group in the same population using individual real-time assays for these viral pathogens (Boivin, G., et al. 2003. *Emerg. Infect. Dis.* 9:634-640). Notably, we were able to show that 6% of
25 hospitalized children had dual viral infections, a finding that has been reported albeit at a lower frequency by other investigators (Grondahl, B., et al. 1999. *J. Clin. Microbiol.* 37:1-7, Kehl, S. C., et al. 2001. 39:1696-1701, Osiowy, C. 1998. *J. Clin. Microbiol.* 36:3149-3154). Rapid identification of these viral pathogens (influenza and HRSV) is of paramount importance for isolation purposes in the hospital setting and early institution of specific antiviral therapy (Whitley, R. J., et al. 2001. *Pediatr. Infect. Dis. J.* 20:127-133). We are currently designing additional multiplex assays
30

based on the same technology to cover the whole spectrum of respiratory pathogens including parainfluenza viruses (PIV), adenoviruses, enteroviruses, and coronaviruses (Treanor, J. 2002. Respiratory Infections, p. 7-26, In Richard J. Whitley, Douglas D. Richman and Frederick G. Hayden (eds.). Clinical Virology, 2nd ed. ASM Press. Washington, D.C.). To this list, we should also add the recently described human metapneumovirus which has been reported by our group and others in up to 10% of ARTI in hospitalized children (Boivin, G., et al, 2003. Emerg. Infect. Dis. 9:634-640, Jartti, T., B. van den Hoogen, R. P. Garofalo, A. D. Osterhaus, and O. Ruuskanen. 2002.. Lancet. 360:1393-1394, Nissen, M. D., et al 2002. Med. J. Aust. 176:188, van den Hoogen, B. G., J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A. Fouchier, and A. D. Osterhaus. 2001.. Nat. Med. 7:719-724):

A specific evaluation of the real-time multiplex PCR assay for influenza A revealed that it was twice as sensitive as the rapid antigen detection test in use at our institution during the winter season of 2001-2002. None of the two PCR-negative, antigen-positive samples were confirmed by a second PCR targeting another conserved gene (M2) of influenza A whereas most (22/25, 88.0%) multiplex PCR-positive, antigen-negative were. In general, the false-negative antigenic test results could be explained by low amounts of viral RNA in those NPA samples as demonstrated by high C_T values in the corresponding real-time PCR assays. Three multiplex PCR test results were not confirmed by the influenza A M2 PCR test and were thus considered false-positive results. However, as we have not formally evaluated the sensitivity of the M2 PCR test and since viral cultures were not routinely done, we cannot rule out the possibility that such discrepant results were indeed true positive. We and other investigators have shown the superiority of RT-PCR tests over conventional methods (antigenic tests and viral culture) for detecting influenza viruses in clinical samples including those sent to the laboratory by mail (Boivin, G., I. Hardy, and A. Kress. 2001. J. Clin. Microbiol. 39:730-732, Ellis, J. S., D. M. Fleming, and M. C. Zambon. 1997. 1996. J. Clin. Microbiol. 35:2076-2082, Kehl, S. C., et al. 2001. 39:1696-1701, Steininger, C., et al. 2002. J. Clin. Microbiol. 40:2051-2056, van Elden, L. J., et al. 2001. J. Clin. Microbiol. 39:196-200). It is now common procedure at our institution

to confirm any negative antigenic tests results for influenza A and B by either viral culture or RT-PCR considering the high specificity but relatively poor sensitivity of the former assays.

5 For HRSV, the multiplex real-time PCR assay was also found to be more sensitive (by approximately 15%) than the rapid antigenic test when a second RT-PCR assay for the HRSV gG gene was used to resolve the discrepancies. Most of the false-negative antigenic test results could be explained by low amounts of viral RNA in the NPA samples as shown by mean C_T values of 32.7 for discordant results compared to
10 28.6 for concordant positive results. The specificity of the multiplex assay was excellent with only one positive result not confirmed by the second PCR test. In contrast, the multiplex PCR assay missed six cases of HRSV which tested positive in both the antigenic test and the second PCR assay for HRSV gG. Notably, four of those six samples tested positive for influenza A in the multiplex PCR assay. Thus,
15 although our multiplex PCR test has the capability of detecting dual infections (as seen in 6% of our cases), it is possible that high amounts of one virus could inhibit amplification of other pathogens. It is noteworthy that the multiplex PCR assay had the ability to amplify both HRSV genotypes as shown by the detection of 15 B and 11 A genotypes using specific PCR assays aimed at detecting variable regions of the
20 HRSV gG gene (Mazzulli, T., et al, 1999. *J. Infect. Dis.* 180:1686-1689). Although the rapid antigenic test had a relatively good performance (sensitivity: 82%, specificity 95%) for detection of HRSV in young children, the real advantage of PCR probably resides in the adult population where viral titers are lower and where antigenic tests are not recommended with upper respiratory tract samples (Englund, J.
25 A., et al 1996.. 34:1649-1653).

There are some limitations to our study which are worth mentioning. First, the absence of circulation of influenza B viruses during the study period prevents adequate validation of our multiplex assay for this pathogen and in particular for its
30 ability to detect mixed (influenza B and HRSV) infections. Second, the performance of our multiplex PCR assay cannot be generalized to other types of samples (throat

swabs, sputum) and to other populations (outpatients, adults) at the present time. Also, the absence of serological testing in our study may have underestimated the rate of viral infections especially for those children who presented late after the onset of symptoms. Finally, although it was relatively easy to discriminate between the different viral pathogens based on their specific T_m values only (Table 14), we sometimes had to confirm viral amplicons by gel electrophoresis, which increases the assay's turnaround time.

In conclusion, we described a rapid and sensitive multiplex real-time PCR assay for detecting influenza viruses and HRSV in children's NPA samples. This new assay is as specific and much more sensitive than currently-available antigen detection tests and could complement the latter in the hospital setting when there is high clinical suspicion despite negative results. Future work is needed to expand the panel of viral pathogens detected by such rapid molecular methods in order to eventually circumvent the need for viral cultures. Also, future evaluation of the multiplex PCR assay is warranted in the adult population with severe ARTI.

Example 10 : Description and Evaluation of the Multiplex Respiratory-1 PCR.

5 Same as example 9, except that hMPV primers (as defined in SEQ. ID. Nos. 95 and 96 or 112 and 114) were added to the multiplex PCR assay (already containing primers of SEQ. ID. Nos. 139+140 for influenza A, 141+142 for influenza B, and 143+144 for hRSV) at a concentration of 0.3 μ M. The cycling conditions included an amplification step of 50 cycles of 15 s at 94°C, 5 s at 58°C, and 28 s at 72°C. The T_m values determined with the LightCycler instrument were 91°C, 85°C, 83°C, 79°C, and 82°C/77°C for the internal control, influenza A, influenza B, hRSV, and hMPV N/L genes, respectively (Fig. 7A for hMPV N primers of SEQ. ID. Nos. 95 and 96 and Fig. 7B for hMPV L primers of SEQ. ID. Nos. 112 and 114). The lower limit of detection of the multiplex respiratory-1 PCR was 10, 50, 100, and 100 copies for influenza A, influenza B, hRSV, and hMPV, respectively, in the presence of 500 copies of an internal control (plasmid flanked by influenza B complementary primer sequences). The multiplex respiratory-1 assay was found to be specific with no amplification of adenoviruses, enteroviruses, rhinoviruses, parainfluenza viruses 1-3, coronaviruses, herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, HHV-6, HHV-8, and Epstein-Barr virus.

10 The multiplex respiratory-1 PCR was evaluated with NPA samples from 248 children \leq 3 years with acute respiratory tract infections and 108 adults \geq 50 years with exacerbation of chronic obstructive pulmonary disease or pneumonia requiring hospitalization during the 2002-03 winter/spring period in Québec City, Canada. In children, the detection rate for influenza A, influenza B, hRSV, and hMPV was 9/248 (3.6%), 4/248 (1.6%), 123/248 (49.6%), and 13/248 (5.2%), respectively. Five (2.0%) of the 248 children had a mixed viral infection. None of the NPA samples was found to contain PCR-inhibitory substances as shown by successful amplification of the internal control in all negative samples. In adults, the detection rate for influenza A, influenza B, hRSV, and hMPV was 3/108 (2.8%), 0/108 (0%), 13/108 (12.0%), and

2/108 (1.8%), respectively. One patient had a mixed viral infection (influenza A and hMPV). No samples contained PCR-inhibitory samples.

Example 11: Description and evaluation of the multiplex respiratory-2 PCR.

5

Same as example 9, except that the multiplex PCR assay is composed of the following PCR primers for detection of parainfluenza-1 (SEQ. ID. Nos. 147 and 148), parainfluenza-3 (SEQ. ID. Nos. 151 and 152), human adenoviruses (SEQ. ID. Nos. 153 and 155), and rhinoviruses/enteroviruses (SEQ. ID. Nos. 160 and 161). Primers are added in the PCR reaction mixture at a concentration of 0.2 μ M (SEQ. ID. Nos. 147 and 151), 0.3 μ M (SEQ. ID. Nos. 153 and 155), 0.4 μ M (SEQ. ID. Nos. 148 and 152), and 0.5 μ M (SEQ. ID. Nos. 160 and 161). The cycling conditions included an amplification step of 50 cycles of 15 s at 94°C, 5 s at 58°C, and 26 s at 72°C. The T_m values determined with the LightCycler instrument were 91.0°C, 80.0°C, 77.5°C, 89.0°C, 82.0°C, and 85.0°C for the internal control, parainfluenza-1, parainfluenza-3, adenoviruses, rhinoviruses, and enteroviruses, respectively (Fig. 8). The lower limit of detection of the multiplex respiratory-2 PCR was 50, 100, 10, 50, and 200 copies for parainfluenza-1, parainfluenza-3, adenoviruses, rhinoviruses, and enteroviruses, respectively, in the presence of 500 copies of an internal control (plasmid flanked by rhinovirus/enterovirus complementary primer sequences). The multiplex respiratory-2 assay was found to be specific with no amplification of influenza A, influenza B, hRSV, hMPV, coronavirus, herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, HHV-6, HHV-8, and Epstein-Barr virus.

25

Example 12 : Description of real-time PCR assays for the SARS-coronavirus.

30 Same as example 9, except that the PCR assay is composed uniquely of primers (two different possible sets) for the SARS-coronavirus as defined in SEQ. ID. Nos. 156-157 and 158-159. The concentration of the primers in the PCR reaction mixture is 0.5 μ M. The amplification step included 50 cycles of 15 s at 94°C, 5 s at 58°C, and 20 s at 72°C. The T_m for both PCR products is 83°C (Fig. 12).

Table 1: List of hMPV sequences revealed in the present invention

SEQ ID NO.	Isolate No.	Target gene
2	hMPV-118	Nucleoprotein
3	hMPV-174	Nucleoprotein
4	hMPV-176	Nucleoprotein
5	hMPV-193	Nucleoprotein
6	C-77807	Nucleoprotein
7	C-77748	Nucleoprotein
8	hMPV-217	Nucleoprotein
10	hMPV-163	Nucleoprotein
11	hMPV-174	Nucleoprotein
12	hMPV-184	Nucleoprotein
13	hMPV-185	Nucleoprotein
14	C-76837	Nucleoprotein
15	C-77807	Nucleoprotein
16	C-78123	Nucleoprotein
17	C-78132	Nucleoprotein
18	C-78163	Nucleoprotein
19	C-91205	Nucleoprotein
20	C-91364	Nucleoprotein
21	C-91830	Nucleoprotein
22	hMPV-Q86	Nucleoprotein
23	hMPV-Q97	Nucleoprotein
24	Can 97-83	Nucleoprotein
25	Can 98-75	Nucleoprotein
26	Can 98-75	Fusion type II
27	C-67345	Fusion type I
28	Can 97-83	Fusion type I
29	C-68661	Fusion type I
30	C-73750	Fusion type I
31	C-74549	Fusion type I
32	C-74783	Fusion type I
33	C-76837	Fusion type I
34	C-77748	Fusion type I
35	C-77807	Fusion type I
36	C-78132	Fusion type I
37	C-78163	Fusion type I
38	C-78406	Fusion type I
39	hMPV-174	Fusion type II
40	hMPV-193	Fusion type I
41	hMPV-194	Fusion type I
42	hMPV-198	Fusion type I
43	hMPV-217	Fusion type II
44	hMPV-208	Fusion type I
45	hMPV-223	Fusion type I
46	hMPV-228	Fusion type I

47	C-85885	Fusion type I
48	C-60298	Fusion type I
49	C-63778	Fusion type II
50	C-64199	Fusion type II
51	C-64200	Fusion type II
52	C-64536	Fusion type II
53	C-73769	Fusion type II
54	C-74501	Fusion type II
55	C-78429	Fusion type II
56	C-78562	Fusion type II
57	hMPV-118	Fusion type II
58	hMPV-200	Fusion type I
59	hMPV-176	Fusion type I
60	hMPV-193	Glycoprotein
61	hMPV-228	Glycoprotein
62	C-77748	Glycoprotein
63	C-78132	Glycoprotein
64	C-78406	Glycoprotein
65	C-73750	Glycoprotein
66	C-60298	Glycoprotein
67	C-74783	Glycoprotein
68	C-74549	Glycoprotein
69	C-77807	Glycoprotein
70	C-78163	Glycoprotein
71	C-68661	Glycoprotein
72	C-88448	Glycoprotein
73	C-88470	Glycoprotein
74	C-86316	Glycoprotein
76	hMPV-118	Polymerase
77	hMPV-163	Polymerase
78	hMPV-174	Polymerase
79	hMPV-184	Polymerase
80	hMPV-196	Polymerase
81	C-76837	Polymerase
82	C-77807	Polymerase
83	hMPV-185	Polymerase
84	C-78123	Polymerase
85	C-91205	Polymerase
86	C-91364	Polymerase
87	C-91749	Polymerase
88	hMPV-Q86	Polymerase
89	hMPV-Q97	Polymerase
90	Can 97-83	Polymerase

Table 2: List of hMPV PCR primers developed in the present invention

SEQ ID NO.	Target gene	Originating DNA	
		Position ^a	SEQ ID NO.
91	Nucleoprotein (N)	25	1
92	Nucleoprotein (N)	97	1
93	Nucleoprotein (N)	146 ^b	1
94	Nucleoprotein (N)	1025 ^b	1
95	Nucleoprotein (N)	58	9
96	Nucleoprotein (N)	986 ^b	9
97	Fusion (F)	3052	1
98	Fusion (F)	3810 ^b	1
99	Fusion (F)	4671 ^b	1
100	Matrix (M)	2165	1
101	Matrix (M)	2943 ^b	1
102	Phosphoprotein (P)	1248	1
103	Phosphoprotein (P)	2124 ^b	1
104	Glycoprotein (G)	6231	1
105	Glycoprotein (G)	6247	1
106	Glycoprotein (G)	6957 ^b	1
107	Glycoprotein (G)	6981 ^b	1
108	Glycoprotein (G)	6235	1
109	Glycoprotein (G)	7227 ^b	1
110	RNA polymerase (L)	142	75
111	RNA polymerase (L)	691 ^b	75
112	RNA polymerase (L)	7308	1
113	RNA polymerase (L)	7857 ^b	1
114	RNA polymerase (L)	7616	1

^a Position refers to nucleotide position of 5' end of primer. Oligonucleotides are 17-20 bp in length.

^b Primer is reverse-complement of target sequence.

Table 3: List of hMPV probes developed in the present invention

SEQ ID NO.	Target gene	Originating DNA	
		Position ^a	SEQ ID NO.
115	Nucleoprotein (N)	786	1
116	Nucleoprotein (N)	808	1
117	Fusion (F)	3163	1
118	Fusion (F)	3187	1
119	Matrix (M)	2636	1
120	Matrix (M)	2659	1
121	Phosphoprotein (P)	1492	1
122	Phosphoprotein (P)	1518	1
123	Glycoprotein (G)	6509	1
124	Glycoprotein (G)	6530	1
125	RNA polymerase (L)	7600	1
126	RNA polymerase (L)	7627	1
127	RNA polymerase (L)	7331	1
128	Nucleoprotein (N)	824	9
129	RNA polymerase (L)	434	75

^a Position refers to nucleotide position of 5' end of probe. Oligonucleotides are 21-25 bp in length.

Table 4: Length of amplicons obtained with different hMPV primer pairs which are objects of the present invention

SEQ ID NO.	Target Gene	Length of amplicon
91 + 94	Nucleoprotein (N)	1001 bp
92 + 94	Nucleoprotein (N)	929 bp
91 + 93	Nucleoprotein (N)	122 bp
97 + 99	Fusion (F)	1620 bp
97 + 98	Fusion (F)	759 bp
100 + 101	Matrix (M)	779 bp
102 + 103	Phosphoprotein (P)	877 bp
104 + 107	Glycoprotein (G)	751 bp
105 + 106	Glycoprotein (G)	711 bp
108 + 109	Glycoprotein (G)	993 bp
112 + 113	RNA polymerase (L)	550 bp
112 + 114	RNA polymerase (L)	308 bp

Table 5: Comparative evaluation of different hMPV primers for detection of hMPV strains

Strains No.	Type of sample	Year	N Primers		M primers		F primers		P primers		L primers	
			SEQ. ID. Nos. 92+94	SEQ. ID. Nos. 100+101	SEQ. ID. Nos. 97+98	SEQ. ID. Nos. 102+103	SEQ. ID. Nos. 112 + 113					
	I or S		+/-	T _m (°C)	+/-	T _m (°C)	+/-	T _m (°C)	+/-	T _m (°C)	+/-	T _m (°C)
C-74501	I	2000	+	82.92	-	83.65	-	81.51	+	80.86	+	78.14
C-74783	I	2000	+	82.76	+	83.49	-	81.51	+	80.86	+	78.20
C-76837	I	2000	+	82.94	+	83.43	+	83.17	+	80.86	-	77.87
C-77719	I	2001	+	83.26	+	84.64	-	-	-	-	+	77.51
C-77738	I	2001	+	82.99	-	-	-	-	-	-	+	77.38
C-77748	I	2001	+	83.06	+	82.96	+	83.10	+	81.27	+	77.38
C-77807	I	2001	+	82.99	+	83.26	+	83.25	+	80.65	+	78.34
C-78024	I	2001	+	82.86	+	83.95	-	-	-	-	-	-
C-78028	I	2001	+	82.98	+	83.13	-	-	-	-	+	78.32
C-78123	I	2001	+	82.83	-	-	-	-	-	-	+	78.48
C-85984	I	2002	+	82.59	+	83.21	+	83.51	+	79.99	+	77.97
C-85448	I	2002	+	83.66	+	82.72	-	-	+	80.31	+	78.88
C-85983	I	2002	+	82.59	+	83.03	+	83.88	+	80.46	+	78.01
C-85988	I	2002	+	82.17	-	-	+	84.39	-	-	+	78.06
C-86316	I	2002	+	82.64	+	82.75	+	83.18	+	80.18	+	78.02
C-85126	I	2002	+	81.89	+	82.05	+	82.39	+	80.00	+	78.04
C-85473	I	2002	+	82.39	+	82.57	+	82.91	+	80.74	+	77.82
C-85332	I	2002	+	81.98	-	-	-	-	-	-	+	77.72
C-85596	I	2002	+	82.24	+	82.73	+	83.17	+	80.35	+	77.58
C-85542	I	2002	+	82.22	+	82.72	-	-	+	80.08	+	77.67
HMPV-118	S	2002	+	82.47	-	-	-	-	-	-	ND	ND
HMPV-174	S	2002	+	82.18	+	82.06	+	83.16	+	80.17	+	78.20
HMPV-176	S	2002	+	81.41	-	-	+	83.97	-	-	+	77.81
HMPV-193	S	2002	+	82.22	+	81.89	+	83.00	+	80.58	+	77.94
HMPV-194	S	2002	+	82.24	+	81.32	+	82.98	-	-	+	77.84
HMPV-198	S	2002	+	82.66	-	-	-	-	-	-	-	-
HMPV-200	S	2002	+	82.53	-	-	+	83.46	-	-	+	77.62
HMPV-208	S	2002	+	82.11	+	81.81	+	83.33	+	80.06	+	78.40
HMPV-217	S	2002	+	82.13	+	81.58	+	83.01	-	-	+	77.76

64

HMPV- S	2002	+	81.89	+	82.36	+	83.04	-	+	78.10
223										
Mean			82.63 ± 0.87		82.75 ± 0.80		83.29 ± 0.45		80.48 ± 0.46	77.99 ± 0.33

Note: I = viral isolates; S = clinical specimens; Tm = melting temperature as determined by a LightCycler instrument.

Table 6: Size of the viral fusion (F) gene fragments obtained for different hMPV isolates following enzymatic digestion with restriction endonucleases

SEQ ID NO.	Fragments obtained after digestion with the restriction endonuclease		F genotype ^a
	ApaI	Avr II	
35	532 bp + 227 bp	759 bp	I
58	532 bp + 227 bp	759 bp	I
39	759 bp	447 bp + 312 bp	II
40	532 bp + 227 bp	759 bp	I
41	532 bp + 227 bp	759 bp	I
43	759 bp	447 bp + 312 bp	II
44	532 bp + 227 bp	759 bp	I
59	532 bp + 227 bp	759 bp	I
45	532 bp + 227 bp	759 bp	I

5 ^aAs determined by DNA sequencing and phylogenetic studies.

Table 7. Type of laboratory confirmation by type of infection

Laboratory test	hMPV		hRSV		Influenza A		Adenovirus		PIV 2	
	Tests done	Positive	Tests Done	Positive	Tests done	Positive	Tests done	Positive	Tests done	Positive
PCR	208	12 5.8%	208	106 51.0%	208	45 21.6%	NA	NA	NA	NA
Culture	100	2 2%	100	31 31%	100	14 14%	100	6 6%	100	1 1%
Antigen detection (Immunofluorescence)	NA	NA	NA	NA	NA	NA	81	1 1%	76	1 1.3%
Antigen detection (ELISA)	NA	NA	204	94 46.1%	100	14 14%	NA	NA	NA	NA
Total (+) in at least one test	12 (5.8%)	118 (56.7%)	49 (23.6%)	6 (6%)	2 (2%)					

Delay between onset of symptoms and NPA, days	Mean/median
6.3/5.0	5.2/4.0
8.7/5.0	6.0/6.5
3.0/3.0	

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus; PIV, parainfluenza virus; NPA, nasopharyngeal aspirate; NA, not available.

Table 8. Signs and symptoms by type of viral infection

Signs and symptoms	EMPV	hRSV	Influenza A	Single virus	Multiple viruses	No virus detected	Total
	N=12	N=118	N=49	N=141	N=23	N=44	N=208
Fever	8 67%	67 57%	38 78%	85 60%	17 74%	25 57%	127 61%
Cough	12 100%	117 99%	47 96%	138 98%	23 100%	40 90%	201 97%
Rhinorrhea	11 92%	107 91%	41 84%	123 87%	22 96%	42 96%	187 90%
Retractions	11 92%	112 95%	40 82%	125 89%	22 96%	39 89%	186 89%
Wheezing	10 83%	77 65%	28 57%	83 59%	19 83%	31 71%	133 64%
Lacrymation	3 25%	37 31%	15 31%	46 33%	6 26%	11 25%	63 30%
Diarrhea	1	19	13	24	5	10	39

	8%	17%	27%	17%	22%	23%	19%
Vomiting	3	9	5	10	4	1	15
	25%	8%	10%	7%	17%	2%	7%
Other	0	31	9	33	4	9	46
		26%	18%	23%	17%	21%	22%

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus.

Table 9. Final diagnoses (complications) by type of viral infection

Complications	hMPV N = 12	HRSV N = 118	Influenza A N = 49	Single virus N = 141	Multiple viruses N = 23	No virus detected N = 44	Total N = 208
Bronchiolitis	8 66.7%	99 83.9%	25 51.0%	98 69.5%	19 82.6%	25 56.8%	142 68.3%
Otitis	6 50.0%	70 59.3%	27 55.1%	78 55.3%	15 65.2%	24 54.6%	117 56.3%
Pneumonia	2 16.7%	30 25.4%	18 36.7%	39 27.7%	7 30.4%	12 27.3%	58 27.9%
Laryngotracheobronchitis	0	10 8.5%	6 12.2%	9 6.4%	4 17.4%	1 2.3%	14 6.7%
Sinusitis	0	3 2.5%	3 6.1%	2 1.4%	2 8.7%	1 2.3%	5 2.4%
Pharyngitis	0	1 0.9%	0	2 1.4%	0	2 4.6%	4 1.9%
Flu syndrome	0	2 1.7%	0	2 1.4%	0	4 9.1%	6 2.9%

	0	2	0	2	0	1	3
Croup	0	2	0	2	0	1	3
		1.7%		1.4%		2.3%	1.4%
Other	1	4	3	9	0	5	14
	8.3%	3.4%	6.1%	6.4%		11.4%	6.7%

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus.

Table 10: List of PCR primers used for amplification of respiratory viruses

Primer SEQ ID NO.	Virus	Target Gene	Originating DNA	
			Position ^a	SEQ ID NO.
139	Influenza A	Matrix	32 / 7	130-131
140	Influenza A	Matrix	276 ^b / 251 ^b	130-131
141	Influenza B	Matrix	82	132
142	Influenza B	Matrix	605 ^b	132
143	RSV	Fusion	1111	133
144	RSV	Fusion	1490 ^b	133
95	hMPV	Nucleocapsid	58	9
96	hMPV	Nucleocapsid	986 ^b	9
110	hMPV	Polymerase	142	75
111	hMPV	Polymerase	691 ^b	75
145	PIV-1	Nucleocapsid	64	134
146	PIV-1	Nucleocapsid	147 ^b	134
149	PIV-3	Nucleocapsid	416	135
150	PIV-3	Nucleocapsid	649 ^b	135
154	Adenovirus	Hexon	154	136
155	Adenovirus	Hexon	368 ^b	136
160	Entero/Rhinovirus	5'-non coding region	94 / 71	137/138
161	Entero/Rhinovirus	5'-non coding region / VP2	746 ^b / 603 ^b	137/138
141	IC ^c multiplex 1	DNA polymerase HSV-2	1	170
142	IC ^c multiplex 1	DNA polymerase HSV-2	558 ^b	170
160	IC ^c multiplex 2	DNA polymerase HSV-2	1	171
161	IC ^c multiplex 2	DNA polymerase HSV-2	554 ^b	171
112	hMPV	Polymerase	7308	1
114	hMPV	Polymerase	7616	1
147	PIV-1	Nucleocapsid	822	134
148	PIV-1	Nucleocapsid	1029	134
151	PIV-3	Nucleocapsid	792	135
152	PIV-3	Nucleocapsid	902	135
153	Adenovirus	Hexon	7	136
156	Sars-CoV	nsp9		
157	Sars-CoV	nsp9		
158	Sars-CoV	nsp11		
159	Sars-CoV	nsp11		

^a Position refers to nucleotide position of 5'-end of primer. Oligonucleotides are 16-26 bp in length.

^b Primer is reverse-complement of target sequence.

^c IC refers to the internal control used to monitor the efficiency of the PCR amplification

Table 11: List of viral probes developed in the present invention

Probe SEQ ID NO.	Target	Position ^a	Originating DNA SEQ ID NO.
162	Influenza A	114 ^b / 89 ^b	130/131
163	Influenza B	383	132
164	hRSV	1391 ^b	133
128	hMPV	824	9
129	hMPV	434	75
165	PIV-1	96	134
166	PIV- 3	616 ^b	135
167	Adenovirus	228	136
168	Rhinovirus	467 ^b	138
169	Enterovirus	644 ^b	137
172	Internal Control ^c	321 ^b / 325 ^b	170/171

^aPosition refers to nucleotide position of 5'-end of primer. Oligonucleotides are 20-23 bp in length.

^bProbe is reverse-complement of target sequence.

^cA modified DNA polymerase gene sequence of herpes simplex virus (HSV) type 2 serves as the internal control template.

Table 12: Length of amplicons obtained with the different viral primer pairs

Primer SEQ ID NO.	Virus	Target gene	Length of amplicons
139 + 140	Influenza A	Matrix	245 bp
141 + 142	Influenza B	Matrix	524 bp
143 + 144	hRSV	Fusion	380 bp
95 + 96	hMPV	Nucleocapsid	929 bp
110 + 111	hMPV	Polymerase	550 bp
145 + 146	PIV-1	Nucleocapsid	84 bp
149 + 150	PIV-3	Nucleocapsid	234 bp
154 + 155	Adenoviruses	Hexon	215 bp
160 + 161	Rhinoviruses	5'-non coding region – VP2	533 bp
160 + 161	Enteroviruses	5'-non coding region	653 bp
141 + 142	IC multiplex 1	DNA polymerase HSV-2	558 bp
160 + 161	IC multiplex 2	DNA polymerase HSV-2	554 bp
112 + 114	hMPV	Polymerase	308 bp
147 + 148	PIV-1	Nucleocapsid	208 bp
151 + 152	PIV-3	Nucleocapsid	111 bp
153 + 155	Adenovirus	Hexon	362 bp
156 + 157	Sars-CoV	nsp9	198 bp
158 + 159	Sars-CoV	nsp11	368 bp

Table 13: Selection of primer sets with resulting melting temperature (T_m) values of the corresponding amplicons for each multiplex assay

Primer SEQ ID NO.	Target	Multiplex NO.	T_m (°C)
139 + 140	Influenza A	1	85
141 + 142	Influenza B	1	83
143 + 144	hRSV	1	79
95 + 96 or 112 + 114	hMPV	1	82 or 77
141 + 142	Internal Control	1	91
147 + 148	Parainfluenza 1	2	80.0
151 + 152	Parainfluenza 3	2	77.5
153 + 155	Adenovirus	2	89.0
160 + 161	Rhinovirus	2	82.0
160 + 161	Enterovirus	2	85.0
160 + 161	Internal Control	2	91

- 76 -

Table 14. Evaluation of the multiplex PCR respiratory assay with temporally-different strains of influenza (Flu) and human respiratory syncytial (HRSV) viruses.

Virus	Subtype / Genotype ^a	Year	Type	Strain	T _m (°C)
Flu A	H1	99-00	clinical	-	85.10
Flu A	H1	99-00	clinical	-	85.39
Flu A	H1	00-01	clinical	-	85.12
Flu A	H1	00-01	clinical	-	85.20
Flu A	H1	00-01	clinical	-	85.04
Flu A	H1	01-02	clinical	-	84.62
Flu A	H1	01-02	clinical	-	85.07
Flu A	H1	02-03	clinical	-	85.50
Flu A	H1	02-03	clinical	-	85.29
Flu A	H1	95	vaccine	A/Beijing/262/95	85.06
Flu A	H1	33	vaccine	A/WSN/33	85.25
Mean AH1					85.15±0.22
Flu A	H3	98-99	clinical	-	85.58
Flu A	H3	98-99	clinical	-	85.18
Flu A	H3	98-99	clinical	-	85.35
Flu A	H3	98-99	clinical	-	85.57
Flu A	H3	98-99	clinical	-	85.37
Flu A	H3	01-02	clinical	-	85.07
Flu A	H3	01-02	clinical	-	85.65
Flu A	H3	02-03	clinical	-	84.92
Flu A	H3	99	vaccine	A/Panama/2007/99	85.18
Flu A	H3	97	vaccine	A/Sydney/5/97	85.06
Mean AH3					85.31±0.25
Mean FluA					85.27±0.22
Flu B	-	98-99	clinical	-	83.87
Flu B	-	98-99	clinical	-	83.12
Flu B	-	00-01	clinical	-	83.01
Flu B	-	00-01	clinical	-	83.03
Flu B	-	00-01	clinical	-	82.88
Flu B	-	00-01	clinical	-	83.75
Flu B	-	00-01	clinical	-	83.17
Flu B	-	02-03	clinical	-	83.89
Flu B	-	02-03	clinical	-	83.84
Flu B	-	97	vaccine	B/Harbin/7/97	84.12
Mean FluB					83.47±0.46

Table 14. Evaluation of the multiplex PCR respiratory assay with temporally-different strains of influenza (Flu) and human respiratory syncytial (HRSV) viruses. (Continued).

HRSV	B	99-00	clinical	-	79.32
HRSV	A	99-00	clinical	-	79.83
HRSV	A	00-01	clinical	-	79.06
HRSV	A	00-01	clinical	-	78.85
HRSV	B	01-02	clinical	-	79.34
HRSV	B	01-02	clinical	-	79.52
HRSV	B	01-02	clinical	-	79.98
HRSV	B	01-02	clinical	-	79.52
HRSV	A	01-02	clinical	-	79.84
HRSV	B	01-02	clinical	-	79.42
HRSV	B	01-02	clinical	-	79.49
HRSV	B	01-02	clinical	-	79.48
HRSV	B	01-02	clinical	-	79.55
HRSV	B	01-02	clinical	-	79.32
HRSV	A	01-02	clinical	-	79.77
HRSV	A	01-02	clinical	-	79.92
HRSV	A	01-02	clinical	-	79.40
Mean HRSV-A					79.52±0.43
Mean HRSV-B					79.49±0.19
Mean HRSV					79.51±0.30

5

^a Subtyping was performed by multiplex PCR for the influenza hemagglutinin gene (2) whereas genotyping was done by conventional PCR for the HRSV G gene (22)

- 78 -

Table 15. Evaluation of the multiplex PCR respiratory assay for detection of influenza A (Flu A) virus.

		Antigenic test (Directigen Flu A+B) (n = 172)		Flu A M2 PCR assay ^a (n = 27)	
		+	-	+	-
Multiplex PCR	+	17	25	22	3
	-	2	128	0	2

5 Sensitivity: 39/39 = 100%
 Specificity: 130/133 = 97.7%
 Positive predictive value: 39/42 = 92.8%
 Negative predictive value: 130/130 = 100%

10 ^a Only performed for samples showing discordant results with the
 multiplex PCR assay and the antigenic test.

Table 16: Evaluation of discordant test results for influenza A (Flu A) virus.

Sample No.	Multiplex PCR Flu A results (C _T) ^a	Antigenic test Flu A results	M2 PCR Flu A results	Other PCR- amplified viruses ^b
16	-	+	-	HRSV
23	+(27)	-	+	
24	-	+	-	HRSV
27	+(28)	-	+	HRSV
35	+(28)	-	+	HRSV
36	+(32)	-	+	
40	+(34)	-	+	
43	+(36)	-	+	HRSV
44	+(35)	-	+	
50	+(34)	-	+	
51	+(33)	-	+	HRSV
103	+(35)	-	+	
107	+(35)	-	+	
114	+(37)	-	-	
118	+(38)	-	+	HRSV
120	+(36)	-	+	HRSV
125	+(38)	-	+	
130	+(35)	-	+	HRSV
131	+(36)	-	-	
132	+(24)	-	+	HRSV
134	+(36)	-	-	
141	+(28)	-	+	
152	+(34)	-	+	
158	+(32)	-	+	
160	+(33)	-	+	HRSV
161	+(28)	-	+	HRSV
163	+(32)	-	+	

^a Cycle threshold value as determined by LightCycler.

^b Viruses amplified by the multiplex PCR assay i. e. influenza (Flu) A and B as well as the human respiratory syncytial virus (HRSV).

Table 17: Evaluation of the multiplex PCR respiratory assay for detection of human respiratory syncytial virus (HRSV).

		Antigenic test (RSV TcstPack) (n = 204)		HRSV gG PCR assays ^a (n = 32)	
		+	-	+	-
		Multiplex PCR	+	83	21
	-	11	89	6	5

5 Sensitivity: 103/109 = 94.5%
 Specificity: 94/95 = 98.9%
 Positive predictive value: 103/104 = 99.0%
 Negative predictive value: 94/100 = 94.0%

10 ^a Only performed for samples showing discordant results with the multiplex PCR assay and the antigenic test.

- 81 -

Table 18: Evaluation of discordant test results for human respiratory syncytial virus (HRSV).

Sample No.	Multiplex PCR HRSV results (C _T) ^a	Antigenic test HRSV results	Glycoprotein G PCR HRSV results (genotype)	Other PCR- amplified viruses ^b
16	+(32)	-	+(B)	
17	+(27)	-	+(B)	
26	+(36)	-	+(B)	
34	-	+	-	
35	+(33)	-	+(B)	Flu A
43	+(36)	-	+(A)	Flu A
46	+(34)	-	+(B)	
55	+(34)	-	+(B)	
58	+(33)	-	+(B)	
62	-	+	+(A)	Flu A
70	+(37)	-	+(B)	
71	+(35)	-	+(B)	
72	+(34)	-	+(B)	
73	+(26)	-	+(A)	
79	+(33)	-	+(B)	
80	-	+	-	
91	+(35)	-	+(A)	
95	+(29)	-	+(B)	
100	+(30)	-	+(A)	
112	-	+	-	
129	+(34)	-	+(B)	
130	+(35)	-	+(B)	Flu A
134	-	+	+(A)	Flu A
139	-	+	+(A)	
142	-	+	+(A)	Flu A
144	-	+	+(B)	Flu A
150	+(34)	-	-	
187	+(31)	-	+(A)	
191	+(29)	-	+(A)	

Table 18: Evaluation of discordant test results for human respiratory syncytial virus (HRSV). (Continued).

193	-	+	+(A)
211	-	+	-
212	-	+	-

5

^a Cycle threshold value as determined by Lightcycler.

^b Viruses amplified by the multiplex PCR assay i. e. influenza (Flu) A and B as well as the human respiratory syncytial virus (HRSV).

CLAIMS:

1- A method for detecting and/or quantifying human metapneumovirus (hMPV) in a sample said method comprising:

5 -providing at least one probe or primer specific for a nucleic acid sequence of said hMPV;

-contacting said at least one probe and/or primer with said sample to allow annealing of said probe and/or primer with said nucleic acid sequence; and

-detecting and/or quantifying said nucleic acid sequence using said annealed probe and/or primer.

10

2- The method as claimed in claim 1 wherein said nucleic acid sequence is comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

15

3- The method as claimed in claim 2 wherein said nucleic acid sequence is selected from any one of SEQ ID NO 2-8, 10-74, 76-90 or fragments thereof.

4- The method as claimed in claim 3 wherein said probe or primer is at least 10
20 nucleotides in length.

5- A method for detecting and/or quantifying human metapneumovirus (hMPV) in a sample said method comprising:

25 -performing reverse transcription using a template RNA derived from said sample to obtain a nucleic acid product;

-amplifying said nucleic acid product using a pair of oligonucleotide primers wherein said primers are specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion

- 84 -

(F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes to produce an amplification product; and
-detecting and/or quantifying said amplification product.

- 5 6- The method as claimed in claim 5 wherein said oligonucleotide primers are at least 10 nucleotides in length and capable of hybridizing with any one of SEQ ID 2-8, 10-74, 76-90.
- 7- The method as claimed in claim 5 or 6 wherein said step of performing reverse
10 transcription comprises contacting said template RNA with a primer selected from SEQ ID Nos 91-114 and wherein said oligonucleotide primers for PCR are selected from SEQ ID Nos 91-114.
- 8- The method as claimed in any one of claim 5-7 wherein said oligonucleotide
15 primers are pairs of primers selected from SEQ ID Nos 91 and 94, 92 and 94, 91 and 93, 97 and 99, 97 and 98, 100 and 101, 102 and 103, 104 and 107, 105 and 106, 108 and 109, 112 and 113 and 112 and 114.
- 9- The method as claimed in claim 5 wherein said template RNA is contacted
20 with primer selected from SEQ ID NO 91-94 and 112-114 and wherein said oligonucleotide primers are selected from SEQ ID NO 91-94 and 112-114.
- 10- The method as claimed in any one of claim 5-9 wherein said step of
amplifying is performed using PCR.
- 25 11- The method as claimed in claim 10 wherein said PCR is RT-PCR.
- 12- The method as claimed in claim 11 wherein said RT-PCR is real time RT-
PCR.

30

- 85 -

- 13- The method as claimed in claim 11 or 12 wherein said RT-PCR comprises detecting said amplification products by characteristic melting temperature of said amplification products.
- 5 14- The method as claimed in claim 11 or 12 wherein said RT-PCR comprises detecting and/or quantifying said amplification products with probes specific for said products.
- 15- The method as claimed in claim 14 wherein said probes are selected from SEQ
10 ID no 115-129.
- 16- A composition for detecting a hMPV said composition comprising a combination of oligonucleotides for performing reverse transcription of a template RNA from said hMPV virus and for an amplification reaction of a product obtained
15 from said reverse transcription wherein said oligonucleotides for said amplification reaction are specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.
- 20 17- The composition of claim 16 wherein said oligonucleotides for said amplification reaction are primers selected from the group comprising SEQ ID Nos 91-114 and combination thereof.
- 18- A kit comprising a combination of oligonucleotides wherein the oligonucleotides
25 are selected from:
SEQ ID NOs: 91-114 and the pairs of SEQ ID Nos 91 and 94, 92 and 94, 91 and 93, 97 and 99, 97 and 98, 100 and 101, 102 and 103, 104 and 107, 105 and 106, 108 and 109, 112 and 113 and 112 and 114.
- 30 19- A method for typing an hMPV strain which comprises the steps of:

- 86 -

-amplifying an hMPV nucleic acid fragment and detecting specific viral sequences;

-digesting said fragment with one or more restriction endonuclease; and

-analysing the restriction fragment length polymorphisms.

5

20- The method as claimed in claim 19 wherein said nucleotide sequences are found in fusion(F) or glycoprotein (G) gene.

21- The method as claimed in claim 20 wherein said sequences are selected from
10 SEQ ID NO 26-74.

22- A method for detecting and/or quantifying two or more respiratory viruses in a sample said method comprising:

-providing at least two probes and/or primers specific for a nucleic acid
15 sequences in said two or more respiratory viruses;

-contacting said at least two probes and/or primers with said sample to allow annealing of said probes and/or primers with said nucleic acid sequences; and

-detecting and/or quantifying said nucleic acid sequences using said annealed probes and/or primers.

20

23- The method as claimed in claim 22 wherein at least one of said nucleic acid sequences is comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

25

24- The method as claimed in claim 23 wherein said nucleic acid sequence is selected from any one of SEQ ID NO 2-8, 10-74, 76-90 or fragments thereof.

25- The method as claimed in claim 24 wherein said probes and/or primers are at
30 least 10 nucleotides in length.

- 87 -

- 26- A method for detecting and/or quantifying two or more respiratory viruses in a sample said method comprising:
- 5 -performing reverse transcription using a template RNA derived from said sample to obtain nucleic acid products for each of said viruses;
-amplifying said nucleic acid products using two or more pairs of oligonucleotide primers to produce an amplification product; and
-detecting and/or quantifying said amplification products.
- 10 27- The method as claimed in claim 26 wherein at least one of said primers is specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.
- 15 28- The method as claimed in claim 27 wherein said oligonucleotide primers specific for a sequence comprised in a hMPV gene are capable of hybridizing with any one of SEQ ID 2-8, 10-74, 76-90.
- 20 29- The method as claimed in claim 28 wherein said oligonucleotide primers are at least 10 nucleotides in length.
- 30- The method as claimed in claim 29 wherein said oligonucleotide primer
25 specific for a sequence comprised in a hMPV gene are selected from SEQ ID Nos 91-114.
- 31- The method as claimed in any one of claim 26-30 wherein said at least two
30 respiratory viruses comprise influenza A and B, human respiratory syncytial viruses A and B, parainfluenza viruses (PIV) types 1-4, adenoviruses, rhinoviruses,

- 88 -

- enteroviruses and coronaviruses or any combination thereof and wherein said primers and said two or more viruses are selected such that the detection and or quantification is specific for each of said viruses.
- 5 32- The method as claimed in claim 31 wherein said oligonucleotide primers are at least 10 nucleotides in length and capable of hybridizing with any one of SEQ ID NO 130-138 and 170-171.
- 10 33- The method as claimed in claim 31 or 32 wherein said at least two viruses are influenza A, human Respiratory syncytial virus, human metapneumovirus and influenza B.
- 15 34- The method as claimed in claim 31 or 32 wherein said at least two viruses are Parainfluenza 1, Rhinovirus, Adenovirus, Parainfluenza 3, Enterovirus, and coronavirus.
- 20 35- The method as claimed in claim 31 wherein said pairs of oligonucleotide primers are selected from SEQ ID Nos 139 and 140, 141 and 142, 143 and 144, 92 and 94, 112 and 113, 112 and 114, 145 and 146, 147 and 148, 149 and 150, 151 and 152, 154 and 155, 153 and 155, 156 and 157, 158 and 159, 160 and 161.
- 25 36- The method as claimed in any one of claim 26-35 wherein said step of amplifying is performed using PCR and said primer are selected such that the products of the amplifications can be distinguished.
- 30 37- The method as claimed in claim 36 wherein said PCR is RT-PCR.
- 38- The method as claimed in claim 37 wherein said RT-PCR is real time RT-PCR.
- 30

- 89 -

- 39- The method as claimed in claim 37 or 38 wherein said RT-PCR comprises detecting said amplification products by characteristic melting temperature of said amplification products.
- 5 40- The method as claimed in claim 37 or 38 wherein said RT-PCR comprises detecting and/or quantifying said amplification products with probes specific for said products.
- 41- The method as claimed in claim 40 wherein said probes are selected from SEQ
10 ID no 162-169 and 172.
- 42- A composition for detecting at least two respiratory viruses said viruses comprising at least hMPV said composition comprising a combination of oligonucleotides for performing reverse transcription of a template RNA from said
15 least two respiratory viruses and for an amplification reaction of a product obtained from said reverse transcription wherein said oligonucleotides for said amplification reaction comprise oligonucleotides specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic
20 (SH) genes.
- 43- The composition of claim 42 wherein said oligonucleotides for said amplification reaction are primers selected from the group comprising SEQ ID Nos 91-114 and combination thereof.
- 25 44- A method for simultaneously detecting two or more respiratory tract viruses in a sample, said method comprising:

- 90 -

Selecting primers specific for a nucleic acid sequence in each of said two or more viruses, said primers to be used in an amplification reaction for detection of said nucleic acid sequences;

5 distributing said primers in one or more assay mixture comprising said sample and at least two pairs of primers; and

wherein said selecting and said distributing is based on said detection of said nucleic acid sequence of said two or more viruses being substantially free of overlap and
10 enabling to distinguish between said two or more viruses.

45- The method as claimed in claim 44 wherein said amplification reaction is PCR.

15

46- The method as claimed in claim 45 wherein said PCR is RT-PCR.

47- The method as claimed in claim 45 wherein said RT-PCR is real time RT-PCR.

20

48- The method as claimed in claim 24 wherein said detection is melting temperature.

49- An isolated nucleic acid comprising a sequence that hybridizes under stringent
25 conditions to a hybridization probe the nucleotide sequence of which consists of any one of SEQ ID NO 2-8, 10-74, 76-90 or complements thereof.

50- A kit comprising a nucleic acid probe that is at least 10 nucleotides in length and is selected from a group consisting sequences hybridizable to SEQ ID Nos 2-8, 10-74,
30 76-90 or fragments thereof.

- 91 -

- 51- A human metapneumovirus (hMPV) deposited with the International Depository Authority of Canada under Accession number IDAC 111203-01 (CAN97-83).
- 5 52- A human metapneumovirus (hMPV) deposited with the International Depository Authority of Canada under Accession number IDAC 111203-02 (CAN98-75).




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4

5/13




FIGURE 5




FIGURE 6

7/13





FIGURE 7




FIGURE 8

9/13




FIGURE 9

11/13




FIGURE 10 B

12/13




FIGURE 11

13/13




FIGURE 12

SEQUENCE LISTING

<110> Boivin, Guy

<120> METHOD FOR DETECTING RESPIRATORY VIRUSES

<130> 6013-148PCT

<150> CA 2,411,264

<151> 2002-12-19

<150> CA 2,418,004

<151> 2003-01-24

<160> 172

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 13350

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(13450)

<223> human metapneumovirus, strain 00-1
Accession number af371337

<400> 1

gtataaatta	gattccaaaa	aaatatggga	caagtgaaaa	tgtctcttca	agggattcac	60
ctgagtgatt	tatcatacaa	gcatgctata	ttaaaagagt	ctcagtcacac	aataaaaaaga	120
gatgtgggta	caacaactgc	agtgacaccc	tcatcattgc	aacaagaaat	aacctgtgtg	180
tgtggagaaa	ttctgtatgc	taaacatgct	gactacaaat	atgctgcaga	aataggaata	240
caatatatta	gcacagcttt	aggatcagag	agagtgcagc	agattctgag	gaactcaggc	300
agtgaaagcc	aagtgtcttt	aaccagaacg	tactctctgg	ggaaaattaa	aaacaataaaa	360
ggagaagatt	tacagatggt	agacatacac	ggggtagaga	agagctgggt	agaagagata	420
gacaaagaag	caaggaaaac	aatggcaacc	ttgcttaagg	aatcatcagg	taatatccca	480
caaaatcaga	ggccctcagc	accagacaca	cccataatct	tattatgtgt	aggtgcctta	540
atattcacta	aaactagcfc	aacctagaa	gtggactag	agaccacagt	cagaagggct	600
aaccgtgtac	taagtgtatg	actcaagaga	taccctagaa	tggacatacc	aaagattgcc	660
agatccttct	atgacttatt	tgaacaaaa	gtgtatcaca	gaagtttgtt	cattgagtat	720
ggcaaagcat	taggctcatt	atctacaggc	agcaaagcag	aaagtctatt	tgtaaata	780
ttcatgcaag	cttatggggc	cggccaaca	atgctaaggt	ggggggctcat	tgccaggtca	840
tccaacaata	taatgttagg	acatgtatcc	gtccaagctg	agttaaaaa	ggcacagaa	900
gctctatgct	tggtgtgaga	aatgggccct	gaatctggac	ttctacattt	aaggcaaacg	960
ccaaaagctg	gactgttatt	actagccaac	tgtcccaact	ttgcaagtgt	tgttctcggg	1020
aatgcctcag	gcttaggcat	aatcggtatg	tatcgagggg	gagtaacaaa	cacagaatta	1080
ttttcagcag	ctgaaagtta	tgccaaaagt	ttgaaaagaa	gcaataaaat	aaatttctct	1140
tcattaggac	ttacagatga	agagaaagag	gctgcagaac	atctcttaa	tgtagtgac	1200
gacagtcaaa	atgattatga	gtaattaaaa	aagtgggaca	agtcaaaatg	tcattccctg	1260
aaggaaaaag	tattcttttc	atgggtaatg	aagcagcaaa	attagcagaa	gctttccaga	1320
aatcattaag	aaaaccagg	cataaaagat	ctcaatctat	tataggagaa	aaagtgaata	1380
ctgatatcaga	aacattggaa	ttacctacta	tcagttagacc	tgcaaaaacca	accataccgt	1440
cagaaccaaa	gtagcatgg	acagataaag	gtggggcaac	caaaactgaa	ataaagcaag	1500
caarcaaagt	catggatccc	attgaagaag	aagagcttac	cgagaagaag	gtgctaccct	1560
ccagtgtatg	gaaaaccctt	gcagaaaaga	aactgaaacc	atcaactaac	accaaaaaga	1620
aggtttcatt	tacaccaaat	gaaccagggg	aatatacaaa	gttggaaaaa	gatgctctag	1680
atttgctctc	agataatgaa	gaagaagatg	cagaatcttc	aatcttaacc	tttgaagaaa	1740
gagatacttc	atcartaagc	attgaggcca	gattggaatc	aatagaggag	aaattaagca	1800
tgatattagg	gctattaaga	acactcaaca	ttgctacagc	aggaccaca	gcagcaagag	1860
atgggatcag	agatgcaatg	attggcgtaa	gagaggaatt	aatagcagac	ataataaagg	1920
aagctaaagg	gaaagcagca	gaaatgatgg	aagaggaat	gagtcaacga	tcaaaaatag	1980
gaaatggatg	tgtaaaaata	acagaaaaag	caaaagagct	caacaaaatt	gttgaagatg	2040
aaagcacaag	tggagaatcc	gaagaagaag	aagaaccaaa	agacacacaa	gaccaatagt	2100
aagaagatga	catttaccag	ttatttatgt	agtttaataa	aaataaaca	tgggacaagt	2160
aaaaatggag	tcttacctag	tagacaccta	tcaaggcatt	ccttacacag	cagctgttca	2220
agttgatcta	atagaaaagg	acctgttacc	tgcaagccta	acaatatggt	tccttttgtt	2280
tcaggccaac	acaccaccag	cagtgctgct	cgatcagcta	aaaaccctga	caataaccac	2340
tctgtatgct	gcatcacaaa	atggtccaat	actcaaagtg	aatgcatcag	cccaaggtgc	2400

agcaatgtct	gtacttccca	aaaaatttga	agtcaatgcy	actgtagcac	tcgatgaata	2460
tagcaaactg	gaatttgaca	aactcacagt	ctgtgaagta	aaaacagttt	acttaacaac	2520
catgaaacca	tacgggatgg	tatcaaaatt	tgtgagctca	gccaaatcag	ttggcaaaaa	2580
aacacatgat	ctaaticgcac	tatgtgattt	tatggatcta	gaaaagaaca	cacctgttac	2640
aataccagca	ttcatcaaat	cagtttcaat	caaagagagt	gagtcagcta	ctgttgaagc	2700
tgctataaagc	agtgaagcag	accaagctct	aacacaggcc	aaaattgcac	cttatgctgg	2760
artaattatg	atcatgacta	tgaaacaatcc	caaaggcata	ttcaaaaagc	ttggagctgg	2820
gactcaagtc	atagtagaac	taggagcata	tgtccaggct	gaaagcataa	gcaaaaatag	2880
caagacttgg	agccatcaag	ggacaagata	tgtcttgaag	tccagataac	aaccaagcac	2940
cttggccaag	agctactaac	cctatctcat	agatcataaa	gtcaccattc	tagttatata	3000
aaaaatcaagt	tagaacaaga	atataatcaa	tcaagaacgg	gacaaaataa	aatgtcttgg	3060
aaagtgggtga	tcattttttc	attgttaata	acacctcaac	acggctctta	agagagctac	3120
ttagaagagt	catgtagcac	tataactgaa	ggatattctca	gtgttctgag	gacaggttgg	3180
tacaccaatg	tttttacact	ggaggttaggc	gatgtagaga	accttacatg	tgccgatgga	3240
cccagcttaa	taaaaacaga	attagacctg	accaaaagtg	cactaagaga	gctcagaaca	3300
gtttctgctg	atcaactggc	aagagaggag	caaattgaaa	atcccagaca	atctagattc	3360
gttctaggag	caatagcact	cgggtgttga	actgagctg	cagttacagc	aggtgtttga	3420
attgccaaga	ccatccggct	tgaaagtga	gtaacagcaa	taagaatgc	ctcaaaaag	3480
accaatgaag	cagtatctac	attggggaat	ggagttctg	tgttggcaac	tgcatgaga	3540
gagctgaaag	attttgtgag	caagaatcta	acacgtgcaa	tcaacaaaaa	caagtgcgac	3600
attgtgacc	tgaaaatggc	cgttagcttc	agtcaattca	acagaagggt	cctaaatgtt	3660
gtgctggcaat	cttcagacaa	cgctggaata	acacagcaa	tatctttgga	cttaagtaca	3720
gatgctgaac	tagccagagc	tgttccaac	atgccaaat	ctgcaggaca	aataaaactg	3780
atgttggaga	accgtgcaat	ggtaagaaga	aaagggttcg	gattcctgat	aggagtttac	3840
ggaagctccg	taatttacct	ggtgcaactg	ccaacttttg	gggttataga	cacgccttgc	3900
tgatagtaa	aagcagcccc	ttcttgttca	ggaaaaaagg	gaaactatgc	ttgcctctta	3960
agagaagacc	aaggatggta	ttgtcaaaat	gcaggggtcaa	ctgtttacta	cccaaatgaa	4020
aaagactgtg	aaacaagagg	agaccatgtc	ttttgagaca	cagcagcagg	aatcaatggt	4080
gctgagcagt	caaaggagtg	caacataaac	atattcta	ctaattacc	atgcaaggtt	4140
agcacaggaa	gacatcctat	cagtatgggt	gcactatctc	ctcttggggc	tttgggtgct	4200
tgctacaagg	gagtgagctg	ttccattggc	agcaacagag	tagggatcat	caagcaactg	4260
aaacaaggct	gctcttatat	aaccaaccaa	gacgcagaca	cagtgacaat	agcaacaact	4320
gtataccagc	taagcaaggt	tgaaggcgaa	cagcatgta	taaaaggaag	gccaggttca	4380
agcagctttg	accagtcaca	gtttcctgaa	gatcaattca	atgttgcact	tgaccaagtt	4440
ttcagagaca	ttgagaacag	tcaggccttg	gtggatcaat	caaacagaat	cctaagcagt	4500
gcagagaaag	gaaacactgg	cttcatcatt	gtaataatc	taattgctgt	ccttggctct	4560
accatgatcc	tagtgagtg	ttttatcata	ataaaagaaa	caaaagaaac	caagaggaga	4620
cctccagagc	tgagtggtgt	cacaaacaat	ggcttcatac	cacataatta	gtaatttaa	4680
aataaagttaa	attaaaaata	atataaatta	aaaataaaaa	tttgggacaa	atcaaatgt	4740
ctcgcaaggc	tcctgtgcaa	tatgaagtc	ggggcaaatg	caatagagga	agtgagtgca	4800
agtttaacca	caattactgg	agttggccag	atagatactt	atataaaga	tcaaatatt	4860
tattaaatca	acttttaagg	aacactgata	gagctgatgg	cttatcaata	aatcaggag	4920
caggcagaga	agataggaca	caagattttg	tcctaggttc	caccaatgtg	gttcaagggt	4980
ataattgatg	taaccaaaagc	atacaaaaag	ctgcagctg	ttacagtcta	cataatataa	5040
tcaaaacaat	acaagaagtt	gaagttaggc	aggctgaga	taacaaacta	ctgcagaca	5100
aacatgtagc	acttcacaac	ttagtcttat	cttataatgga	gatgagcaaa	actcctgcat	5160
ctttaatcaa	caatctcaag	agactgcca	gagagaaaact	gaaaaaatta	gcaagctca	5220
taattgactt	atcagcaggt	gctgaaaaatg	actcttcata	tgcttgcaca	gacagtgaaa	5280
gcactaatca	agtgagtgga	gcattggtcca	gttttcatta	ctatagaggt	tgatgactag	5340
atatggactc	acaaggactt	aaaagaagct	ttatctgatg	ggatagtgaa	gtctcact	5400
aacatttaca	attgtttatt	agaaaacata	gaaatttat	atgtcaaggc	ttacttaagt	5460
tagtaaaaac	acatcagagt	gggataaatg	acaatgataa	cattagatgt	cattaaagt	5520
gatgggtctt	caaaaaatg	tactcacctc	aaaaaataa	ttaaagacca	ctctggtaaa	5580
gtgcttattg	tacttaagtt	aatattagct	ttactaacat	ttctcacagt	aacaatcacc	5640
atcaattata	taaaagtgga	aaacaatctg	caaatatgcc	agtcaaaaac	tgaatcagac	5700
aaaaaggact	catcatcaaa	taccacatca	gtcacaacca	agactactct	aatcagtat	5760
atcacacagt	attttaaaag	tttgattcaa	aggtatacaa	actctgcaat	aaacagtgac	5820
acatgctgga	aaataaacag	aaatcaatgc	acaaatataa	caacatacaa	atttttatgt	5880
tttaaatctg	aagacacaaa	aaccaacaat	tgatgataaac	tgacagattt	atgcagaaac	5940
aaaccaaaac	cagcagtttg	agtgatcac	atagtagaat	gccattgtat	atacacagtt	6000
aaatgggaag	gctatcatta	cccaaccgat	gaaaccaca	cctaaatggt	aacaccagat	6060
taggatccat	craagtctgt	tagttcaaca	atrttagttat	ttaaaaatat	tttgaaaaac	6120
agtaagtttc	tatgatactt	cataataata	agtaataatt	aatgtcttaa	tcatactcac	6180
aacattattc	gaaaccataa	ctattcaatt	taaaaagtaa	aaaacaataa	catgggacaa	6240
gtagttatgg	aggtgaaagt	ggagaacatt	cgaaacaatg	atatgtctcaa	agcaagagta	6300
aaaaactgta	tggcaccgag	caaatgcttt	aaaaatgctt	ctttggctct	cataggaata	6360
actacattg	gtattgacct	caatatctat	ctgatcataa	actataaaat	gcaaaaaaac	6420
acatctgaat	cagaacatca	caccagctca	tcacccatgg	aatccagcag	agaaactcca	6480
acggtcccca	cagacaactc	agacaccaac	tcaagcccac	agcatccaac	tcaacagctc	6540
acagaaggct	ccacactcta	ctttgcagct	tcagcaagct	caccagagac	agaaccaaca	6600
tcaacaccag	atacaacaaa	ccgcccggcc	ttcgtcgaca	cacacacaac	accaccaagc	6660
gcaagcagaa	caaagacaag	tccggcagtc	cacacaaaaa	acaacccaag	gacaagctct	6720

agaacacatt	ctccaccacg	ggcaacgaca	aggacggcac	gcagaaaccac	cactctccgc	6780
acaagcagca	caagaaagag	accgctccaca	gcatccagttc	aacctgacat	cagcgcaaca	6840
accacacaaa	acgaaagaagc	agcccaaaaa	agcccaaaaa	catctgcaag	caacaacaga	6900
atacaaaagga	aaagcgtgga	ggccaacaca	tcaacaacat	acaaccaaac	tagttaacaa	6960
aaaatacaaaa	ataactctaa	gataaacctat	gcagacacca	acaatggaga	agccaaaaga	7020
caattcacaa	tcccccaaa	aaggcaacaa	cacctatatta	gctctgccc	aatctccctg	7080
gaaaaaacac	tgcgccat	accaaaaaata	ccacaaccac	cccaagaaaa	aaactgggca	7140
aaacaacacc	caagagacaa	ataacaatgg	atcctctcaa	tgaatccaat	gttaatgtct	7200
atcttctcga	ctcatatctt	aaaggagtga	tttctcttag	tgagactaat	gcaattgggt	7260
catgtctctt	aaaaagacct	tacctaaaaa	atgacaacac	tgcaaaagtt	gccatagaga	7320
atcctgttat	cgagcatgrr	agactcaaaa	atgcagtcaa	ttctaagatg	aaaaatcag	7380
attacaagat	agtagagcca	gtaaacatgc	aacatgaaat	tatgaaagat	gtacacagtt	7440
gtgagctcac	atfattaaaa	cagtttttaa	caaggagtaa	aaatattagc	actctcaaat	7500
taaatatgat	atgtgattgg	ctgcagttaa	agctcaatc	agatgatacc	tcaatcctaa	7560
gttttataga	tgtagaattt	atacctagct	gggtaagcaa	ttggtttagt	aatrggtaca	7620
atcraaacaa	gttgattctg	gaattcagga	aagaagaagt	aataagaact	ggttcaatct	7680
tggtgaggtc	tttgggtaaa	ttagtttttg	ttgtatcatc	atatggatgt	atagtcaaga	7740
gcaacaaaag	caaaaagagt	agcttcttca	catacaatca	actgttaaca	tggaagatg	7800
tgatgttaag	tagattcaat	gcaaatrttt	gtatatgggt	aagcaacagt	ctgaatgaaa	7860
atcaagaag	gctagggttg	agaagtaatc	tgcaaggcat	attaactaat	aagctatatg	7920
aaactgtaga	ttatatgett	agtrttatgt	taaggattat	tttctcactt	gtgaaagagt	7980
tccaaggtct	tattatgagt	gaaattctta	ggattactga	acatgctcaa	ttcagtacta	8040
gatttagaac	factttatta	aatggattaa	ctgatcaat	aacaaaaata	aaaaataaaa	8100
acagactcag	agttcatggt	accgtgttag	aaaataatga	ttatccaatg	tacgaagtgt	8160
tacttaagtt	attaggagat	actttgagat	gtattaaatt	attaatcaat	aaaaacttag	8220
agaatgctgc	tgaattatac	tatatattta	gaatattcgg	tcacccaatg	gtagatgaaa	8280
gagatgcaat	ggatgctgct	aaattaaaca	atgaaatcac	aaaaatcctt	aggtgggaga	8340
cttgacaga	actaagaggg	gcattcatat	gcattcatat	caaaggattt	gtagacaca	8400
acaaaagatg	gccccaaatt	aaaaacttaa	aagtgcctag	taagagatgg	actiatgtact	8460
tcaagcaaa	aagttacccc	agtcaacttg	aattraagcga	acaagatttt	rtagagcttg	8520
ctgcaataca	gtttgaaaca	gagttttctg	tccctgaaaa	aaaccaactt	gagatggtat	8580
taaatgataa	agctatatca	cctcctaaaa	gattaatatg	gtctgtgtrt	ccaaaaaatt	8640
acttaacctga	gaaaaataaaa	aatcgatatac	tagaagagac	tttcaatgca	agtgatagtc	8700
tcaaaacaag	aagagtacta	gagtactatt	tgaaagataa	taaattcagac	caaaaagac	8760
rtaaaagtta	tgtrgttaaa	caagaatatr	taaatgataa	ggatcatatt	ctctcgttaa	8820
ctggaaaaga	aagagaatta	agtgtaggta	gaatgtttgc	tatgcaacca	ggaaaacagc	8880
gacaaataca	aatattggct	gaaaaattgt	tagctgataa	tattgtacct	tttttccag	8940
aaaccttaac	aaagtatggt	gatctagatc	ttcagagaat	aatggaaatc	aaatcggaac	9000
tttcttctat	taaaaactaga	agaaatgata	gttataataa	ttacattgca	agagcatcca	9060
tagtaacaga	tttaagtaag	ttcaaccaag	cccttaggta	tgaaaactaca	gcgatctgtg	9120
cggatgtagc	agtagaacta	catggaacac	aaagcctatt	cigtgtggtta	catcttatcg	9180
tcctatgac	aaacaatgata	tgtgcctata	gacatgccc	accagaaaca	aaaggtgaat	9240
atgatataga	taagatagaa	gagcaaaagt	gtttatatag	atatcatatg	ggtggatatt	9300
aaggatgggt	tcaaaaactc	tggaacaatgg	agctatatc	tctattagai	gttgtatctg	9360
taaaaaacacg	atgtcaaatg	acatctttat	taaacgggtga	caaccaatca	atagatgtaa	9420
gtaaacaggt	taagttatct	gagggtttag	atgaaagtga	agcagattat	agcttggctg	9480
taaaaatggt	aaagaaata	agagatgcat	acagaaatat	agggcataaa	cttaagagag	9540
ggaaacata	tatatcaaga	gatcttcagt	ttataagtaa	ggtgattcaa	tctgagagag	9600
taatgcatcc	taccctata	aaaaagatct	taagagtggg	accatggata	aacacaatat	9660
tagatgacat	taaaaaccagt	gcagagtcaa	tagggagtct	atgtcaggaa	ttagaartta	9720
ggggggaaag	cataatagtt	agctctgat	taaggaattt	ttggctgtat	aatittataca	9780
tgcatgaaac	aaagcaacac	ccccagtagc	ggaagcagtt	attcaaacaa	ctaaaataaaa	9840
cattaacatc	agtgcaagaga	ttttttgaaa	taaaaaagga	aaatgaagta	gtagatctat	9900
ggatgaaacat	accaatgcag	tttggaggag	gagatccagt	agcttctct	agatcrrtct	9960
atagaaggac	ccctgatttt	ttactgaag	caatcagctca	tggtgatatt	ctgttaagaa	10020
tatcagccaa	cataagaaat	gaagcgaaaa	taagtttctt	caaagcctta	ctgtcaatag	10080
aaaaaaatga	acgtgtcaca	ctgacaacac	taatggagaga	tcctcaagct	gttggctcag	10140
agcgacaagc	aaaagtaaca	agtgatatca	atagacaagc	agttaccagc	atcttaagtc	10200
tttctcaaaa	tcaacttttc	agcgatagtg	ctatacacta	cagtagaaat	gaagaagagg	10260
tcggaatcat	tgctgacaac	ataacacctg	tttatcctca	tggaactgaga	gttttgfatg	10320
aatcattacc	ttttcataaa	gctgaaaaag	ttgtgaaat	gatatacagga	acgaaatcca	10380
taaccaactt	attacagaga	acatctgcta	ttaatgggtga	agatattgac	agagctggtat	10440
ccatgatgct	ggagaacctta	ggattartat	ctagaatatt	gtcagtagtt	gttgatagta	10500
tagaaattcc	aaccaaatct	aatggtaggc	tgatatgttg	tcagatatct	agaaccctaa	10560
gggagacatc	atggaaatag	atggaaatag	ttggagtaac	atcccctagc	atcactacat	10620
cctatgatgt	catatagca	actagctctc	atrtgaaagg	gataatcatt	gaaaagttca	10680
gtactgacag	aactacaaga	ggtcaagag	gtccaaagag	ccctgggta	gggtcgagca	10740
ctcaagagaa	aaaattagtt	cctgtttata	acagacaaat	tctttcaaaa	caacaaagag	10800
aacagctaga	agcaattgga	aaaaagagat	gggtatataa	agggacacca	ggttaagac	10860
gattactcaa	taagatttgt	cttggaaagt	taggcattag	ttacaatgt	gtaaaacctt	10920
tattacctag	gtttatgagt	gtaaaattcc	tacacaggtt	atctgtcagt	agtagaccta	10980
tgaattccc	agcatcagtt	ccagcttata	gaacaacaaa	ttaccatrtt	gacactagtc	11040

ctattaatca	agcactaagt	gagagatttg	ggaatgaaga	tattaatttg	gtcttccaaa	11100
atgcaatcag	ctgtggaatt	agcataatga	gtgtagtaga	acaattaact	ggtaggagtc	11160
caaaaacgtt	agttttaata	cctcaattag	aagaaataga	cattatgcca	ccaccagtgt	11220
ttcaagggaa	attcaattat	aagctagtag	ataagataac	ttctgatcaa	catatcttca	11280
gtccagacaa	aatagatatt	ttaacactgg	ggaaaatgct	catgcccact	ataaaaagtc	11340
agaaaaacaga	tcagttcctg	aacaagagag	agaattatit	ccatgggaat	aatctttattg	11400
agtctttgtc	agcagcgtta	gcatgtcatt	gggtgtggat	attaacagag	caatgtatag	11460
aaaataatat	tttcaagaaa	gactggggtg	acgggttcat	atcggatcat	gctrrtatgg	11520
actttcaaaat	attcctatgt	gtctttaaaa	ctaaaactttt	atgtagttgg	gggtcccnaag	11580
ggaaaaacat	taaagatgaa	gatatagtag	atgaatcaat	agataaaactg	ttaaggattg	11640
ataatacttt	ttggagaatg	ttcagcaagg	ttatgtrtga	arcaaagggt	aagaaaagga	11700
taatgttata	tgatgtaaaa	tttctatcat	tagtaggita	taragggtt	aagaattggg	11760
ttatagaaca	gttgagatca	gctgagttgc	atgaggtacc	ttggattgtc	aatgccgaag	11820
gtgatctggg	tgagatcaag	tcaattaaaa	tctatttgca	actgatagag	caaagttaf	11880
ttttaagaat	aactgttttg	aactatacag	atatggcaca	tgctctcaca	agattaatca	11940
gaaagaagtt	gatgtgtgat	aatgcactat	taactccgat	tccatcccca	atggttaatt	12000
taactcaagt	tattgatcct	acagaacaat	tagcttatt	ccctaagata	acatttgaaa	12060
ggctaaaaaa	ttatgacact	agttcaaat	atgctaaaagg	aaagctaaaca	aggaattaca	12120
tgatactggt	gccatggcaa	catgttaata	gatataactt	tgtctttagt	tctactggat	12180
gtaaaagrtag	tctaaaaaca	tgcarttggaa	aacttatgaa	agatctaaac	cctaaagtcc	12240
tgtactttat	tgagaaaggg	gcaggaaatt	ggatggccag	aacagcatgt	gaatatcctg	12300
acatcaaat	tgatatacaga	agtttaaaag	afgacrtga	tcatacattat	cctttggaa	12360
accagagagt	tataggagaa	ttaagcagga	taatagatag	cggtgaaggg	ctttcaatgg	12420
aaaacaacaga	tgcaactcaa	aaaactcatt	gggatttgat	acacagagta	agcaaagatg	12480
cttttattaat	aactttatgt	gatgcagaat	ttaaggacag	agatgatttt	tttaagatgg	12540
taattctatg	gaggaacat	gtattatcat	gcagaatttg	cactacttat	gggacagacc	12600
tctattttat	cgcaaatgat	catgctaaag	actgcaatgt	aaaattacct	ttttttgtga	12660
gatcattagc	cacttttatt	atgcaaggtta	gtaaacgttc	aggctcagaa	tgctacatac	12720
tcttaacact	aggccaccac	aacaattttac	cctgcccag	agaaatacaa	aartctaaaga	12780
tgaaaaatagc	agrtgtgtaat	gattttttatg	ctgcaaaaaa	actttgcaat	aaatctattg	12840
aaagcaactg	taaatacact	ttatcagggc	taagaatacc	gataaataag	aaagaattaa	12900
atagacagag	aaagttatta	acactacaaa	gcaaccattc	ttctgtagca	acagttggag	12960
gtagcaaggt	catagagtct	aaatggtraa	caaacaaaggc	aaacacata	attgatgggt	13020
tagaacatat	tttaaatct	ccaaaagggtg	aattaaatta	tgattttttt	gaagcattag	13080
aaaataactta	ccctaataatg	attaaactaa	tagataatct	agggaaatgca	gagataaaaa	13140
aactgatcaa	agtaactgga	tatatgtctg	taagtaaaaa	atgaaaaatg	ataaaaaatga	13200
taaaataggt	gacaacttca	tactattcca	aagtaatcat	ttgattatgc	aattatgtaa	13260
tagttaaatta	aaaactaaaa	atcaaaagtt	agaaactaac	aactgtcatt	aagtttatta	13320
aaaataagaa	attataattg	gatgtatcgc				13350<210> 2

<211> 782
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(782)
 <223> human metapneumovirus, strain Quebec Isolate No hmpv-118

<400> 2						
atgtaggcac	cacaactgca	gtgacacctt	catcattgca	gcaagagata	acacttttgt	60
gtggagagat	tctttacact	aaacatactg	attacaaata	tgctgcagag	atagggatac	120
aatatatttg	cacggctcta	ggatcagaaa	gagtacaaca	gattttaaga	aattcaggyca	180
gtgaagttca	gggtgttcta	accaagacat	actcrttagg	gaaaggtaaa	aatagtaaag	240
gggaagagtt	gcaaatgtta	gatatacatg	gagtggaaa	gagttgggta	gaagaaatag	300
acaaagagggc	aagaaaaaca	atgggtgactt	tgctaaagga	atcatcaggt	aacatcccac	360
aaaaccagag	gccttcagca	ccagacacac	caataatttt	attatgtgta	gggtctttaa	420
tattcacraa	actagcatca	acaatagaag	ttggactaga	gactacagtt	agaagagcta	480
acagagtgct	aagtgatgcy	actcaaagat	accctaggg	agatatacca	aagattgcta	540
gatctttcta	tgaactatft	gagcagaag	tgtattacag	gagtctattc	attgagtatg	600
ggaaagcttt	aggctcatct	tgcacagga	gcaaagcaga	aagttttgtt	gtaaatataf	660
ttatgccagc	ttatggagcc	ggctcaaacaa	tgctaaagtg	gggtgtcatt	gccagatcat	720
ctaataatac	attgctaggg	catgtatctg	tgcaacctgg	atttgaagca	agtcacagag	780
gt						782

<210> 3
 <211> 878
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene

<222> (1)...(878)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-174

<400> 3
 atgtgggtac caccactgca gtgacaccct catcattgca acaagaata acgctgttgt 60
 gtggagaaat tctgtatgct aaacatgctg attacaaata tgctgcagaa ataggaatac 120
 aatataattag cacagcttta ggatcagaga gaggtcagca gattctgagg aactcaggca 180
 gtgaagtcca agtggcttta accagaacgt actctctggg gaaagttaaa aacaataaag 240
 gagaagattt acagatgtta gacatacacg gggtagagaa gagctgggta gaagagatag 300
 acaaaagaagc aaggaaaaca atggcaacct tgcttaagga atcatcaggt aatatcccgc 360
 aaaatcagag gccctcagca ccagacacac ccataatctt attatgtgta ggtgccttaa 420
 tatttactaa actagcatca accatagaag tgggactaga gaccacagtc agaagggcta 480
 accgtgtact aagtgatgca ctcaagagat accctagaat ggacatccca aaaattgcca 540
 gatccttcta tgacttattt gaacaaaaag tgtatcacag aagtttgctt attgagtatg 600
 gcaaaagcatt aggctcatca tctacaggca gcaaaagcaga aagcttattt gttaatatat 660
 tcaatcaagc ttatggagcc ggtcaacaa tgctaaggta ggggttcatt gccaggtcat 720
 ccaacaatat aatgttatga catgtatctg tccaagctga gttaaacaca ggtcacagaa 780
 gtctatgact tgggtcagaga aatgggtcct gaatctggac ttctacattt aaggcaaaagc 840
 ccaaaagctg gactgtatca cttagcact tcccaact 878

<210> 4
 <211> 876
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(876)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-176

<400> 4
 atgtaggccc cacaactgca gtgacaccct catcattgca gcaagagata acacttttgt 60
 gtggagagat tctttacact aaacatactg attacaaata tgctgcagag atagggatac 120
 aatataatttg cacggctcta ggatcagaaa gaggtaaca gattttaaga aattcaggta 180
 gtgaagttca ggtggttcta accaagacat actccttagg gaaaggtaaa aaragtaaa 240
 gggaagaggt gcaaatgtta gatatacatg gaggtaaaa gagttgggta gaagaatag 300
 acaaaagagcc aagaaagaca atgggtgact tgctaaagga atcatcaggt aacatcccac 360
 aaaaccagag gccctcagca ccagacacac caataatttt attatgtgta ggtgcgttaa 420
 tattcactaa actagcatca acaatagaag ttggactaga gactacagtt agaagagcta 480
 acagagtgct aagtgatgca ctcaaaagat accctagggt agatatacca aagattgcta 540
 gatcttttta tgaactatct gaggagaaag tgtattacag gaggctatct attgagtatg 600
 gaaaagcttt aggtctatct tcaacaggaa gcaaaagcaga aagtttgctt gtaaatatat 660
 ttatgcaagc ttatggagcc ggtcaaacaa tgctaaggta ggggttcatt gccagatcat 720
 ctacaacat aatgctaggg catgtatctg tgcaagctga attgaaacaa gttacagagg 780
 tttatgattt ggtgagagaa atgggtcctg aatctgggct ttactctta agaacaagtc 840
 caaaggcagg actgttatcg tggctaattg cccaat 876

<210> 5
 <211> 869
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(869)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-193

<400> 5
 atgtgggtac aacaactgca gtgacaccct catcattgca acaagaata acgctgttgt 60
 gtggagaaat tctgtatgct aaacatgctg attacaaata tgctgcagaa ataggaatac 120
 aatataattag cacagcttta ggatcagaga gaggtcagca gattctgagg aactcaggta 180
 gtgaagtcca agtggcttta accagaacgt actctctggg gaaagttaaa aacaataaag 240
 gagaagattt acagatgtta gacatacacg gggtagagaa gagctgggta gaagagatag 300
 acaaaagaagc aaggaaaaca atggcaacct tgcttaagga atcatcaggt aatatcccac 360
 aaaatcagag gccctcagca ccagacacac ccataatctt attatgtgta ggtgccttaa 420
 tatttactaa gctagcatca accatagaag tgggactaga gaccacagtc agaagggcta 480
 accgtgtact aagtgatgca ctcaagagat accctagaat ggacatccca aaaattgcca 540
 gatccttcta tgacttattt gaacaaaaag tgtatcacag aagtttgctt attgagtatg 600
 gtaaaagcatt aggatcatca tctacaggca gcaaaagcaga aagcttattt gttaatatat 660

6/52

tcatgcaagc	ttatggagcc	ggtcaaacaa	tgctaaggctg	gggggtcatt	gccaggtcat	720
ccaacaatat	aatggttagga	catgtatccg	tccaaggctg	agttaaaaca	ggtcacagaa	780
gtctatgact	tggtgcgaga	aatgggtcct	gaatctggac	ttctacattt	aaggcaaacg	840
ccaaaagctg	gactgttatc	actagccaa				869

<210> 6
 <211> 848
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(848)
 <223> human metapneumovirus, strain Quebec Isolate No C-77807

<400> 6	atgtaggcac	cacaactgca	gtgacacctt	catcattgca	acaagaaata	acacttttgt	60
	gtggggaaat	tctttacact	aaacacactg	attacaata	tgctgctgag	ataggaatgc	120
	aatatatttg	cacagctcta	ggatcagaaa	gagtacaaca	gattttgaga	aactcaggta	180
	gtgaagtcca	ggtggtttta	accaaaacat	actccttagg	gaaaggcaaa	aacagtaaag	240
	gggaagagct	gcagatgta	gatatacatg	gagvggaaaa	gagttgggta	gaagaaatag	300
	acaaaagaggc	aagaaagaca	atggtaactt	tgcttaagga	gtcatcaggt	aacatcccac	360
	aaaaccagag	accttcagca	ccagacacac	caataatttt	attatgtgta	ggtgccctaa	420
	tattcactaa	actagcatca	acaatagaag	ttggattaga	gactacagtt	agaagagcta	480
	atagagtgct	aagtgtgca	ctcaaaagat	accttagggg	agatatacca	aagattgcta	540
	gatcttttta	tgaactatct	gaacaaaaag	tgtactacag	aagtttattc	attgagtacg	600
	gaaaagcttt	aggctcatct	tcaacaggaa	gcaaagcaga	aagtttggtt	gtaaatata	660
	ttatgcaagc	ttatggagct	ggtcaaacac	tgctaaggctg	gggtgtcatt	gccagatcat	720
	ccaacaacat	aatgctaggg	catgtatctg	tgcaatctga	attgaaagca	ttcacagagg	780
	tttatgactt	ggtgagagaa	atgggtcctg	aatctgggct	tttacatcta	agacaaagtc	840
	caaaggca						848

<210> 7
 <211> 894
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(894)
 <223> human metapneumovirus, strain Quebec Isolate No C-77748

<400> 7	atgtgggtac	aacaactgca	gtgacacctt	catcattgca	acaagaaata	acgctgttgt	60
	gtggagaaat	tctgtatgct	aaacatgctg	attacaata	tgctgcagaa	ataggaatac	120
	aatatatttg	cacagcttta	ggatcagaga	gagtgagca	garrctgagg	aactcaggca	180
	gtgaagtcca	agtggtctta	accagaacgt	actctctggg	gaaagttaaa	aacaataaag	240
	gagaagattt	acagatgta	gacatacacg	gggtagagaa	gagctgggta	gaagagatag	300
	acaaaagaagc	aaggaaaaca	atggcaacct	tgcttaagga	atcatcaggt	aatatcccac	360
	aaaatcagag	gccctcagca	ccagacacac	ccataatctt	attatgtgta	ggtgccttaa	420
	tatttactaa	gctagcatca	acctatagaag	tgggactaga	gaccacagtc	agaagggcta	480
	accgtgtact	aagtgatgca	cctaagagat	accttagaat	ggacatccca	aaaattgcca	540
	gatccittcta	tgacttattt	gaacaaaaag	tgtatcacag	aagtttggtc	attgagtatg	600
	gcaaagcatt	aggctcatca	tctacaggca	gcaaagcaga	aagtctattt	gcttatatat	660
	tcatgagagc	ttatggagcc	ggtccaacaa	tgctaaggctg	gggggtcatt	gccagatcat	720
	ccaacaatat	aatggttagga	catgtatctg	tccaagctga	atttaaacaa	gacacagaag	780
	tccatgactt	ggtggtagaa	atggggcctg	aatctggact	ttctacttta	aggcaagcc	840
	caaaagctgg	actgtttaca	ctagccaact	gtcccaactt	tgcaagtgtt	gttc	894

<210> 8
 <211> 850
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(850)
 <223> human metapneumovirus, strain Quebec Isolate No hMPV-217

```

<400> 8
atgtgggtac aacaactgca gtgacaccct catcattgca acaagaaata acgctgttgt 60
gtggagaaat tctgtatgct aaacatgctg attacaaata tgctgcagaa ataggaatac 120
aatatattag cacagcttta ggatcagaga gagtgcagca gattctgagg aactcaggta 180
gtgaagtcca agtggcttta accagaacgt acictctggg gaaagttaaa aacaataaag 240
gagaagattt acagatgtta gacatacacg gggtagagaa gagctgggta gaagagatag 300
acaaagaagc aaggaaaaca atggcaacct tgcttaagga atcatcaggt aatataccac 360
aaaatcagag gccctcagca ccagacacac ccataatctt attatgtgta ggtgccttaa 420
tatttactaa gctagcatca accatagaag tgggactaga gaccacagtc agaagggcta 480
accgtgtract aagtgatgca ctcaagagat accctagaat ggacatccca aaaattgccca 540
gatccttcta tgacttattt gaacaaaaag tgtatcacag aagtgtgttc attgagtatg 600
gtaaagcatt aggatcatca tctacaggca gcaaaagcaga aagtctattt gttaatata 660
tcatgcaagc ttatggagcc ggtcaacaaa tgctaagggt gggggctcatt gcccaagtc 720
ccaacaatat aatgttagga catgtatccg tccaagctga attaaaaaca ggtccagaa 780
gtccatgact tgggtcgaga aatggggcct gaatctggac ttctactttt aaggcaaagc 840
ccaaaagctg
    
```

```

<210> 9
<211> 1185
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(1185)
<223> human metapneumovirus, strain 00-1, accession
        number af371337
    
```

```

<400> 9
argtctcttc aagggattca cctgagtgat ttatcataca agcatgctat attaaaagag 60
tctcagtaca caataaaaag agatgtgggt acaacaactg cagtgcacc ctcacattg 120
caacaagaaa taacactgtt gtgtggagaa attctgtatg ctaaacatgc tgactacaaa 180
tatgctgcag aaataggaat acaatatatt agcacagctt taggatcaga gagagtgcag 240
cagattctga ggaactcagg cagtgaagtc caagtggctt taaccagaac gtactctctg 300
gggaaaatta aaaacaataa aggagaagat ttacagatgt tagacataca cggggtagag 360
aagagctggg tagaagagat agacaaaaga gcaaggaaa caatggcaac ctfgcttaag 420
gaatctcag gtaatatccc acaaaatcag aggcctcag caccagacac acccataatc 480
ttattatgtg taggtgcctt aatattcact aaactagcat caaccataga agtgggacta 540
gagaccacag tcagaagggc taaccgtgta ctaagtgatg cactcaagag ataccctaga 600
atggacatac caaagattgc cagatccttc tatgacttat ttgaacaaa agtgtatcac 660
agaagtttgt tcattgagta tggcaagca ttaggctcat catctacagg cagcaaagca 720
gaaagtctat ttgttaatat attcatgcaa gcttatgggg cgggtcaaac aatgctaagg 780
tgggggggtca ttgccaggtc atccaacaat ataatgttag gacatgtatc cgtccaagct 840
gagttaaaac aggtcacaga agtctatgac ttgggtcgag aaatgggctc tgaatctgga 900
cttctacatt taaggcaaaag cccaaaagct ggactgttat cactagccaa ctgtcccaac 960
tttgcaagtg ttgttctcgg aaatgacctca ggcttaggca taatcggtat gtatcgaggg 1020
agagtaccaa acacagaatt attttcagca gctgaaagtt atgccaaaag tttgaaagaa 1080
agcaataaaa taaatctctc ttcattagga ctacagatg aagagaaaga ggtgcagaa 1140
catttcttaa atgtgagtga cgacagtcaa aatgattatg agtaa 1185
    
```

```

<210> 10
<211> 700
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(700)
<223> human metapneumovirus, strain Quebec Isolate No
        hmpv-163
    
```

```

<400> 10
tgcagaaata ggaatacaat atattagcac agcttttagga tcagagagag tgcagcagat 60
tctgaggaac tcaggcagtg aagtccaagt ggtcttaacc agaacgtact cctggggaa 120
agttaaaaac aataaaggag aagatttaca gatgttagac atacacgggg tagagaagag 180
ctgggtagaa gagatagaca aagaagcaag gaaaacaatg gcaaccttgc ttaaggaatc 240
atcaggtaat atccccaca atcagaggcc ctcagcacc a gacacacca taatcttatt 300
atgtgtaggt gccttaatat ttactaaact agcatcaacc atagaagtgg gactagagac 360
cacagtccaa agggccaacc gtgtactaag tgatgcactc aagagatacc ctagaatgga 420
catccccaaa attggcagat ccttctatga cttattttaa caaaaagtgt atcacagaag 480
ttgttctcatt gagtatggca aagcattagg ctcatctct acaggcagca aagcagaag 540
tctatttgtt aatatattca tgcaagctta tggagccggt caaacatgc taaggttggg 600
    
```

8/52

ggtaattgcc aggtcatcca acaatataat gttaggacat gtatccgtcc aagctgagtt 660
 aaaacaggtc acagaagtct atgacttggg gcgagaaatg 700

<210> 11
 <211> 705
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(705)
 <223> human metapneumovirus, strain Quebec Isolate No
 hmpv-174

<400> 11
 tattagcaca gctrraggat cagagagagt gcagcagatt ctgaggaact caggcagtga 60
 agtccaagtg gtcttaacca gaacgtactc ictggggaaa gttaaaaaca ataaaggaga 120
 agatrtacag atgttagaca tacacggggg agagaagagc igggtagaag agatagacaa 180
 agaagcaagg aaaacaatgg caaccttgct taaggaaatca tcaggttaata tccccaaaaa 240
 tcagaggccc tcagcaccag acacacccat aatcttatta tgtgtagggt ccttaatatt 300
 tactaaacta gcatcaacca tagaagtggg actagagacc acagtcagaa gggctaaccg 360
 tgtactaagt gatgcactca agagatacc tagaatggac atcccaaaaa ttgccagatc 420
 cttctatgac ttatttgaac aaaaagtgt tccacagaagt ttgttcattg agtatggcaa 480
 agcattagtc tcatcatcta caggcagcaa agcagaaagt gtatttgtta atatatccat 540
 gcaagcttat ggagccggtc aaacaatgct gagggtgggg gtcattgcca ggtcatccaa 600
 caatataatg ttaggacatg tatccgtcct agctgagcta aaaccggcca cagaagtcta 660
 tgacttgggt cgagaaatga ttcttgaatc tngacttcta catta 705

<210> 12
 <211> 700
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(700)
 <223> human metapneumovirus, strain Quebec Isolate No
 hmpv-184

<400> 12
 aaatatgctg cagaaatagg aatacaatat attagcacag ctttaggatc agagagagtg 60
 cagcagattc tgaggaactc aggcagtga gtccaagtgg tcttaaccag aacgtactct 120
 ctggggaaag ttaaaaacaa taaaggagaa gatttacaga tgttagacat acacggggta 180
 gagaagagct gggtagaaga gatagacaaa gaagcaagga aaacaatggc aaccttgctt 240
 aaggaatcat caggtaatat cccacaaaaat cagagggcct cagcaccaga cacaccata 300
 atcttattat gtgtagggtc cttaatatrt actaaactag catcaaccat agaagtggga 360
 ctagagacca cagtcagaag ggccaaccgt gtactaagtg atgcactcaa gagataccct 420
 agaattggaca tcccaaaaaat tgcagatcc ttctatgact tatttgaaca aaaagtgtat 480
 cacagaagtt tgttcattga gtatggcaaa gcattaggct catcatctac aggcagcaaa 540
 gcagaaagtc tatttgttaa tatattcatg caagcttatg gagccgggtca aacaatgcta 600
 aggtgggggg taattgccag atcatccaac aatataatgt taggacatgt atccgtccaa 660
 gctgagttaa aacaggtcac agaagtctat gacttagtgc 700

<210> 13
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No
 hmpv-185

<400> 13
 taggaataca atatattagc acagctctag gatcagagag agtacagcag attctaagaa 60
 actcaggcag tgaagtccaa gtggttttaa ccagaacgta ctccrrgggg aaagttaaaa 120
 acaacaagg agaagattta cagatgttag acatacacgg agtagagaaa agctgggtgg 180
 aagagataga caaagaagca agaaaaacaa tggcaacttt gcttaaagaa tcatcaggca 240
 atattccaca aaatcagagg ccttcagcac cagacacacc tataatctta ttatgtgtag 300
 gtgccttaat attraccaa ctagcatcaa ctatagaagt gggattagag accacagtca 360
 gaagagctaa ccgtgtacta agtgatgcac tcaaaagata ccctaggatg gacataccaa 420

9/52

aaatcgctag	atctttctat	gacttatttg	aacaaaaagt	gtattacaga	agcttggtca	480
ttgagtatgg	caaagcatta	ggctcatcct	ctacaggcag	caaagcagaa	agtrttattcg	540
ttaatatatt	catgcaagct	tacgggtgctg	gtcaaaaat	gctgaggtgg	ggagtcattg	600
ccaggctatc	taacaatata	atggttaggac	atgtaictgt	ccaagctgag		650

<210> 14
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No C-76837

<400> 14	acaaatatgc	atcataaata	ggaatacaat	atatttagcac	agcttttagag	atcagagaga	60
	gtgcagcaga	tcctaaggaa	ctcaggcagt	gaagtccaag	tggtcttaac	cagaacgtac	120
	tctctgggga	aaagttaaaaa	caataaagga	gaagattttac	agatgttaga	catacacggg	180
	gtagagaaga	gctgggtaga	agagatagac	aaagaagcaa	ggaaaacaat	ggcaaccttg	240
	cttaaggaat	catcaggtaa	tatccccaaa	aatcagaggc	cctcagcacc	agacacacc	300
	ataatcttat	tatgtgtagg	tgcccttaata	tttactaaac	tagcatcaac	catagaagtg	360
	ggactagaga	ccacagtcag	aagggctaac	cgtgtactaa	gtgatgcact	caagagatac	420
	cctagaatgg	acatcccaaa	aatigccaga	tccttctatg	acttatttga	acaaaaagtg	480
	tatcacagaa	gtttgttcat	tgagtatggc	aaagcattag	gctcatcctc	tacaggcagc	540
	aaagcagaaa	gtctattttgt	taatataatc	atgcaagctt	atggagccgg	tcaaaccaatg	600
	ctaaggtggg	gggtcattgc	caggtcatcc	aacaatataa	tgttaggata		650

<210> 15
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No C-77807

<400> 15	gtatgctaaa	catgctgatt	acaaatatgc	tgacagaata	ggaatacaat	atatttagcac	60
	agcttttaga	tcagagagag	tgacagcagat	tctgaggaac	tcaggcagtg	aagtcacaagt	120
	ggtcttaacc	agaacgtract	ctctggggaa	agttaaaaac	aataaaaagga	gaagattttac	180
	agatgttaga	catacacggg	gtagagaaga	gctgggtaga	agagatagac	aaagaagcaa	240
	ggaaaacaat	ggcaaccttg	cttaaggaat	catcaggtaa	tatccccaaa	aatcagaggc	300
	cctcagcacc	agacacacc	ataatcttat	tatgtgtagg	tgcccttaata	tttactaaac	360
	tagcatcaac	catagaagtg	ggactagaga	ccacagtcag	aagggctaac	cgtgtactaa	420
	gtgatgcact	caagagatac	cctagaatgg	acatcccaaa	aatigccaga	tccttctatg	480
	acttatttga	acaaaaagtg	tatcacagaa	gtttgttcat	tgagtatggc	aaagcattag	540
	gctcatcctc	tacaggcagc	aaagcagaaa	gtctattttgt	taatataatc	atgcaagctt	600
	atggagccgg	tcaaaccaatg	ctaaggtggg	gggtcattgc	caggtcatcc		650

<210> 16
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No hMPV-C-78123

<400> 16	ttaggatcag	agagagtgc	gcagattcta	aggaactcag	gcagtgaagt	ccaagtggtc	60
	ttaaccagaa	cgtaactcct	ggggaaagtt	aaaaacaata	aaggagaaga	tttacagatg	120
	ttagacatac	acggggtaga	gaagagctgg	gtagaagaga	tagacaaaga	agcaaggaaa	180
	acaaatggcaa	ccttgcttaa	ggaatcatca	ggtaatatcc	cacaaaatca	gaggccctca	240
	gcaccagaca	caccataat	cttattatgt	gtaggtgcct	taatatttac	taaacragca	300
	tcaaccatag	aagtgggact	agagaccaca	gtcagaaggg	ctaaccgtgt	actaagtgat	360
	gcactcaaga	gataccctag	aatggacatc	ccaaaaattg	ccagatccct	ctatgactta	420

10/52

tttgaacaaa	aagtgtatca	cagaagttg	ttcattgagt	atggcaaagc	attaggctca	480
tcaictacag	gcagcaaagc	agaaagtcta	tttgtaata	tattcatgca	agcrtatgga	540
gcccgtcaaa	caatgctaag	giggggggtc	attgccaggt	catccaacaa	tataatgta	600
ggacatgtat	ccgtccaagc	tgagttaaaa	caggtcacag	aagtctatga		650

<210> 17
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(700)
 <223> human metapneumovirus, strain Quebec Isolate No C-78132

<400> 17	cagaaagagt	acaacagatt	ttgagaaact	caggtagtga	agttcaggtg	gttttaacca	60
	aaacatactc	cttagggaaa	ggcaaaaaaca	gtaaagggga	agagctgcag	atgttagata	120
	tacatggagt	ggaaaagagt	tggttagaag	aaatagacaa	agaggcaaga	aagacaatgg	180
	taactttgct	taaggagtca	tcaggtaaca	tcccacaaaa	ccagagacct	tcagcaccag	240
	acacaccaat	aattttatta	tgtgtaggtg	ccctaattat	cactaaacta	gcatctacaa	300
	tagaagttag	attagagact	acagttagaa	gagctaatag	agtgctaagt	gatgcactca	360
	aaagataccc	tagggtagat	ataccaaaga	ttgctagatc	ttttatgaa	ctatttgac	420
	aaaaagtgtg	ctacagaagt	ttattcattg	agtacggaaa	agctttagcc	tcatcttcaa	480
	caggaagcaa	agcagaaagt	ttgtttgtaa	atataattat	gcaagcttat	ggagctggtc	540
	aaacactgct	aaggtggggg	gtcattgcca	gatcatccaa	caacataatg	ctagggcatg	600
	tatctgtgca	atctgaattg	aagcaagtta	cagaggttta	tgacttggtg		650

<210> 18
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No C-78163

<400> 18	ggatcagaaa	gagrtacaaca	gattttgaga	aactcaggtg	gtgaagttca	ggtggtttta	60
	accataaacat	actccttagg	gaaaggcaaa	aacagttaaag	gggaagagct	gcagatgtta	120
	gatatacatg	gagrtgaaaa	gagttgggta	gaagaatatg	acaaagaggc	aagaaagaca	180
	atggttaactt	tgcttaagga	gtcatcaggt	aacatcccac	aaaaccagag	accttcagca	240
	ccagacacac	caataatttt	attatgtgta	ggtgccttaa	tattcactaa	actagcatca	300
	acaatagaag	ttggattaga	gactacagtt	agaagagcta	atagagtgtc	aagtgatgca	360
	ctcaaaaagat	accctagggg	agatatacca	aagattgcta	gatcttttta	tgactatatt	420
	gaacaaaaag	tgtactacag	aagtttattc	attgagtacg	gaaaagcttt	aggctcatct	480
	tcaacaggaa	gcaaaagcaga	aagtttgttt	gtaaatatat	ttatgcaagc	ttatggagct	540
	ggtcaaacac	tgctaagggt	gggtgtcatt	gccagatcat	ccaacaacat	aatgctaggg	600
	catgtatctg	tgcaatctga	attgaaacaa	gttacagagg	tttatgactt		650

<210> 19
 <211> 600
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(600)
 <223> human metapneumovirus, strain Quebec Isolate No C-91205

<400> 19	atattagcac	agctctaggg	atcagagaga	gtacagcaga	ttctaagaaa	ctcaggcagt	60
	gaagtccaag	tggttttaac	cagaacgtac	iccittgggg	aagttaaaaa	caacaaagga	120
	gaagatttac	agatgtttag	catcacggga	gtagagaaaa	gctgggtgga	agagatagac	180
	aaagaagcaa	gaaaaacaat	ggcaactttg	cttaaagaat	catcaggcaa	tattccacaa	240
	aatcagaggc	cttcagcacc	agacacacct	ataatcttat	tatgtgtagg	tgcccttaata	300
	tttaccaaac	tagcatcaac	tatagaagtg	ggattagaga	ccacagtcag	aagagctaac	360
	cgtgtactaa	gtgatgcact	caaaagatac	cctaggatgg	acataccaaa	aatcgtctaga	420

11/52

tctttctatg	acttatttga	acaaaaagtg	tattacagaa	gcttgttcat	tgagtatggc	480
aaagcattag	gctcatcctc	tacaggcagc	aaagcagaaa	gtttattcgt	taatataatc	540
atgcaagctt	acgggtgctg	tcaaacaatg	ctgaggtg	gagtcattgc	caggtcatct	600

<210> 20
 <211> 700
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(700)
 <223> human metapneumovirus, strain Quebec Isolate No C-91364

<400> 20						
gattacaaat	atgctgctga	gataggaatg	caatatattt	gcacagctct	aggatcagaa	60
agagtacaac	agattttgag	aaactcaggt	agtgaagttc	agggtggtct	aacccaaaaca	120
tactccttag	ggaaaggcaa	aaacagtaaa	ggggaagagc	tcagatggtt	agatatacat	180
ggagtgga	agagtgggt	agaagaaata	gacaaagagg	caagaaagac	aatggtaact	240
tigcttaagg	agtcatcagg	taacatccca	caaaaccaga	gaccttcagc	accagacaca	300
ccaataat	tattatgtgt	aggtgcccta	atattcacta	aactagcatic	aacaatagaa	360
gttggattag	agactacagt	tagaagagct	aatagaggtg	taagtgatgc	actcaaaaga	420
taaccctagg	tagatatacc	aaagattgct	agatcttttt	atgaactatt	tgaacaaaaa	480
gtgtactaca	gaagtttatt	cattgagtac	ggaaaagctt	taggctcatic	ttcaacagga	540
agcaaaagcag	aaagttctgt	tgtaaatata	ttatgcaag	cttatggagc	tggctcaaca	600
ctgctaaggt	ggggtgtcat	tgccagatca	tccaacaaca	taatgctagg	gcatgtratct	660
gtgcaatctg	aattgaagca	agttacagag	gtrtatgact			700

<210> 21
 <211> 600
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(600)
 <223> human metapneumovirus, strain quebec isolate No C-91830

<400> 21						
cagctctagg	atcagaaaga	gtacaacaga	ttttgagaaa	ctcaggtagt	gaagttcagg	60
tggttctaac	caaaacatac	tccttaggga	aaggcaaaaa	cagtaaaggg	gaagagctgc	120
agatgttaga	tatacatgga	gtggaaaaga	gttgggtaga	agaaatagac	aaagaggcaa	180
gaaagacaat	ggtaactttg	cttaaggagt	catcaggtaa	catcccacaa	aaccagagac	240
cttcagcacc	agacacacca	ataattttat	tatgtgtagg	tgcttaata	ttcactaac	300
tagcatcaac	aatagaagtt	ggattagaga	ctacagttag	agagactaat	agagtgtctaa	360
gtgatgcact	caaaagatac	cctagggtag	atataccaaa	gattgctaga	tctttttatg	420
aactatttga	acaaaaagtg	tactacagaa	gcttattcat	tgagtacgga	aaagcttttag	480
gctcatcttc	aacaggaagc	aaagcagaga	gtttgtttgt	aaatatattt	atgcaagctt	540
atggagctgg	tcaaacactg	ctaaggtggg	gtgtcattgc	cagatcatcc	aacaacataa	600

<210> 22
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec isolate No hMPV-Q86

<400> 22						
atgctgatta	caaatatgct	gcagaaatag	gaatacaata	tattagcaca	gctctagggt	60
cagagaaggt	acagcagatt	ctaagaaact	caggcagtga	agtccaagcg	gttttaacca	120
gaacgtactc	tttggggaaa	gttaaaaaaca	ataaaggaga	agatttacag	atgttagaca	180
tacacggagt	agaaaaaagc	tgggtggaag	agatagacaa	agaagcaaga	aaaacaatgg	240
caactttact	taaagaatca	tcaggttaata	ttccacaaaa	tcagaggcct	tcagcaccag	300
acacacctat	aatcttatta	tgtgtagggt	ccttaattatt	caccaaacta	gcatcaacta	360
tagaagtggg	attagagacc	acagtcagaa	gagctaaccg	tgtactaagt	gatgcactca	420
aaagatacc	tagaatggac	ataccaaaaa	ttgctagatc	cttctatgac	ttatttgaac	480

12/52

aaaaagtgta	tcacagaagt	ttgttcattg	agtatgggca	aagcattagg	ctcatcctct	540
acaggcagca	aagcagaaaag	tttattcgtc	aatatattca	tgcaagctta	tggtgctggg	600
caaacaatgc	tgagggtgggg	gggttatcgc	caggtcattct	aacaatataa		650

<210> 23
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec isolate No
 hMPV-Q97

<400> 23	tagcacagct	ctaggatcag	agagagtaca	gcagattcta	agaaactcag	gcagtgaagt	60
	ccaagtgggt	ttaaccagaa	cgtactcctt	ggggaaaagt	aaaaacaaca	aaggagaaga	120
	tttacagatg	ttagacatac	acgggagtga	gaaaagctgg	gtggaagaga	tagacaaaga	180
	agcaagaaaa	acaatggcaa	ctttgcttaa	agaatcatca	ggcaatattc	cacaaaatca	240
	gaggccrtca	gcaccagaca	cacctataat	citattatgt	giagggtgcct	taatatttac	300
	caaactagca	tcaactatag	aagtgggatt	agagaccaca	gtcagaagag	ctaaccgtgt	360
	actaagtgtg	gcactcaaaa	gatacccctag	gatggacata	ccaaaaatcg	ctagatcttt	420
	ctatagctta	tttgaacaaa	aagtgtatta	cagaagcttg	ttcattgagt	atggcaaagc	480
	attaggctca	tcctctacag	gcagcaaagc	agaaagtttt	attcgttaat	atattcatgc	540
	aagcttacgg	tgctgggtcaa	acaatgctga	gggtggggagt	cattggccagg	tcattctaac	600
	atataatggt	aggacatgta	tctgtccaag	ctgagttaaa	acaagtcacg		650

<210> 24
 <211> 741
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(741)
 <223> human metapneumovirus, strain Can 97-83

<400> 24	agtgacacc	tcattcattg	aacaagaat	aacactattg	tgtggagaaa	ttctatatgc	60
	taagcatgct	gattacaat	atgctgcaga	aataggaata	caatatatta	gcacagctct	120
	aggatcagag	agagtacagc	agattctaag	aaactcaggg	agtgaagtcc	aagtgggtttt	180
	aaccagaacg	tactccttgg	ggaaagttaa	aaacaacaaa	ggagaagatt	tacagatggt	240
	agacatacac	ggagttagaga	aaagctgggt	ggaaagagata	gacaaagaag	caagaaaaac	300
	aatggcaact	ttgcttaaa	aatcatcagg	caatattcca	caaaatcaga	ggccttcagc	360
	accagaacaca	cctataatct	tattatgtgt	aggtgcctta	atattttacca	aactagcattc	420
	aactatagaa	gtgggattag	agaccacagt	cagaagagct	aaccgtgtac	taagtgatgc	480
	actcaaaaga	taccctagga	tggacatacc	aaaaatcgct	agatctttct	atgatttatt	540
	tgaacaaaaa	gtgtartaca	gaagtttgtt	cattgagtat	ggcaaagcat	taggctcattc	600
	ctctacaggc	agcaaagcag	aaagtttatt	cgtaaatata	ttcatgcaag	cttacgggtgc	660
	tggtcaaaaca	atgctgaggt	ggggagtcat	tgccaggtca	tctaacaata	taatgttagg	720
	acatgcatct	gtccaagctg	a				741

<210> 25
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Can 98-75

<400> 25	caatatattt	gcacggctct	aggatcagaa	agagtacaac	agattttaag	aaattcaggg	60
	agtgaagttc	aggtggttct	aaccaagaca	tactcttag	ggaaaggtaa	aaatagtaaa	120
	ggggaagagt	tgcaaatggt	agatatacat	ggagtggaaa	agagtgggt	agaagaata	180
	gacaaagagg	caagaaaaac	aatggtgact	ttgctaaagg	aatcatcagg	taacatcca	240
	caaaaccaga	ggccttcagc	accagacaca	ccaataattt	tattatgtgt	aggtgcttta	300
	atattcacta	aactagcattc	aacaatagaa	gttggactag	agactacagt	tagaagagct	360
	aacagagtgc	taagtgatgc	gctcaaaaga	taccctaggg	tagatatacc	gaagattgct	420
	agatctttct	atgaactatt	tgagcagaaa	gtgtattaca	ggagtctatt	cattgagtat	480

13/52

gggaaagcct	taggctcatic	ttcaacagga	agcaaagcag	aaagtttgtt	tgtaaatata	540
tttatgcaag	cttatggagc	cggtcaaaca	atgctaaggt	ggggtgtcat	tgccagatca	600
tctaacaaca	taatgctagg	acatgtgtct	gtgcaagctg	aattgaagca		650

<210> 26
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Can 98-75

<400> 26	atgtccttga	aagtgggat	tatcatttcg	ttactcataa	cacctcagca	cggtactaaa	60
	gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatatctcag	tgttttaaga	120
	acaggttggt	acaccaatgt	ctttacatta	gaagtgggtg	atggtgaaaa	tcttacatgt	180
	actgatggac	ctagcttaat	caaaacagaa	cttgacctaa	cmetaaggtgc	tctaagagaa	240
	ctcaaaaacag	tttctgctga	tcagttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
	tcaaggrttg	tcctaggtgc	aatagctctt	gggtgttgcca	cagcagcagc	agtcacagca	360
	ggcattgcca	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	caaaaggtgct	420
	ctcaaaaacaa	ccaacgagcc	agtatccaca	ctaggaatg	gagtgcgagt	cctagccacc	480
	gcagtaagag	agctgaaaag	atrrgtgagc	aaaaacctga	ctagtgcaat	taacaagaac	540
	aaatgtgaca	ttgctgacct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
	ctaaatgttg	tgccggcagt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
	ctaatgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgaggagacag	720
	ataaaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 27
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-67345

<400> 27	atgtccttga	aagtgggat	cattttttca	ttgctaataa	cacctcaaca	cggtcctaaa	60
	gagagctacc	tagaagaatc	atgtatcact	ataactgagg	gatatcttag	tggtctgaga	120
	acaggttggt	ataccaacgt	ttttacatta	gaggtgggtg	atgtagaaaa	ccttacatgt	180
	tctgatggac	ctagccraat	aaaaacagaa	ttagatctga	cmetaaggtgc	actaagagag	240
	ctcaaaaacag	tcctgctga	ccaattggca	agagaggaac	aaattgagaa	tcccagacaa	300
	tttaggtttg	ttctgggagc	aatagcactc	gggtgttgcaa	cagcagctgc	agtcacagca	360
	gggtgttgcaa	ttgccaaaac	catccggctt	gagagtgaag	tcacagcaat	taagaatgcc	420
	ctcaaaaacag	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	ggtggcaact	480
	gcagtggagc	agctgaaaga	ctttgtgagc	aagaatttaa	ctcgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgatgacct	aaaaatggcc	gttagcttca	gtcaattcaa	cagaaggttt	600
	ctaaatgttg	tgccggcaatt	ttcagacaat	gctggataaa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaaat	agctaggggc	gtttccaaca	tgccgacatc	tgaggagacaa	720
	ataaaaattga	tgttggagaa	ccgtgcgatg	gtaagaaga			759

<210> 28
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Can 97-83

<400> 28	ataaaaatgt	cttggaaagt	ggtgatcatt	ttttcattgc	taataacacc	tcaaacaggt	60
	cttaaaagaga	gctacctaga	agaatcatgt	agcactataa	ctgagggata	tcttagtggt	120
	ctgaggacag	gttggtatc	caacgttttt	acattagagg	tggtgtgatg	agaaaacctt	180
	acatgttctg	atggacctag	cctaataaaa	acagaattag	atctgaccaa	aagtgcacta	240
	agagagctca	aaacagtctc	tgctgaccaa	rtggcaagag	aggaacaaat	tgagaatccc	300
	agacaatcta	ggtttgttct	aggagcaata	gcactcgggtg	ttgcaacagc	agctgcagtc	360

14/52

acagcagggtg	ttgcaattgc	caaaaccatc	cggtctgaga	gtgaagtcac	agcaattaag	420
aatgccctca	aaacgaccaa	tgaagcagta	tctacattgg	ggaatggagt	tcgagtgttg	480
gcaactgcag	tgagagagct	gaaagacitt	gtgagcaaga	atttaactcg	tgcaatcaac	540
aaaaacaagt	gcgacattga	tgacctaaaa	atggccgtta	gcttcagtea	attcaacaga	600
aggtttctaa	atgtttgtcg	gcaattttca	gacaatgctg	gaataacacc	agcaatatct	660
ttggacttaa	tgacagatgc	tgaactagcc	agggccgtt	ctaacatgcc	gacatctgca	720
ggacaaataa	aattgatgtt	ggagaaccgt	gcgatggtg			759

<210> 29
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain quebec isolate No C-68661

<400> 29						
atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
acaggttggg	ataccaacgt	ttttacactg	gaggtagggt	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtgaggg	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaaatggcc	gtagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 30
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec isolate No C-73750

<400> 30						
atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
acaggttggg	ataccaacgt	ttttacactg	gaggtagggt	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtgaggg	aactgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaaatggcc	gtagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 31
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec isolate No C-74549

<400> 31

15/52

atgtcttggg	aagtgggtgat	cattttttca	ttgctaataa	cacctcaaca	cggtctttaa	60
gagagctacc	tagaagaatc	atgtagcact	ataactgagg	gatatcttag	tgttctgagg	120
acaggttggg	ataccaacgt	ttttacatta	gaggtgggtg	atgtagaaaa	ccttacatgt	180
tctgatggac	ctagccraat	aaaaacagaa	ttagatctga	ccaaaagtgc	actaagagag	240
ctcaaaaacag	tctctgctga	ccaattggca	agagaggaac	aaattgagaa	tcccagacaa	300
tctaggtttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agtcacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gagagtgaag	tcacagcaat	taagaatgcc	420
ctcaaaaacga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaga	ctttgtgagc	aagaatttaa	ctcgtgcaat	caacaaaaac	540
aagtgcgaca	ttgatgacct	aaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgtrg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagggcc	gtttctaaca	tgccgacatc	tcaggacaa	720
ataaaaattga	tgttggagaa	ccgcgcgatg	gtaagaaga			759

<210> 32
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-74783

<400> 32	atgtcttggg	aagtgggtgat	cattttttca	ttgctaataa	cacctcaaca	cggtctttaa	60
	gagagctacc	tagaagaatc	atgtagcact	ataactgagg	gatatcttag	tgttctgagg	120
	acaggttggg	ataccaacgt	ttttacatta	gaggtgggtg	atgtagaaaa	ccttacatgt	180
	tctgatggac	ctagccraat	aaaaacagaa	ttagatctga	ccaaaagtgc	actaagagag	240
	ctcaaaaacag	tctctgctga	ccaattggca	agagaggaac	aaattgagaa	tcccagacaa	300
	tctaggtttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agtcacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gagagtgaag	tcacagcaat	taagaatgcc	420
	ctcaaaaacga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtggagag	agctgaaaga	ctttgtgagc	aagaatttaa	ctcgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgatgacct	aaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
	ctaaatgtrg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagggcc	gtttctaaca	tgccgacatc	tcaggacaa	720
	ataaaaattga	tgttggagaa	ccgcgcgatg	gtaagaaga			759

<210> 33
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-76837

<400> 33	atgtcttggg	aagtgggtgat	cattttttca	ttgtaataa	cacctcaaca	cggtctttaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
	acaggttggg	ataccaacgt	ttttacactg	gaggtagggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagccta	aaaaacagaa	ttagatctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtggagg	aactgaaaga	ttttgtgagc	aagaattcaa	cacgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
	ctaaatgtrg	tgcggaatt	ttcagacaat	gctggaataa	caccacaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttcaaca	tgccaacatc	tcaggacaa	720
	ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 34
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>

<221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec isolate No
 C-77748

<400> 34
 atgtcttggg aagtgggtgat ctttttttca ttgttaataa cacttcaaca cggctcttaaa 60
 gagagctatt tagaagagtc atgtagcact ataactgaag gatatctcag tgttctgagg 120
 acaggttggg ataccaacgt ttttacactg aaggtaggtg atgtagagaa ccttacatgt 180
 gctgatggac cttagcttaat aaaaacagaa tttagactga ccaaaagtgc actaagagaa 240
 ctcaagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
 tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttggggaaatg gagttcgagt gttggcaact 480
 gcagtgaggg agctgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaaggttt 600
 ctaaatgttg tgcggcaatt ttcagacaat gctggaataa caccagcaat atccttggac 660
 ttaatgacag atgctgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttggagaa ccgtgcaatg gtaagaaga 759

<210> 35
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec isolate No
 C-77807

<400> 35
 atgtcttggg aagtgggtgat ctttttttca ttgttaataa cacttcaaca cggctcttaaa 60
 gagagctatt tagaagagtc atgtagcact ataactgaag gatatctcag tgttctgagg 120
 acaggttggg ataccaacgt ttttacactg aaggtaggtg atgtagagaa ccttacatgt 180
 gctgatggac cttagcttaat aaaaacagaa tttagactga ccaaaagtgc actaagagaa 240
 ctcaagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
 tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttggggaaatg gagttcgagt gttggcaact 480
 gcagtgaggg aactgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaaggttt 600
 ctaaatgttg tgcggcaatt ttcagacaat gctggaataa caccagcaat atccttggac 660
 ttaatgacag atgctgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttggagaa ccgtgcaatg gtaagaaga 759

<210> 36
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec isolate No
 C-78132

<400> 36
 atgtcttggg aagtgggtgat ctttttttca ttgttaataa cacctcaaca cggctcttaaa 60
 gagagctatt tagaagagtc atgtagcact ataactgaag gatatctcag tgttctgagg 120
 acaggttggg ataccaacgt ttttacactg gaggtaggtg atgtagagaa ccttacatgt 180
 gctgatggac cttagcttaat aaaaacagaa tttagactga ccaaaagtgc actaagagaa 240
 ctcaagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
 tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttggggaaatg gagttcgagt gttggcaact 480
 gcagtgaggg aactgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaaggttt 600
 ctaaatgttg tgcggcaatt ttcagacaat gctggaataa caccagcaat atccttggac 660
 ttaatgacag atgctgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttggagaa ccgtgcaatg gtaagaaga 759

<210> 37
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-78163

<400> 37	atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
	acaggttggg	ataccaacgt	ttttacactg	gaggtaggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	ttagatctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtgaggg	aactgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gtagcttca	gtcaattcaa	cagaaggttt	600
	ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
	ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 38
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-78406

<400> 38	atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
	acaggttggg	ataccaacgt	ttttacactg	gaggtaggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	ttagatctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtgaggg	aactgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gtagcttca	gtcaattcaa	cagaaggttt	600
	ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
	ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 39
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No hMPV-174

<400> 39	atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
	acaggttggg	ataccaacgt	ttttacactg	gaggtaggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	ttagacttga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480

18/52

gcagtgagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaaggttt	600
ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 40
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No hmpv-193

<400> 40	atgtcttggg	aagtgggtgat	cattttttca	ttgtaataa	cacctcaaca	cggtcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatattctcag	tgttctgagg	120
	acaggtrtgg	ataccaacgt	ttttacactg	gaggtagggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcga	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtgagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaaggttt	600
	ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
	ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 41
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain quebec isolate No hmpv-194

<400> 41	atgtcttggg	aagtgggtgat	cattttttca	ttgtaataa	cacctcaaca	cggttttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatattctcag	tgttctgagg	120
	acaggtrtgg	ataccaacgt	ttttacactg	gaggtagggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcga	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtgagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaaggttt	600
	ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
	ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 42
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No hmpv-198

<400> 42	atgtcttggg	aagtgggtgat	cattttttca	ttgtaataa	cacctcaaca	cggtcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatattctcag	tgttctgagg	120

19/52

acaggttggg	ataccaacgt	ttttacactg	gaggtagggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
gcagtgagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gtagcttca	gtcaattcaa	cagaaggttt	600
ctaaatggtg	tgcggaatt	ttcagacaat	gctggaaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 43
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No hmpv-217

<400> 43	atgtcttggg	aagtggat	cattttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
	acaggttggg	ataccaacgt	ttttacactg	gaggtagggtg	atgttagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
	gcagtgagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gtagcttca	gtcaattcaa	cagaaggttt	600
	ctaaatggtg	tgcggaatt	ttcagacaat	gctggaaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
	ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 44
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No hmpv-208

<400> 44	atgtcttggg	aagtggat	cattttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
	acaggttggg	ataccaacgt	ttttacactg	gaggtagggtg	atgttagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
	gcagtgaggg	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gtagcttca	gtcaattcaa	cagaaggttt	600
	ctaaatggtg	tgcggaatt	ttcagacaat	gctggaaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
	ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 45
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No hMPV-223

<400> 45
 atgtcrttga aagtgggtgat ctttttttca ttgttaataa cacctcaaca cggctcttaaa 60
 gagagctatt tagaagagtc atgtagcact ataactgaag gatattctcag tgttctgagg 120
 acaggttggg ataccaacgt ttttacctg gaggttaggtg atgtagagaa cttacatgt 180
 gctgatggac cttagcttaat aaaaacagaa tttagacctga ccaaaagtgc actaagagag 240
 ctcaagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
 tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggcctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcgagt gttggcaact 480
 gcagtgagag agctgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaaggttt 600
 ctaaatggtg tgccgcaatt ttcagacaat gctggaataa caccagcaat atccttggac 660
 ttaatgacag atgctgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttggagaa ccgtgcaatg gtaagaaga 759

<210> 46
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No hMPV-228

<400> 46
 atgtcrttga aagtgggtgat ctttttttca ttgttaataa cacctcaaca cggctcttaaa 60
 gagagctatt tagaagagtc atgtagcact ataactgaag gatattctcag tgttctgagg 120
 acaggttggg ataccaacgt ttttacctg gaggttaggtg atgtagagaa cttacatgt 180
 gctgatggac cttagcttaat aaaaacagaa tttagacctga ccaaaagtgc actaagagag 240
 ctcaagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
 tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggcctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcgagt gttggcaact 480
 gcagtgagag agctgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaaggttt 600
 ctaaatggtg tgccgcaatt ttcagacaat gctggaataa caccagcaat atccttggac 660
 ttaatgacag atgctgaacr agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttggagaa ccgtgcaatg gtaagaaga 759

<210> 47
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-85885

<400> 47
 atgtcrttga aagtgggtgat ctttttttca ttgttaataa cacctcaaca cggctcttaaa 60
 gagagctatt tagaagagtc atgtagcact ataactgaag gatattctcag tgttctgagg 120
 acaggttggg ataccaacgt ttttacctg gaggttaggtg atgtagagaa cttacatgt 180
 gctgatggac cttagcttaat aaaaacagaa tttagacctga ccaaaagtgc actaagagag 240
 ctcaagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
 tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggcctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcgagt gttggcaact 480
 gcagtgagag agctgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaaggttt 600
 ctaaatggtg tgccgcaatt ttcagacaat gctggaataa caccagcaat atccttggac 660
 ttaatgacag atgctgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttggagaa ccgtgcaatg gtaagaaga 759

<210> 48
 <211> 759

<212> DNA
<213> human metapneumovirus

<220> gene
<221> (1)...(759)
<223> human metapneumovirus, strain Quebec Isolate No C-60298

<400> 48
 argtcttggga aagtgggtgat cactttttca ttgttaataa cacctcaaca cggctttaaa 60
 gagagctatt tagaagagtc atgtagcact ataactgaag gatattctcag tgttctgagg 120
 acaggttggt ataccaacgt ttttacctg gaggtagggt atgtagagaa ctttacatgt 180
 gctgatggac cttagctaat aaaaacagaa tttagatctga ccaaaagtgc actaagagag 240
 ctcaaaaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
 tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
 ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
 ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcagat gttggcaact 480
 gcagtgaggg aactgaaaga ttttgtgagc aagaatctaa cagtgcaat caacaaaaac 540
 aagtgcgaca ttgctgacct gaaaatggcc gtttagcttca gtcaattcaa cagaaggttt 600
 ctaaattgtg tgcggcaatt ttcagacaat gctggaataa caccagcaat atccttggac 660
 ttaatgacag atgctgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
 ataaaactga tgttgagaaa ccgtgcaatg gtaagaaga 759

<210> 49
<211> 759
<212> PNA
<213> human metapneumovirus

<220> gene
<221> (1)...(759)
<223> human metapneumovirus, strain Quebec Isolate No C-63778

<400> 49
 atgtcttggga aagtgggtgat tatcatttcg ttactcataa cacctcagca cggactaaag 60
 gaaagttatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttttaaga 120
 acaggttggt acaccaatgt ctttacatta gaagttggtg atgttgaaaa tcttacatgt 180
 actgatggac cttagctaat caaaacagaa cttgacctaa ccaaaagtgc tctaagagaa 240
 ctcaaaaacag tttctgctga tcagrttagcg agagaagaac aaattgaaa tcccagacaa 300
 tcaagggtttg tcctaggtgc aatagctctt ggtgttgcca cagcagcagc agtcacagca 360
 ggcattgcca tagccaaaac cataaggctt gagagtgaag tgaatgcaat caaagggtct 420
 ctcaaaaacaa ccaacgaggc agtatccaca ctaggaaaatg gagtgcgagt cctagccacc 480
 gcagtaagag agctgaaaga atttgtgagc aaaaacctga ctagtgcaat taacaagaac 540
 aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattc 600
 ctaaattgtg tgcggcagtt ttcagacaat gcagggataa caccagcaat atcattggac 660
 ctaatgactg atgctgagct ggccagaact gtatcataca tgccaacatt tgcaggacaa 720
 ataaaactaa tgttagagaa ccgtgcaatg gtaagaaga 759

<210> 50
<211> 759
<212> DNA
<213> human metapneumovirus

<220> gene
<221> (1)...(759)
<223> human metapneumovirus, strain Quebec Isolate No C-64199

<400> 50
 atgtcttggga aagtgggtgat tatcatttcg ttactcataa cacttcagca cggactaaaa 60
 gaaagttatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttttaaga 120
 acaggttggt acaccaatgt ctttacatta gaagttggtg atgttgaaaa tcttacatgt 180
 actgatggac cttagctaat caaaacagaa cttagacctaa ccaaaagtgc tctaagagaa 240
 ctcaaaaacag tttctgctga tcagtttagcg agagaagaac aaattgaaa tcccagacaa 300
 tcaagggtttg tcctaggtgc aatagctctt ggtgttgcca cagcagcagc agtcacagca 360
 ggcattgcca tagccaaaac cataaggctt gagagtgaag tgaatgcaat caaagatgct 420
 ctcaaaaacaa ccaacgaggc agtatccaca ctaggaaaatg gagtgcgagt cctagccacc 480
 gcagtaagag agctgaaaga atttgtgagc aaaaacctga ctagtgcaat taacaagaac 540
 aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattc 600

22/52

craaatggtg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgcaggacag	720
ataaaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 51
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-64200

<400> 51						
atgtcttggg	aagtgggtgat	tatcatttcg	ttactcataa	cacctcagca	gggactaaaa	60
gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatattctcag	tgttttaaga	120
acaggttggg	acaccaatgt	ctttacatta	gaagttgggtg	atggttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240
ctcaaaacag	tttctgctga	tcagttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaaggtttg	tcctaggtgc	aatagctctt	ggtggttgcca	cagcagcagc	agtcacagca	360
ggcattgcga	tagccaaaac	cataaggctt	gagagtgaag	tgaaatgcaat	caaagggtgct	420
ctcaaaacaa	ccaacgaggg	agtatccaca	ctaggaatg	gagtgcgagt	cctagccacc	480
gcagtaagag	agctgaaaga	atttgtgagc	aaaaacctga	ctagtgcgaat	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatggtg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgcaggacag	720
ataaaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 52
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-64536

<400> 52						
atgtcttggg	aagtgggtgat	tatcatttcg	ttactcataa	cacctcagca	gggactaaaa	60
gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatattctcag	tgttttaaga	120
acaggttggg	acaccaatgt	ctttacatta	gaagttgggtg	atggttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240
ctcaaaacag	tttctgctga	tcagttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaaggtttg	tcctaggtgc	aatagctctt	ggtggttgcca	cagcagcagc	agtcacagca	360
ggcattgcga	tagccaaaac	cataaggctt	gagagtgaag	tgaaatgcaat	caaagggtgct	420
ctcaaaacaa	ccaacgaggg	agtatccaca	ctaggaatg	gagtgcgagt	cctagccacc	480
gcagtaagag	agctgaaaga	atttgtgagc	aaaaacctga	ctagtgcgaat	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatggtg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgcaggacag	720
ataaaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 53
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-73769

<400> 53						
atgtcttggg	aagtgggtgat	tatcatttcg	ttactcatac	cacttcagca	gggactaaaa	60
gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatattctcag	tgttttaaga	120
ccaggttggg	acaccaatgt	ctttacatta	gaagttgggtg	atggttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240

23/52

ctcaaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaagggtttg	tcctaggtgc	aatagctctt	gggtgttgcca	cagcagcagc	agtcacagca	360
ggcattgcca	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	caaagggtct	420
ctcaaaaacaa	craacgagggc	agtatccaca	ctagggaaatg	gagtgcgagt	cctagccacc	480
gcagtaagag	agttgaaaga	atgtgtgagc	aaaaacctga	ctagtgcaat	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tggcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattagac	660
ctaartgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgcaggacag	720
ataaaaactaa	tgtttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 54
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-74501

<400> 54	atgtcttggg	aagtgggtgat	tatcatttctg	ttactcataa	cacttcagca	cggactaaaa	60
	gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatatctcag	tgttttaaga	120
	acagggttgg	acaaccaatgt	cttiacatta	gaagttgggtg	atggttgaaaa	tcttacatgt	180
	actgatggac	ctagcttaat	caaaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240
	ctcaaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
	tcaagggtttg	tcctaggtgc	aatagctctt	gggtgttgcca	cagcagcagc	agtcacagca	360
	ggcattgcca	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	caaagggtct	420
	ctcaaaaacaa	ccaacgagggc	agtatccaca	ctagggaaatg	gagtgcgagt	cctagccact	480
	gcagtaagag	agctgaaaga	atgtgtgagc	aaaaacctga	ctagtgcaat	taacaagaac	540
	aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
	ctaaatgttg	tggcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattagac	660
	ctaartgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgcaggacag	720
	ataaaaactaa	tgtttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 55
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-78429

<400> 55	atgtcttggg	aagtgggtggt	catcatttctg	ttactcataa	caccccagca	cgggctaag	60
	gagagttatt	tggaagaatc	atgcagtact	ataactgagg	gatacctcag	tgttttaaga	120
	acaggctgg	acattaatgt	cttcacatta	gaagttgggtg	atggttgaaaa	tcttacatgt	180
	actgatggac	ctagcttaat	caaaaacagaa	cttgacctaa	caaaaagtgc	tttaagggaa	240
	ctcaaaaacag	tctctgctga	tcagtttagcg	agagaggagc	aaattgaaaa	tcccagacaa	300
	tcaagatttg	tcctaggtgc	aatagctctc	ggagrtgcta	cagcagcagc	agtcacagca	360
	ggcattgcaa	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	taaagggtct	420
	ctcaaaaacaa	ctaataaagc	agtatccaca	ctagggaaatg	gtgtgagggt	cctagccact	480
	gcagtgagag	agctaaaaga	atgtgtgagc	aaaaatctga	ctagtgcaat	caacaggaac	540
	aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattt	600
	ctaartgctg	tggcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattgac	660
	ctaartgactg	atgctgaatt	ggccagagct	gtatcataca	tgccaacatc	tgcaggacag	720
	ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 56
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-78652

```

<400> 56
atgtccttggg aagtgggtgat catcatttcg ttactcataa caccccagca cgggctaaag      60
gagagttatt  tggagaagaatc atgcagtagt ataactgagg gatacctcag tgttttaaga    120
acgggctggg  acaccaaatgt  cttcacatta  gaagttgggtg atggtgaaaa tcttacatgt    180
actgatggac  cttagcttaat  caaaacagaa  cttgacctaa  caaaaagtgc  ttttaagggaa  240
ctcaaaaacag tctctgctga  tcagttaacg  agagaggagc  aaattgaaaa  tcccagacaa   300
tcaagatttg  tcctaggtgc  aatagctctc  ggagttgcta  cagcagcagc  agtcacagca   360
ggcattgcaa  tagccaaaac  cataaggctt  gagagtgagg  tgaatgcaat  taaaggtgct   420
ctcaaaaacaa ctaatgaagc  agtatccaca  ttaggaaatg  gtgtgctggg  cctagccact   480
gcagtgagag  agctaaaaga  atttgtgagc  aaaaacttga  ctagtgcaat  caacaggaac   540
aaatgtgaca  ttgctgatct  gaagatggct  gtcagcttca  gtcaattcaa  cagaagattt   600
ctaaatgctg  tgcggcagtt  ttcagacaat  gcagggataa  caccagcaat  atcattggac   660
ctaactgactg atgctgaatt  ggccagagct  gtatcataca  tgccaacatc  tgcaggacag   720
ataaaaactga tgttggagaa  ccgtgcaatg  gtaagaaga

```

```

<210> 57
<211> 759
<212> DNA
<213> human metapneumovirus

```

```

<220>
<221> gene
<222> (1)...(759)
<223> human metapneumovirus, strain Quebec isolate No
hmpv-118

```

```

<400> 57
atgtccttggg aaggggtgat  tatcatttcg ttactcataa cacctcagca cggactaaaa      60
gaaagttatt  tagaagaatc  atgtagtact  ataactgaag  gatattctcag tgtrttaaga    120
acaggttggg  acaccaatgt  ctttacatta  gaagttgggtg atggtgaaaa tcttacatgt    180
actgatggac  cttagcttaat  caaaacagaa  cttgacctaa  ccaaaagtgc  tctgagagaa   240
ctcaaaaacag tttctgctga  tcagttaacg  agagaagaac  aaattgaaaa  tcccagacaa   300
tcaaggtttg  tcctaggtgc  aatagctctc  ggtgttgcca  cagcagcagc  agtcacagca   360
ggcattgcaa  tagccaaaac  cataaggctt  gagagtgagg  tgaatgcaat  caaaggtgct   420
ctcaaaaacaa ccaacgaggc  agtatccaca  ctaggaaatg  gagtgcgagt  cctagccacc   480
gcagtaagag  agctgaaaga  atttgtgagc  aaaaacctga  ccagtgcaat  taacaagaac   540
aaatgtgaca  ttgctgatct  gaagatggct  gtcagcttca  gtcaattcaa  cagaagattc   600
ctaaatgctg  tgcggcagtt  ttcagacaat  gcagggataa  caccagcaat  atcattagac   660
ctaactgactg atgctgagct  ggccagagct  gtatcataca  tgccaacatc  tgcagggcag   720
ataaaaactaa tgttagagaa  ccgtgcaatg  gtaagaaga

```

```

<210> 58
<211> 759
<212> DNA
<213> human metapneumovirus

```

```

<220>
<221> gene
<222> (1)...(759)
<223> human metapneumovirus, strain Quebec isolate No
hmpv-200

```

```

<400> 58
atgtccttggg aagtgggtgat  ctttttttcg ttactcataa cacctcagca cggactaaaa      60
gaaagttatt  tagaagaatc  atgtagtact  ataactgaag  gatattctcag tgtrttaaga    120
acaggttggg  acaccaatgt  ctttacatta  gaagttgggtg atggtgaaaa tcttacatgt    180
actgatggac  cttagcttaat  caaaacagaa  cttgacctaa  ccaaaagtgc  tctaagagaa   240
ctcaaaaacag tttctgctga  tcagttaacg  agagaagaac  aaattgaaaa  tcccagacaa   300
tcaaggtttg  tcctaggtgc  aatagctctc  ggtgttgcca  cagcagcagc  agtcacagca   360
ggcattgcaa  tagccaaaac  cataaggctt  gagagtgagg  tgaatgcaat  caaaggtgct   420
ctcaaaaacaa ccaacgaggc  agtatccaca  ctaggaaatg  gagtgcgagt  cctagccacc   480
gcagtaagag  agctgaaaga  atttgtgagc  aaaaacctga  ccagtgcaat  taacaagaac   540
aaatgtgaca  ttgctgatct  gaagatggct  gtcagcttca  gtcaattcaa  cagaagattc   600
ctaaatgctg  tgcggcagtt  ttcagacaat  gcagggataa  caccagcaat  atcattagac   660
ctaactgactg atgctgagct  ggccagagct  gtatcataca  tgccaacatc  tgcagggcag   720
ataaaaactaa tgttagagaa  ccgtgcaatg  gtaagaaga

```

```

<210> 59
<211> 759
<212> DNA
<213> human metapneumovirus

```

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-176

```
<400> 59
atgtccttggga aagtggtgat tatcatttcg ttactcataa cacctcagca cggactaaaa 60
gaaagtttatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttctaaga 120
acaggttggtt acaccaatgt ctttacatta gaagttgggtg atggtgaaaa tcttacatgt 180
actgatggac ctagcttaat caaacagaa cttgacctaa ccaaaagtgc ttttagagaa 240
ctcaaaacag tttctgctga tcagttagcg agagaagaac aaattgaaaa tcccagacaa 300
tcaaggtttg tcctaggtgc aatagctctc ggagttgcca cagcagcagc agtcacagca 360
ggcattgcaa tagcctaaaac tataaggctt gagagtgaag tgaatgcaat caaaggtgct 420
ctcaaaacaa ccaatgaggc agtatcaaca ctaggaaatg gagtgccggg cctagccact 480
gcagtaagag agctgaaaga atttgtgagc aaaaacctga ctagtgcgat caacaagaac 540
aaatgtgaca ttgctgattt gaagatggct gtcagcttca gtcagttcaa cagaagattc 600
ctaaatggtt tgccgcagtt ttcagacaat gcagggataa caccagcaat atcattggac 660
ctgatgactg atgctgagct ggccagagct gtatcataca tgccaacatc tgcaggacag 720
ataaaactaa tgrtagagaa ccgtgcaatg gtaagaaga 759
```

<210> 60
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-193

```
<400> 60
atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataag aataactaca 120
ttgagtatag cccfcaatat ctatctgatc ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaac tccaacggtc 240
cccattggact acccagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccaacacaaa caagccgcc gcccttcgtc gacacacaca caacaccacc aagtgcaagc 420
agaacaaaga caagtccggc agtccacaca aaaaacaatc caaggataag cctcagaaca 480
cattccccac catgggcaat gacaaggacg gtccgcggaa ccaccactct ccgcacaagc 540
agcacaagaa aaagaccgct tacagcatca gtccaacctg acagcagcgc aacaacccac 600
aaacacgaag aagcaagccc agtgagcccg caaacatctg caagcacagc aagaccacaa 660
aggaaggtca tggaggccag cacatcaaca acatacaatc aaactagtta a 711
```

<210> 61
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-228

```
<400> 61
atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataag aataactaca 120
ttgagtatag cccfcaatat ctatctgatc ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaac tccaacggtc 240
cccattggact acccagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccaacacaaa caagccgcc gcccttcgtc gacacacaca caacaccacc aagtgcaagc 420
agaacaaaga caagtccggc agtccacaca aaaaacaatc caaggataag cctcagaaca 480
cattccccac catgggcaat gacaaggacg gtccgcggaa ccaccactct ccgcacaagc 540
agcacaagaa aaagaccgct tacagcatca gtccaacctg acagcagcgc aacaacccac 600
aaacacgaag aagcaagccc agtgagcccg caaacatctg caagcacagc aagaccacaa 660
aggaaggtca tggaggccag cacatcaaca acatacaatc aaactagtta a 711
```

<210> 62
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-77748

<400> 62
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
 ttgagtatag ccccaaatat ctatctaate ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaaac tccaacagtc 240
 cctatggaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
 ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccagacacaa caagccgccc gccctttgtc gacacacaca caacaccacc aagtgcaagc 420
 agaacaagga caagtccggc agtccacaca aaaaacaatc caaggacaag cccagaaca 480
 cattrccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
 agcacaagaa aaagaccgtc tacagcatca gtccaacctg acagcagcgc aacaaccac 600
 aaacacgaag aagcaagccc agtgagcccc caaacatctg cgagcacagc aagaccacaa 660
 aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711

<210> 63
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-78132

<400> 63
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
 ttgagtatag ccccaaatat ctatctgac ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaaac tccaacagtc 240
 cctatggaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
 ggctccacac tccactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccagacacaa caagccgccc gccctttgtc gacacacaca caacaccacc aagtgcaagc 420
 agaacaagga caagtccggc agtccacaca aaaaacaatc taaagataag cccagaata 480
 cattrccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
 agcacaagaa aaagaccgtc tacagcatca gtccaacctg acagcagcgc aacaactcac 600
 aaacacgaag aagcaagccc agtgagcccc caaacatctg caagcacagc aagaccacaa 660
 aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711

<210> 64
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-78406

<400> 64
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
 ttgagtatag ccccaaatat ctatctgac ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaaac tccaacagtc 240
 cctatggaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
 ggctccacac tccactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccagacacaa caagccgccc gccctttgtc gacacacaca caacaccacc aagtgcaagc 420
 agaacaagga caagtccggc agtccacaca aaaaacaatc taaagataag cccagaata 480
 cattrccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
 agcacaagaa aaagaccgtc tacagcatca gtccaacctg acagcagcac aacaactcac 600

27/52

```

aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711
    
```

```

<210> 65
<211> 711
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(711)
<223> human metapneumovirus, strain Quebec Isolate No
        C-73750
    
```

```

<400> 65
atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaaat gccctcttga tcctaataagg aataactaca 120
ttgagtatag ccctcaacat ctatctgatc ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ctcatcacc ctaggaatcca gcagggaaac tccaacgggtc 240
cctatagaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
ggctccacac tccactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccagacacaa caagccgccc gcccttcgct gacacacaca caacaccacc aagtgaagc 420
agaacaagga caagtccggc agtccacaca aaaaacaatc taagataag ccccgagaaca 480
cattccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcataagaa aaagaccgtc cacagcatca gtccaacctg acagcagcac aacaaccac 600
aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acacacaacc aaactagtta a 711
    
```

```

<210> 66
<211> 660
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(660)
<223> human metapneumovirus, strain Quebec Isolate No
        C-60298
    
```

```

<400> 66
atggagggtga aagtggagaa cattcagaca atagacatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gttagcaaat ctttaaaaaat gcttctttaa tcctcatagg aataactaca 120
ctgagtatag ctctcaatat ctatctgatc ataaactaca caatacaaaa aacctcatct 180
gaatcagaac accacaccag ctaccacccc acagaatcca acaaggaagc ttcaacaatc 240
tccacagaca acccagacat caatccaac tcacagcatc caactcaaca gtccacagaa 300
aaccccacac tcaaccccgc agcatcagtg agcccacag aacagaacc agcatcaaca 360
ccagacacaa caaacccgct gtcctccgta gacaggtcca cagcaaac aagtgaagc 420
agaacaagaa caaaaccgac agtccacaca agaaacaacc caagcacagc ttccagtaca 480
caatccccac cacgggcaac aacgaaggca atccgcagag ccaccacttt ccgcatgagc 540
agcacaggaa aaagaccaac cacaacatca gtccagtccg acagcagcac cacaacccaa 600
aatcatggaag aaacagggtc agcgaaccca caggcatctg taagcaaat gcaaaactag 660
    
```

```

<210> 67
<211> 654
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(654)
<223> human metapneumovirus, strain Quebec Isolate No
        C-74783
    
```

```

<400> 67
atggagggtga aagtggagaa cattcagaca atagacatgc tcaaagcaag agtgaaaaat 60
cgtgtggcat gttagcaaat ctttaaaaaat gcttctttaa tcctcatagg aataactaca 120
ctgagtatag ctctcaatat ctatttgatc ataaaccaca caatacaaaa aaccacatct 180
gaatcagaac accacaccag ctaccacccc acagaatcca acaaggaagc ttcaacaatc 240
tccacagaca acccagacat caatccaac tcacagcatc caactcaaca gtctacagaa 300
aaccccacac tcaaccccgc agtatcaaca agcccacag aacagaacc aacatcaaca 360
ccagacacaa caaacccgct gtcctccgta gacaggtcca cagcaaac aagtgaagc 420
agaacaagaa caaaatcgac agtccacaca agaaacaacc caagcacagc ttccagcaca 480
    
```

				28/52		
caatccccac	cacgggcaac	aacgaaggca	atccgcagag	ccaccacttt	ccgcatgagc	540
agcacagaaa	aaagaccaac	cacaacacta	gtccagtacg	acagcagcac	cacaaccxaa	600
aatcatgaag	aaacagggttc	agcgaaccca	caggcatctg	caagcacaat	gtaa	654

<210> 68
 <211> 660
 <212> PNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(660)
 <223> human metapneumovirus, strain Quebec Isolate No C-74549

<400> 68						
atggagggtga	aagtggagaa	cattcgagca	atagacatgc	tcaaagcaag	agtgaaaaat	60
cgtgtggcac	gtagcaaatg	cttcaaaaat	gttccccaa	tcctcacagg	aataaccaca	120
ctgagcatag	ctctcaatat	ccacctgac	ataaaactaca	caatacaaaa	aaccacatct	180
gaatcagaac	accacaccag	ctcaccaccc	acagaatcta	acaagggaagc	ttcaacaatc	240
tccacagaca	accagacat	caatccaaac	tcacagcatc	caactcaaca	gtctacagaa	300
aaccccacac	tcaaccccgc	agtatcaaca	agcccatcag	aaacagaacc	aacatcaaca	360
ccagacacaa	caaaccgct	gtcctcggta	gacagggtcca	cagcacaacc	aagtgaagc	420
agaacaaaga	caaaatcgac	agtccacaca	agaacaacc	caagcacagc	ttccagcaca	480
caatccccac	cacgggcaac	aacgaaggca	atccgcagag	ccaccacttt	ccgcatgagc	540
agcacagaaa	aaagaccaac	cacaacatta	gtccagtacg	acagcagcac	cacaaccxaa	600
aatcatgaag	aaacagggttc	agcgaaccca	caggcatctg	taagcacaat	gtaaaactag	660

<210> 69
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-77807

<400> 69						
atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60
cgtgtggcac	gcagcaaatg	ctttaaaaaat	gcctctttga	tcctaataagg	aataacgaca	120
ttgagtatag	ccctcaacat	ctatctgac	ataaaactata	caatgcaaga	aaacacatcc	180
gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcagggaaac	tccaacggtc	240
cctatagaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300
ggctccacac	tccactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
ccagacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacaccacc	aagtgaagc	420
agaacaagga	caagtccggc	agtccacaca	aaaaacaatc	taaagataag	ccccagaata	480
cattccccac	catgggcaat	gacaaggagc	gtccgtggaa	ccaccactct	ccgcacaagc	540
agcacaagaa	aaagaccgtc	tacagcatca	gtccaacctg	acagcagcac	aacaactcac	600
aaacacgaag	aagcaagccc	agtgagccca	caaacatctg	caagcacagc	aagaccacaa	660
aggaagggca	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711

<210> 70
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-78163

<400> 70						
atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60
cgtgtggcac	gcagcaaatg	ctttaaaaaat	gcctctttga	tcctaataagg	aataactaca	120
ttgagtatag	cccicaacat	ctatctgac	ataaaactata	caatgcaaga	aaacacatcc	180
gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcagggaaac	tccaacggtc	240
cctatagaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300
ggctccacac	tccactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
ccagacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacaccacc	aagtgaagc	420

29/52

```

agaacaagga caagtccggc agtccacaca aaaaacaatc taaagataag ccccagaata 480
cattccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcacaagaa aaagaccgtc tacagcatca gtccaacctg acagcagcac aacaactcac 600
aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711
    
```

```

<210> 71
<211> 711
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(711)
<223> human metapneumovirus, strain Quebec Isolate No
        C-68661
    
```

```

<400> 71
atggagggtga aagtggagaa cattcgaaca atagatagcg tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatt ctttaaaaat gcctctttga tcctaataag aataactaca 120
ttgagtatag ccctcaatat ctatctgacg ataaactata caatgcaaga aaacacatcc 180
aaatcagaac atcacaccag ctcatcaccg atggaatcca gcagggaaac tccaacggtc 240
cctatggaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
ggctccacac ttcactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccagacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgaagc 420
agaacaagga caagtccggc agtccacaca aaaaacaatc caaggataag ccccagaaca 480
cattccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcacaagaa aaagaccgtc cacagcatca gtccaacctg acagcagcgc aacaaccac 600
aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711
    
```

```

<210> 72
<211> 711
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(711)
<223> human metapneumovirus, strain Quebec Isolate No
        C-88448
    
```

```

<400> 72
atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatt ctttaaaaat gcctctttga tcctaataag aataactaca 120
ttgagtatag ccctcaatat ctatcraatc ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ctcatcaccg atggaatcca gcagggaaac tccaacagtc 240
cctatggaca actcagacac caatccaggc tcacagtatc taactcaaca gtccacagaa 300
ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
ccagacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgaagc 420
agaacaagga caagtccggc agtccacaca aaaaacaatc caaggacaag ccccagaaca 480
cattccccac catgggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcacaagaa aaagaccgtc cacagcatca gtccaacctg acagcagcgc aacaaccac 600
aaacacgaag aagcaagccc agtgagcccg caaacatctg cgagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711
    
```

```

<210> 73
<211> 711
<212> DNA
<213> human metapneumovirus
    
```

```

<220>
<221> gene
<222> (1)...(711)
<223> human metapneumovirus, strain Quebec Isolate No
        C-88470
    
```

```

<400> 73
atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatt ctttaaaaat gcctctttga tcctaataag aataactaca 120
ttgagtatag ccctcaatat ctatctgacg ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ctcatcaccg atggaatcca gcagggaaac tccaacggtc 240
    
```

30/52

:ccatggact	accagacac	caatccaggc	tcacagcctc	caactcaaca	gtccacagaa	300
ygctccacac	tctacittgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
-caaacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacaccacc	aagtgcagc	420
agaacaaaga	caagtcgggc	agtcacacaca	aaaaacaatc	caaggataag	cctcagaaca	480
cattccccac	catgggcaat	gacaaggacg	gtcccgggaa	ccaccactct	ccgcacaagc	540
agcacaagaa	aaagaccgctc	tacagcatca	gtccaacctg	acagcagcgc	aacaaccac	600
aaacacgaag	aagcaagccc	agtgagcccc	caaacatctg	caagcacagc	aagaccacaa	660
aggaaggtca	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711

<210> 74
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-86316

<400> 74	atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60
	cgtgtggcac	gcagcaaatg	ctttaaaaaat	gcctcttttga	tccataatagg	aataactaca	120
	ttgagtatag	ccctcaatat	ctatctaate	ataaactata	caatgcaaga	aaacacatcc	180
	gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcaaggaaac	tccaacagtc	240
	cctatggaca	actcagacac	caatccaggc	tcacagatc	caactcaaca	gtccacagaa	300
	ggctccacac	tctactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
	ccagacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacaccacc	aagtgcagc	420
	agaacaagga	caagtccggc	agtccacaca	aaaaacaatc	caaggacaag	cctcagaaca	480
	cattccccac	catgggcaat	gacaaggacg	gtcccgggaa	ccaccactct	ccgcacaagc	540
	agcacaagaa	aaagaccgctc	cacagcatca	gtccaacctg	acagcagcgc	aacaaccac	600
	aaacacgaag	aagcaagccc	agtgagcccc	caaacatctg	cgagcacagc	aagaccacaa	660
	aggaagggca	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711

<210> 75
 <211> 6017
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(6017)
 <223> human metapneumovirus, strain 00-1 accession number af371337

<400> 75	atggatcctc	tcaatgaatc	cactgttaat	gtctatcttc	ctgactcata	tcttaagga	60
	gtgatttctc	ttagtgagac	taatgcaatt	ggttcattgtc	tcttaaaaag	accttaccta	120
	aaaaatgaca	acactgcaaa	agttgccata	gagaatcctg	ttatcgagca	tgtagactc	180
	aaaaatgcag	tcaattctaa	gatgaaaata	tcagattaca	agatagtaga	gccagtaaac	240
	atgcaacatg	aaattatgaa	gaatgtacac	agttgtgagc	tcacattatt	aaaacagttt	300
	ttaacaagga	gtaaaaatat	tagcactctc	aaattaaata	tgatatgtga	ttggctgcag	360
	ttaaagtcta	caccagatga	tacctcaatc	ctaagrttta	tagatgtaga	atctatacct	420
	agctgggtaa	gcaattgggt	tagtaattgg	tacaatctca	acaagttgat	tctggaattc	480
	aggaagaag	aagtaataag	aactggttca	atcttgtgta	ggtcattggg	taaattagtt	540
	ttgtttgtat	catcatatgg	atgtatagtc	aagagcaaca	aaagcaaaag	agtgagcttc	600
	ttcacatata	atcaactggt	aacatggaaa	gatgtgatgt	taagtagatt	caatgcaaat	660
	ttttgtatat	gggtaagcaa	cagtctgaat	gaaaatcaag	aagggctagg	gttgagaagt	720
	aatctgcaag	gcatattaac	taataagcta	tatgaaactg	tagattatat	gcttagttta	780
	tgttgcaatg	aaggtttctc	acttgtgaaa	gagttcgaag	gctttattat	gagtgaattt	840
	cttaggatta	ctgaacatgc	tcaattcagt	actagattta	gaaatacttt	attaatgga	900
	ttaaactgac	aattaacaaa	attaaaaaat	aaaaacagac	tcagagttca	tggtaccgtg	960
	ttagaaaata	atgattatcc	aatgtacgaa	gttgtactta	agttattagg	agatactttg	1020
	agatgtatta	aattattaat	caataaaaaac	ttagagaatg	ctgctgaatt	atactatata	1080
	ttagaatat	tcggtcacc	aatggtagat	gaaagagatg	caatggatgc	tgtaaaatta	1140
	aaacatgaaa	tcacaaaaat	ccttaggtgg	cgagagcttga	cagaactaag	aggggcttc	1200
	atattaagga	ttatcaaagg	attttagtac	aaacaacaaa	gatggcccaa	aattaaaaac	1260
	ttaaaagtgc	ttagtaagag	atggactatg	tacttcaaa	caaaaagtta	ccccagtcaa	1320
	cttgaattaa	cggaacaaga	tttttagag	cttgtctgca	tacagrttga	acaagagrtt	1380
	tctgtccctg	aaaaaaccaa	ccttgagatg	gtattaaatg	ataaagctat	atcacctcct	1440
	aaaagattaa	tatggtctgt	gtatccaaaa	aattactttac	ctgagaaaat	aaaaatcga	1500
	tatctagaag	agactttcaa	tgcaagtgat	agtctcaaaa	caagaagagt	actagagtac	1560

tatttgaag	ataataaatt	cgacccaaaa	gaacttaaaa	gttatgttgt	taaacaagaa	1620
tattttaaag	ataaggatca	tattgtctcg	ctaactggaa	aagaaagaga	attaagtgt	1680
ggtagaatgt	ttgctatgca	accaggaaaa	cagcgacaaa	tacaaatatt	ggctgaaaa	1740
ttgtagctg	ataatatigt	accttttttc	ccagaaacct	taacaaagta	tggtgatcta	1800
gatcttcaga	gaataatgga	aatcaaatcg	gaactttctt	ctattaaaac	tagaagaaat	1860
gatagttata	ataatracat	tgcaagagca	tccatagtaa	cagatttaag	taagttcaac	1920
caagccttta	ggtatgaaac	tacagcgatc	tgtgcggatg	tagcagatga	actacatgga	1980
acacaaagcc	tattctgttg	gttacatctt	atcgtcccta	tgacaacaat	gatatgtgcc	2040
tatagacatg	caccaccaga	aacaaaaggt	gaatatgata	tagataagat	agaagagcaa	2100
agtggtttat	atagatatca	tatgggtggg	attyaaggat	ggtgtcaaaa	actctggaca	2160
atgggaagcta	tatctctatt	agatgttgta	tctgtaaaaa	cacgatgtca	aatgacatct	2220
ttattaacag	tgacaacca	atcaatagat	gtaagtaaac	cagttaagtt	atctgagggt	2280
ttagatgaag	tgaaagcaga	ttatagcttg	gctgtaaaaa	tgtaaaaga	aataagagat	2340
gcatacagaa	atataggcca	taaacttaa	gaaggggaaa	catatatac	aagagatctt	2400
cagtttataa	gtaaggtgat	tcaatctgaa	ggagttaatgc	atcctacccc	tataaaaaag	2460
atcttaagag	gtggacatg	gataaacaca	atattagatg	acattaaaac	cagtgacag	2520
tcaataagga	gtctatgtca	ggaattagaa	tttagggggg	aaagcataat	agttagtctg	2580
atattaagga	atTTTTTggt	gtataatTTA	tacatgcatg	aatcaagca	acacccccta	2640
gcagggaaag	agttattcaa	acaactaaat	aaaacattaa	catcagtgca	gagatttttt	2700
gaaataaada	aggaaaatga	agttagtagat	ctatggatga	acataccaat	gcagtttggg	2760
ggaggagatc	cagtagtctt	ctatagatct	ttctatagaa	ggacccctga	ttttttaact	2820
gaagcaatca	gtcatgtggg	tattctgtta	agaatatcag	ccaacataag	aaatgaagcg	2880
aaataaagtt	tcttcaagc	cttactgtca	atgaaaaaaa	atgaaactgc	tacactgaca	2940
acactaatga	gagatcctca	agctgttggc	tcagagcgac	aagcaaaagt	aacaagtgat	3000
atcaatagaa	cagcagttac	cagcatctta	agtccttctc	caaactcaact	tttcagcgat	3060
agtgctatac	actacagtag	aaatgaagaa	gaggtcggaa	tcattgtctg	caacataaca	3120
cctgtttatc	ctcatggact	gagagttttg	tatgaaatcat	taccttttca	taaagctgaa	3180
aaagttgtga	atattgatate	aggaacgaaa	tccataacca	actttattaca	gagaacatct	3240
gctatttaag	gtgaagatat	tgacagagct	gtatccatga	tgctgggaaa	cctaggatta	3300
ttacttagaa	tattgtcagtt	agttgttgat	agtatagaaa	ttccaaccaa	atcfaatggg	3360
aggctgatata	gttgtcagat	atctagaacc	ctaagggaga	catcatggaa	taatatggaa	3420
atagttggag	taacatcccc	tagcatcact	acatgcatgg	atgtcatata	tgcaactagc	3480
tctcatttga	aagggataat	cattgaaaaa	ttcagcactg	acagaactac	aagaggtcaa	3540
agaggtccaa	agagcccttg	ggtagggctg	agcactcaag	agaaaaaatt	agttcctggt	3600
tataacagac	aaattctttc	aaaacaacaa	agagaacagc	tagaagcaat	tggaanaatg	3660
agatgggtat	ataaagggac	accaggttta	agacgattac	tcaataagat	tigtcttggg	3720
agtttaaggca	ttagttacaa	atgtgtaaaa	cctttattac	ctaggtttat	gagtgtaaat	3780
ttcctacaca	ggttatctgt	cagtagtaga	cctatgggat	tcccagcatc	agttccagct	3840
tatagaacaa	caaattacca	ttttgacact	agtcctatta	atcaagcact	aagtgagaga	3900
tttgggaaag	agaatattaa	tttggctctc	caaaatgcaa	tcagctgtgg	aattagcata	3960
atgaggttag	tagaacaatt	aaactgtagg	agttcaaaa	agttagtttt	aataacctca	4020
ttagaagaaa	tagacattat	gccaccacca	gtgtttcaag	ggaaattcaa	ttataagcta	4080
gtagataaga	taacttttga	tcaacatata	ttcagtcag	acaaaataga	tatgtaaca	4140
ctggggaaaa	gtctcatcct	cactataaaa	ggtcagaaaa	cagatcagtt	cctgaacaa	4200
agagagaatt	atctccatgg	gaataatctt	atggagtctt	tgtcagcagc	gtttagcatgt	4260
cartgggtgt	gcatattaa	agagcaatgt	atagaaaaa	atattttcaa	gaaagactgg	4320
ggtagcgggt	tgatcatcct	tcattgcttt	aatgacttca	aaatattcct	atgtgtcttt	4380
aaaactaaac	ttttatgtag	ttgggggtcc	caagggaaaa	acattaaaga	tgaagatata	4440
gtagatgaat	caatagataa	actgttaagg	attgataata	ctttttggag	aatgttcagc	4500
aaagttatgt	ttgaatcaaa	ggttaagaaa	aggataatgt	tatatgatgt	aaaatttcta	4560
tcatttagtag	gttatatagg	gttttaagaa	tggtttatag	aacagttgga	tcagctgagt	4620
tgcatgaggt	accttggatt	gtcaatgccc	aaggtgatct	ggttgagatc	aagtaatta	4680
aaatctattt	gcaactgata	gagcaagttt	tatttttaag	aataactgtt	ttgaactata	4740
cagatattggc	acatgctctc	acaagattaa	tcagaaaagaa	gttgatgtgt	gataatgcac	4800
tattaactcc	gattccatcc	ccaatgggta	attttaactca	agttattgat	cctacagaac	4860
aattagctta	tttccctaag	ataacatttg	aaaggctaaa	aaattatgac	actagttcaa	4920
attatgctaa	aggaaagcta	acaaggaatt	acatgatact	gttgccatgg	caacatgtta	4980
atagatataa	ctttgtcttt	agttctactg	gagttaaagt	tagtctaaaa	acatgcatgg	5040
gaaaactttat	gaaagatcta	aaccctaagg	ttctgtactt	tattggagaa	ggggcaggaa	5100
attggatggc	cagaacagca	tgatgaatct	ctgacatcaa	atttgtatac	agaagtttaa	5160
aagatgacct	tgatcatcat	tatcctttgg	aataccagag	agttatagga	gaattagca	5220
ggataataga	tagcgggtga	gggctttcaa	tggaacaac	agatgcaact	caaaaaactc	5280
attgggattt	gatacacaga	gtaagcaaa	atgctttatt	aataacttta	tggtatgcag	5340
aatttaagga	cagagatgat	tttttaaga	tgtaattctt	atggaggaaa	catgtattat	5400
catgcagaat	ttgcaactac	tatgggacag	acctctattt	attcgcaaa	tatcatgcta	5460
aagactgcaa	tgtaaaaatta	cctttttttg	tgagatcagt	agccaccttt	attatgcaag	5520
gtagtaact	gtcaggctca	gaatgctaca	tactcttaac	actagggcac	cacaacaatt	5580
taccctgcca	tggaagataa	caaaaattcta	agatgaaaaa	agcagttgtg	aatgattttt	5640
atgctgcaaa	aaaacttga	aataaactta	ttgaagcaa	ctgtaaatca	cttttatcag	5700
ggctaaagaat	accgataaat	aagaaagaat	taaatagaca	gagaaggtta	ttaaacttac	5760
aaagcaacca	tcttctgtta	gcaacagttg	gaggtagcaa	ggtcatagag	tctaaatggt	5820
taacaaacaa	ggcaaacaca	ataattgatt	ggttagaaca	tattttaaat	tctccaaaag	5880

32/52

gtgaattaaa ttatgaittt tttgaagcat tagaaaaaac ttaccctaata atgattaaac 5940
 taatagataa tctagggaat gcagagataa aaaaactgat caaagtaact ggatataatgc 6000
 ttgtaagtaa aaaatga 6017<210> 76
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-118

<400> 76
 taaaatgaaa atatcagatt acaaggtagt agaaccagta aacatgcaac atgaaataat 60
 gaagaatgta cacagctgtg agcacacact attgaaacag tttttaacaa ggagtaaaaa 120
 cattagcact ctcaaattaa atatgatatg tgattggctg caattaaaat ctacatcaga 180
 tggtaacctca atcctaagtt ttatagatgt agaatttata cctagttggg taagcaactg 240
 gtttagtaat tggtaacaat tcaataagtt aattttagaa ttcaggagag aagaagtaat 300
 aagaaccggt tcaatcttgt gcaggtcatt aggtaaatta gtttttattg tatcatcata 360
 tggatgtatc gtcaagagca acaaaagcaa aagagtgagc ttctttacat acaatcaact 420
 gttaacatgg aaagatgtga tgrtaagtcg 450

<210> 77
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-163

<400> 77
 ttgaatatac agattacagg atagtagagc cagtaaacat gcaacatgaa attatgaaga 60
 atgtacacag ttgtgagctc acattattaa aacagttttt aacaaggagt aaaaatatta 120
 gcactctcaa attaaatatg atatgtgatt ggtgcagtt aaaatctaca tcagatgata 180
 cctcaatctt aagttttata gatgtagaat ttatacctag ctgggtaagc aattggttta 240
 gtaattggta caatctcaac aagttgattc tggaaatcag gaaagaagaa gtaataagaa 300
 ctggttcaat cttgtgtagg tcattaggtta aattagtttt tgttgtatca icatatggat 360
 gtatagtcaa gagcaacaaa agcaaaagag tgagcttctt cacatacaat caactgtaa 420
 catggaaga tgtgatgtta agtagattca 450

<210> 78
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-174

<400> 78
 gagaatcctg ttatcgagca tgttagactc aaaaatgcaa tcaatctaaa gatgaaaata 60
 tcagattaca ggatagtaga gccagtaaac atgcaacatg aaattatgaa gaatgtacac 120
 agttgtgagc tcacattatt aaaacagttt ttaacaagga gtaaaaatat tagcactctc 180
 aaattaaata tgatagtga tggctgagc ttaaagtcta catcagatga tacctcaatc 240
 ttaagttta tagatgtaga aittatacct agctgggtaa gcaattgggt tagtaattgg 300
 tacaatctca acaagttgat tctggaattc aggaagaag aagtaataag aactggttca 360
 atcttgtgta ggtcattggg taaattagtt ttgtgtgat catcatatgg atgtatagtc 420
 aagagcaaca aaagcaaaag agtgagcttc ttcacataca atcaactggt aacatggaaa 480
 gatgtgatgt taagtagatt 500

<210> 79
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>

<221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-184

<400> 79
 attgaaatat cagattacag gatagtagag ccagtaaaca tgcaacatga aattatgaag 60
 aatgtacaca gttgtgagct cacattatta aaacagtttt taacaaggag taaaaatatt 120
 agcactctca aattaaatat gatatgtgat tggctgcagt taaagtctac atcagatgat 180
 acctcaatct taagttttat agatgtagaa tttataccta gctgggtaag caattggttt 240
 agtaattggt acaatctcaa caagttgatt ctggaattca ggaaagaaga agtaataaga 300
 actggttcaa tcttgtgtag gtcattagggt aaattagttt ttggtgtatc atcatatgga 360
 tgtatagtca agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgtta 420
 acatggaaag atgtgatggt aagtagattc 450

<210> 80
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-196

<400> 80
 ttgcccatag agaatcctgt tattgagcat gtgagactca aaaatgcagt caattctaaa 60
 atgaaaaat cagattacaa ggtagtagag ccagtaaaca tgcaacatga aataatgaag 120
 aatgtacaca gttgtgagct cacactattg aaacagtttt taacaaggag taaaaacatt 180
 agcactctca aattaaatat gatatgtgat tggctgcaat taaagtctac atcagatgat 240
 acctcaatcc taagtttcat agatgtagaa tttataccta gttgggtaag caactggttt 300
 agtaattggt acaatctcaa taagttaatt ttggaattca gaagagaaga agtaataaga 360
 accggttcaa tcttatgcag gtcattgggt aaattagttt ttattgtatc atcatatgga 420
 tgtatcgtca agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgtta 480
 acatggaaag atgtgatggt 500

<210> 81
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-76837

<400> 81
 agatgaaaat atcagattac aggatagtag agccagtaaa catgcaacat gaaattatga 60
 agaatgtaca cagttgtgag ctacattat taaaacagtt ttaacaagg agtaaaaaata 120
 ttagcactct caaattaaat atgatatgtg attggctgca gttaaagtct acatcagatg 180
 atacctcaat cttaagtttt atagatgtag aattttatacc tagctgggta agcaattggt 240
 ttagtaartg gtacaatctc aacaagttga ttctggaatt caggaagaa gaagtaataa 300
 gaactgggtc aatcttgtgc aggtctttgg gtaaattagt ttttgttcta tcatcatatg 360
 gatgtatagt caagagcaac aaaagcaaaa gagtggagctt cttcacatac aatcaactgt 420
 taacatggaa agatgtgatg ttaagtagat 450

<210> 82
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77807

<400> 82
 taagatgaaa atatcagatt acaggatagt agagccagta aacatgcaac atgaaattat 60
 gaagaatgta cacagttgtg agctcacatt attaaaacag tttttaacaa ggagtaaaaa 120

34/52

tattagcact	ctcaaattaa	atatgatatg	tgattggctg	cagttaaaag	ctacatcaga	180
tgatacctca	atcttaagtt	ttatagatgt	agaatttata	cctagctggg	taagcaatg	240
gtttagtaat	tggtacaatc	tcaacaagtt	gattctggaa	ttcaggaaag	aagaagtaat	300
aagaactggg	tcaatcttgt	gtaggtcatt	gggtaaatta	gtttttgttg	tatcatcata	360
cgatgtata	gtcaagagca	acaaaagcaa	aagagtggag	ttcttcacat	acaatcaact	420
gtaaacatgg	aaagatgtga	tgtaagtag				450

<210> 83
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No HMPV-185

<400> 83						
taaaattgaa	atatacagatt	acaaggtagt	agagccagta	aacatgcaac	atgaaataat	60
gaagaatgta	cacagtgtg	agctcacact	aitgaaacag	tttttaacaa	ggagtaaaaa	120
cattagcact	ctcaaattaa	atatgatatg	tgattggctg	caattaaagt	ctacatcaga	180
tgatacctca	atcctaagtt	tcatagatgt	agaatttata	cctagttggg	taagcaactg	240
gtttagtaat	tggtacaatc	tcaataagtt	aattttggaa	ttcagaagag	aagaagtaat	300
aagaacggg	tcaatcttat	gcaggtcatt	gggtaaatta	gtttttaitg	tatcatcata	360
tgatgtatc	gtcaagagca	acaaaagcaa	aagagtggag	ttcttcacat	acaatcaact	420
gtaaacatgg	aaagatgtga	tgtaagtag				450

<210> 84
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No C-78123

<400> 84						
atcctgttat	cgagcatggt	agactcaaaa	atgcaatcaa	ttctaagatg	aaaatatcag	60
attacaggat	agtagagcca	gtaaacatgc	aacatgaaat	tatgagaagt	gtacacagtt	120
gtgagctcac	attattaaaa	cagtttttaa	caaggagtaa	aaatattagc	actctcaaat	180
taaataatgat	atgtgattgg	ctacagttaa	agctctacatc	agatgatacc	tcaatcttaa	240
gttttataga	tgtagaattt	atacctagct	gggtaagcaa	ttggtttagt	aattgggtaca	300
atctcaacaa	gtrgattctg	gaattcagga	aagaagaagt	aataagaact	ggttcaatct	360
tgtgcaggtc	tttgggtaaa	ttagtttttg	ttgtafcac	atatggatgt	atagtcaaga	420
gcaacaaaaag	caaaagagtg	agcttcttca	catacaatca	actgttaaca	tggaaagatg	480
tgatgttaag	tagattcaat					500

<210> 85
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No C-91205

<400> 85						
caattctaaa	atgaaaatat	cagattacaa	ggtagtagag	ccagtaaaca	tgcaacatga	60
aataatgaag	aatgtacaca	gttgtgagct	cacactattg	aaacagtttt	taacaaggag	120
taaaaacatt	agcactctca	aattaaatat	gatatgtgat	tggctgcaat	taaagtctac	180
atcagatgat	acctcaatcc	taagtttcat	agatgtagaa	tttataccta	gttgggtaag	240
caactgggtt	agtaattggg	acaatctcaa	taagttaatt	ttggaattca	gaagagaaga	300
agtaataaga	accggttcaa	tcttatgcag	gtcattgggt	aaattagttt	ttattgtaic	360
atcatatgga	tgtattgtca	agagcaacaa	aagcaaaaaga	gtgagcttct	tcacatacaa	420
tcaactgta	acatggaaaag	atgtgatggt				450

<210> 86

```

<211> 400
<212> DNA
<213> human metapneumovirus

<220>
<221> gene
<222> (1)...(400)
<223> human metapneumovirus, strain Quebec Isolate No
C-91364

<400> 86
ttgcatagag aatcctgtta ttgagcatgt cagactcaaa aatggcagta attctaaaat    60
gaaaatatca gattacaagg tagtagaacC agtaaacatg caacatgaaa taatgaagaa    120
tgtacacagc tggtagcaca cactattgaa acagttttta acaaggagta aaaacattag    180
cactctcaaa ttaaataatga tatgtgattg gctgcaatta aaatctacat cagatggtag    240
ctcaatccta agttttatag argtagaatt tatacctagt tgggtaagca actggtttag    300
taattggcac aatctcaata agttaatttt agaattcagg agagaagaag taataagaac    360
cggttcaatc ttgtgcaggT cattaggtaa attagttttt    400

<210> 87
<211> 500
<212> DNA
<213> human metapneumovirus

<220>
<221> gene
<222> (1)...(500)
<223> human metapneumovirus, strain Quebec Isolate No
C-91749

<400> 87
atagagaatc ctgttattga gcatgtgaga ctcaaaaatg cagtcaattc taaaatgaaa    60
atatcagatt acaaggtagt agagccagta aacatgcaac atgaaataat gaagaatgta    120
cacagtgttg agctcacact attgaaacag tttttaacta ggagtazaaa cattagcact    180
ctcaaattaa atatgatatg tgattggctg caartaaagt ctacatcaga tgatacctca    240
atcctaagtt tcatagatgt agaatttata cctagtggg taagcaactg gtttagtaat    300
tggtagaact tcaataagtt aattttggaa ttcagaagag aagaagtaat aagaaccggt    360
tcaatctttt gcaggtcatt gggtaaatta gtttttatg tatcatcata tggatgtatc    420
gtcaagagca acaaaagcaa aagagtgagc ttcttcacat acaatcaact gttaacatgg    480
aaagatgtga tgccaagtng    500

<210> 88
<211> 450
<212> DNA
<213> human metapneumovirus

<220>
<221> gene
<222> (1)...(450)
<223> human metapneumovirus, strain Quebec Isolate No
hMPV-Q86

<400> 88
aatctcaaaa tggaaatatc agattacaag gtagtagaac caataaacat gcaacatgaa    60
ataatgaaga atgtacacag ttgtgagctc acactattga aacagttttt aacaaggagt    120
aaaaacatta gcactctcaa attaaatatt atattgtgatt ggctgcaatt aaaatctaca    180
tcagatgata cctcaatcct aagttttata gatgtagaat ttatacctag tgggtaagc    240
aactggttta gtaattggta caatctcaat aagttaattt tagaattcag gagagaggaa    300
gtaataagaa cgggttcaat cttgtgcagg tcattaggta aattagtttt tattgtatca    360
tcatatggat gtatcgtcaa gagcaacaaa agcaaaagag tgagcttctt cacatacaat    420
caactgtraa catggaaga tgtgatgtta    450

<210> 89
<211> 450
<212> DNA
<213> human metapneumovirus

<220>
<221> gene
<222> (1)...(450)
<223> human metapneumovirus, strain Quebec Isolate No
hMPV-Q97

```

<400> 89
 aaaatgaaaa tatcagatta caaggtagta gagccagtaa acatgcaaca tgaataatg 60
 aagaatgtac acagttgtga gctcacacta ttgaaacagt ttttaactag gagtaaaaaac 120
 attagcactc tcaaattaaa tatgatatgt gatggctgc aattaaagtc tacatcagat 180
 gatacctcaa tcctaagttt catagatgta gaatttatac ctagttgggt aagcaactgg 240
 tttagttaatt ggtacaatct caataagtta attttggaaat tcagaagaga agaagtaata 300
 agaaccgggt caatcttatg caggtcattg ggtaaattag tttttattgt atcatcatat 360
 ggatgtatcg tcaagagcaa caaaagcaaa agagttagct tcttcacata caatcaactg 420
 ttaacatgga aagatgtgat gttaagtaga 450

<210> 90
 <211> 537
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(537)
 <223> human metapneumovirus, strain Can 97-83

<400> 90
 agaatcctgt tattgagcat gtgagactca aaaatggcgg tcattctaaa atgaaaatat 60
 cagattacaa ggtagtagag ccagtaaca tgcaacatga aataatgaag aatgtacaca 120
 gttgtgagct cacactattg aaacagtttt taacaaggag taaaaacatt agcactetca 180
 aattgaatat gatatgtgat tggctgcaat taaagtctac atcagatgat acctcaatcc 240
 taagtttcat agatgtagaa ttatcaccta gttgggtaag caactgggtt agtaattggt 300
 acaatctcaa taagttaatt ttggaattca gaagagagga agtaataaga accggttcaa 360
 tcttatgcag gtcattgggt aaattagttt ttattgtatc atcatatgga tgratcgta 420
 agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgta acatggaag 480
 atgtgatggt aagtagattt aatgccaatt tttgtatatg ggtaagcaac agttctg 537

<210> 91
 <211> 20
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 55

<400> 91
 atgggacaag tgaaaatgtc 20

<210> 92
 <211> 19
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 56

<400> 92
 gagtctcagt acacaataa 19

<210> 93
 <211> 18
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 57

<400> 93
 gtcactgcag ttgttgta 18

<210> 94
 <211> 19
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 58

37/52

<400> 94
 jcatttccga gaacaacac 19
 <210> 95
 <211> 19
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 18 multiplex assay
 <400> 95
 gagtctcagt acacaataa 19
 <210> 96
 <211> 19
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 19 multiplex assay
 <400> 96
 gcatttccga gaacaacac 19
 <210> 97
 <211> 18
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 59
 <400> 97
 atgtcttggg aagtgggtg 18
 <210> 98
 <211> 17
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 60
 <400> 98
 tcttcttacc attgcac 17
 <210> 99
 <211> 20
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 61
 <400> 99
 ctaattatgt ggtatgaagc 20
 <210> 100
 <211> 18
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 62
 <400> 100
 atggagtctt acctagta 18
 <210> 101
 <211> 19

38/52

<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 63

<400> 101
aaggtgcttg gttgttatc

19

<210> 102
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 64

<400> 102
atgtcattcc ctgaaggaa

19

<210> 103
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 65

<400> 103
ttaactggta aatctcatc

19

<210> 104
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 66

<400> 104
catgggacaa gtagttatg

19

<210> 105
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 67

<400> 105
atggaggtga aagtggaga

19

<210> 106
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 68

<400> 106
ttaactagtt tggttgtat

19

<210> 107
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 69

39/52

<400> 107
 ttagagtta tttgtatt 19
 <210> 108
 <211> 24
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 70
 <400> 108
 ggacaagtag ttatggaggt gaaa 24
 <210> 109
 <211> 28
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 71
 <400> 109
 ctctttaag atatgagtc gmagrta 28
 <210> 110
 <211> 22
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 20 multiplex assay
 <400> 110
 gttgccatag agaatcctgt ta 22
 <210> 111
 <211> 22
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 21 multiplex assay
 <400> 111
 cattcagact gttgcttacc ca 22
 <210> 112
 <211> 22
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 72
 <400> 112
 gttgccatag agaatcctgt ta 22
 <210> 113
 <211> 22
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> primer no 73
 <400> 113
 cattcagact gttgcttacc ca 22
 <210> 114
 <211> 27
 <212> DNA

40/52

<213> human Metapneumovirus
 <220>
 <223> human Metapneumovirus
 primer A1

<400> 114
 ccaattacta aaccaattgc ttaccca 27

<210> 115
 <211> 21
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> probe no 74

<400> 115
 gcaagcttat ggggccggtc a 21

<210> 116
 <211> 25
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> probe no 75

<400> 116
 acaatgctaa ggtgggggggt cattg 25

<210> 117
 <211> 23
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> probe no 76

<400> 117
 gttctgagga caggttggta cac 23

<210> 118
 <211> 23
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> probe no 77

<400> 118
 aatgttttta cactggaggt agg 23

<210> 119
 <211> 22
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> probe no 78

<400> 119
 gttacaatac cagcattcat ca 22

<210> 120
 <211> 25
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> probe no 79

41/52

<400> 120
 atcagtttca atcaaagaga gtgag 25
 <210> 121
 <211> 25
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> probe no 80
 <400> 121
 taaagcaagc aatcaaagtc atgga 25
 <210> 122
 <211> 25
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> probe no 81
 <400> 122
 cccattgaag aagaagagtc taccg 25
 <210> 123
 <211> 20
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> probe no 82
 <400> 123
 actcaagccc acagcatcca 20
 <210> 124
 <211> 23
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> probe no 83
 <400> 124
 ctcaacagtc cacagaaggc tcc 23
 <210> 125
 <211> 26
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> probe no 84
 <400> 125
 attggtttag taattggtac aatctc 26
 <210> 126
 <211> 26
 <212> DNA
 <213> human metapneumovirus
 <220>
 <223> probe no 85
 <400> 126
 acaagttgat tctggaattc aggaaa 26
 <210> 127
 <211> 25
 <212> DNA

```

<213> human Metapneumovirus
<220>
<223> human Metapneumovirus
      probe A2
<400> 127
cgagcatggt agactcaaaa atgca
      25
<210> 128
<211> 23
<212> DNA
<213> human metapneumovirus
<220>
<223> probe no 33 multiplex assay
<400> 128
atgtatccgt ccaagctgag tta
      23
<210> 129
<211> 26
<212> DNA
<213> human metapneumovirus
<220>
<223> probe no 34 multiplex assay
<400> 129
attggtttag taattggtac aatctc
      26
<210> 130
<211> 1027
<212> DNA
<213> human Influenza A virus
<220>
<221> gene
<222> (1)...(1027)
<223> human Influenza A virus
      strain A/Hong Kong/1180/99(H3N2)
      accession number af386771
<400> 130
agcaaaagca ggtagatatt gaaagatgag ccttctaccc gaggtcgaaa cgtatgttct
      60
ctctatcgtt ccatcaggcc ccctcaaagc cgaaatcgcg cagagacttg aagatgtcctt
      120
tgctgggaaa aacacagatc ttgaggctct catggaatgg ctaaagacaa gaccaatcct
      180
gtcacctctg actaagggga ttttagggtt tgtgttcacg ctaccgtgc ccagtgagcg
      240
aggactgcag cgtagacgct ttgtccaaaa tgccctcaat gggaatgggg atccaaataa
      300
catggacaaa gcagtraaac tgtatagaaa acttaagagg gagataacat tccaargggc
      360
caaagaaata gcactcagtt attctgctgg tgcacttgcc agttgcatgg gcctcatata
      420
caataggatg ggggctgtaa ccactgaagt ggcatttggc ctggtatgtg caacatgtga
      480
acagattgct gactcccagc acaggtctca taggcaaatg gtggcaacaa ccaatccatt
      540
aataagacat gagaacagaa tggfittggc cagcactaca gctaaggcta tggagcaaat
      600
ggctggatca agtgagcagg cagcggaggc catggagatt gctagtcagg ccaggcaaat
      660
gggtgcaggca atgagagccg ttgggactca tcctagctcc agtactgggc taagagatga
      720
tcttcttgaa aatttgcaga cctatcagaa acggatgggg gtgcagatgc aacgattcaa
      780
gtgacccgct tyttgttgc cgcagatca ttgggatcct gcacttgata ttgtggattc
      840
ttgatcgtct tttttcaaa tgcactatc gactctcaa acacggcctt aaaagagggc
      900
cttctatgga aggagtacct gagtctatga gggaaagaata tcgaaaggaa cagcagaatg
      960
ctttggatgc tgaccacagt cattttgtca gcataaagtt ggagtaaaaa actaccttgt
      1020
tcttact
      1027
<210> 131
<211> 987
<212> DNA
<213> human Influenza A virus
<220>
<221> gene
<222> (1)...(987)
<223> human Influenza A virus

```

strain A/Charlottesville/31/95 (H1N1)
accession number af398876

```
<400> 131
atgagtcttc taaccgaggt cgaaacgtac gttctctcta tcgtcccgtc aggccccctc 60
aaagccgaga tcgcacagag acttgaagat gtccttgctg gaaagaacac cgatcttgag 120
gctctcatgg agtggctaaa gacaagaccg atcctgtcac ctctgactaa ggggatttta 180
ggatttgtgt tcacgctcac cgtgccaggt gagcggaggac tgcagcgtag acgctttgtc 240
caaaatgccc ttaatgggaa tggggatcca aataacatgg acagagcagt taaactgtat 300
agaaagctta agagggagat aacattccat ggggccaaag aaatagcact cagttattct 360
gctgggtgcac ttggcctgat atgcgcaacc tgtgaacaga ttgctgactc ccagcataag 420
gaatcagcat ttggcctgat atgcgcaacc tgtgaacaga ttgctgactc ccagcataag 480
tctcataggc aaatggtaac aacaaccaat ccattaataa gacatgagaa cagaatggtt 540
ctggccagca ctacagctaa agctatggag caaatggctg gatcgagtga acaagcagct 600
gaggccatgg aggttgctag tcaggccagg caaatggctg agccaatgag agccaatggg 660
actcatccta gctctgacac ttggtctgaa aatgatcttc ttgaaaattt gcaggcctat 720
cagaaacgaa tgggggtgca gatgcaacga ttcaagtgat cctcttggtt ttgccgcaag 780
tatcattggg attgtgcacc tgatattgtg gattattgat cgcctttttt tcaaatgcat 840
ttatcgtatc tttaaacacg gtctgaaaag agggccttct acggaaggag taccagagtc 900
tatgagggaa gaatatcgag aggaacagca gaatgctgtg gatgctgacg aaggctcattt 960
tgtcagcata gagctggagt aaaaaaac
```

```
<210> 132
<211> 1076
<212> DNA
<213> human Influenza B virus
```

```
<220>
<221> gene
<222> (1)...(1076)
<223> human Influenza B virus
strain B/Nagoya/20/99
```

```
<400> 132
atgtcgctgt ttggagacac aattgcctac ctgctttcat tgacggaaga tggagaaggt 60
aaagcagaac tagcagaaaa attacactgt tggttcgggtg ggaaagaatt tgacctagac 120
tctgccttgg aatggataaa aaacaaaaga tgcttaactg atatacaaaa agcactaatt 180
ggtgcctcta tctgcttttt aaaacccaaa gaccaagaaa gaaaaagaag attcatcaca 240
gagcccctat caggaatggg aacaacagca acaaaaaaga aaggcctgat tctagctgag 300
agaaaaatga gaagatgtgt gagctttcat gaagcatttg aaatagcaga aggccatgaa 360
agctcagcgc tactatattg tctcatggtc atgtacctga accctggaaa ttattcaatg 420
caagtaaaac taggaacgct ctgtgctttg tgcgagaaac aagcatcaca ttcacacagg 480
gctcatagca gagcagcgag atcttcagtg cctggagtgga ggcgagaaat gcaaatggtc 540
tcagctatga acacagcaaa aacaatgaat ggaatgggaa agggagaaga cgtccaaaaa 600
ctggcagaag aactgcaaaag caacattgga gtgttgagat ctcttggagc aagtcaaaaag 660
aatggggaag gaattgcaaa ggatgtaatg gaagtgtctaa agcagagctc tatgggaaat 720
tcagctcttg tgaagaataa cctataatgc ttgaaccatt tcagattctt tcaatttgtt 780
ctttatctt atcagctctc catttcatgg ctggacaat agggcatttg agtcaaataa 840
aaagaggagt aaacatgaaa atacgaataa aaggctcaaa taaagagaca ataaacagag 900
aagtatcaat tttgagacac aattaccaaa aagaaaatcca ggccaaagaa acaatgaagg 960
aagtgtcttc tgacaacata gaagtattga gtgaccacat agtgattgag gggctttctg 1020
ctgaagagat aataaaaatg ggcaaaacag ttttggaggt agaaaaattg cattaa 1076
```

```
<210> 133
<211> 1725
<212> DNA
<213> human Respiratory syncytial Virus
```

```
<220>
<221> gene
<222> (1)...(1725)
<223> human Respiratory syncytial virus
strain BI
accession number af013254
```

```
<400> 133
atggagctgc tgatccacag gttaagtgca atcttcttaa ctcttgctat taatgcattg 60
tacctcacct caagtcagaa cataactgag gagttttacc aatcgacatg tagtgcagtt 120
agcagaggtt attttagtgc ttaagaaca ggttgggtata ccagtgctat aacaatagaa 180
ttaagttaata taaaagaaac caaatgcaat ggaactgaca ctaaagtaaa acttataaaa 240
caagaattag ataagtataa gaatgcagtg acagaattac agctacttat gcaaaacaca 300
ccagctgcc. acaaccgggc cagaagagaa gcaccacagt atatgaacta tacaatcaat 360
```

accactaaaa	acctaadaatgt	atcaataaagc	aagaagagga	aacgaagatt	tctgggcttc	420
ttgttaggtg	taggatctgc	aatagcaagt	ggtatagctg	tatccaaagt	tctacacctt	480
gaaggagaag	tgaacaagat	caaaaatgct	ttgttatcta	caaacaagc	tgtagtcagt	540
ctatcaaatg	gggtcagtg	tttaaccagc	aaagtgttag	atctcaagaa	ttacataaat	600
aaccaattat	faccatag	aaatcaacag	agctgtcgca	tctccaacat	tgaaacagtt	660
atagaattcc	agcagaagaa	cagcagattg	ttggaaatca	acagagaatt	cagtgccaat	720
gcaggtgtaa	caacaccttt	aagcacttac	atgttaacaa	acagtgagtt	actatcattg	780
atcaatgata	tgccataaac	aaatgatcag	aaaaaattaa	tgtcaagcaa	tggtcagata	840
gtaaggcaac	aaagttattc	tatcatgtct	ataataaagg	aagaagtcct	tgcatatggt	900
gtacagctac	ctatctatgg	tgtaatagat	acaccttgct	ggaaattaca	cacatcacct	960
ctatgcacca	ccaacatcaa	agaaggatca	aatatttgtt	taacaaggac	tgatagagga	1020
tggtattgtg	gctcagtaag	atcagtatcc	ttctttccac	aggctgacac	ttgtaaaagta	1080
cagtcacaatc	gagtaattttg	tgacactatg	aacagtttga	cattaccaag	tgaaagtcagc	1140
ctttgtaaca	ctgacatatt	caattccaag	tatgactgca	aaattatgac	atcaaaaaa	1200
gacataagca	gctcagtaag	tacttctctt	ggagctatag	tgtcatgcta	aaaaatcaat	1260
aaatgcactg	catccaacaa	aaatcgtggg	attataaaga	cattttctaa	tggttgtgac	1320
tatgtgtcaa	acaaaggagt	agataactgtg	tcagtgggca	acactttata	ctatgtaaac	1380
aagctggaag	gcaagaacct	ttatgtaaaa	ggggaacctt	taataaatta	ctatgaccct	1440
ctagtgtttc	cttctgatga	gtttgatgca	tcaatatctc	aagtcaatga	aaaaatcaat	1500
caaagttag	cttttattcg	tagatctgat	gaattactac	ataatgtaaa	tactggcaaa	1560
tctactacaa	atattatgat	aactacaatt	attatagtaa	tcattttagt	attgttatca	1620
ttaatagcta	ttggtttgct	gttgatttgc	aaagccaaaa	acacaccagt	tacactaagc	1680
aaagaccaac	taagtggaa	caataatatt	gcattcagca	aatag		1725

<210> 134
 <211> 1575
 <212> DNA
 <213> human Parainfluenza 1 virus

<220>
 <221> gene
 <222> (1)...(1575)
 <223> human Parainfluenza 1 virus strain
 Washington/1964
 accession number nc003461

<400> 134	tactaagtac	ttttgacaca	tttagttcca	ggagaagtga	gagcatcaat	60
atggcccggg	gaggagcaat	tatacctggt	caaagaagta	ccgtttctgt	cttcacatta	120
aagtcrtggc	tgacagatga	tgacagataaa	ttattaatag	caaccacttt	cttagcccac	180
ggcccggagt	cagataaaaca	acactctcaa	agaggaggat	tttttagtct	actccttcca	240
tcattggaca	gtagtccgga	gttatatctc	actacaacg	gtgtcaatgc	tgatgtcaag	300
atggcctaca	acaatataga	gagagatcct	aaaagaacaa	aaacagatgg	gttcattgtc	360
tatgtgat	acatggagta	tgaaagaaca	acagagtggt	tgtttgacc	tatgatcaac	420
aaaacaagag	tgttccaagg	gcaaaagag	aatgcccagc	tagaggcatt	gcttcagaca	480
aagaacccat	ctgcagtctc	cggagctata	atagttcaag	tttggatag	gttggttaaa	540
tatggatctc	gtagtgtctg	tctaagaaaa	ggattcttca	atagattaga	agcattcaga	600
gccataacaa	ccgttaaaag	tgcccctggtc	ttcacaggag	acacagttga	aggtattggt	660
caggatggaa	ggtcacaaca	aaagcttagta	tctcttatgg	tagaaactct	ggtgactatg	720
gcagtgatga	ggtcagattt	aactacatta	gagaagaaca	ttcagattgt	aggaatttac	780
aacacatcca	caggattagc	atctttcatg	aacaccatca	agtatggtgt	agaaacgaag	840
ataagagatg	tgacactatc	aaatctgaga	ccagatataa	ataaattgag	aaagcctggt	900
atggcccggc	tatcaaagg	agcccagcc	ccttttatat	gtatactcag	agaccagtt	960
gatatctatc	ttgcccctgg	aaactatcca	gcactgtgga	gctacgcaat	gggctgtgct	1020
catggagact	acaaagctat	gcaacagtat	gtaactggaa	gaacatattt	ggacatggaa	1080
gtggtaaaaa	ttggacaagc	tgtagctaaa	gatgtctgatt	ccaaaatcag	cagtgctctg	1140
atgttctctac	taggtgtgac	agatacagca	aaagagagac	taagacacca	tctgacaaac	1200
gaggaagaac	gggatgggtg	gtaccacaag	cctacaggtg	gtggagctat	agaagtggca	1260
ctttcaggag	cagacataac	aatgtggatg	gaggacactg	ctgatcggga	caacaagaac	1320
attgatcata	acagcaatga	agaatggatg	aatcactcga	tcagcaacca	cacaatcacg	1380
tggaacaatg	cagaagaact	tgaagaagag	acaaatgatg	aagacatcac	tgatatagaa	1440
attcgtggtg	cacgaaggct	ggccgacaga	aaacagagac	taagccaggc	aaacaataaa	1500
aacaagattg	gcagtgatgc	tgactatgag	aatgatgatg	atgctacagc	ggctgcaggg	1560
cgagacacca	tttaa					1575

<210> 135
 <211> 1548
 <212> DNA
 <213> human Parainfluenza 3 virus

<220>
 <221> gene

<222> (1)...(1548)
 <223> human Parainfluenza 3 virus
 strain GP
 accession number ab012132

<400> 135
 atgttgagcc tatttgatac atttaatgca cgtaggcaag aaaacataac aaaatcagcc 60
 ggtggagcta tcattcctgg acagaaaaat actgtctcta tatttgctct tggaccgaca 120
 ataactgatg ataatgagaa aatgacatta gctcttcttt ttttatctca ttcactggat 180
 aatgagaaac aacatgcaca aagggcaggg ttctctgggt ccttattatc aatggcttat 240
 gccaatccag agctctacct aacaacaaat ggaagtaatg cagatgtcaa gtatgtcata 300
 tacatgatcg agaaagatct aaaacggcaa aagatggag gatttgggt taagacgaga 360
 gagatggtat atgacaagac aactgattgg atatttggaa gtgacctgga ttgtgatcag 420
 gaaactatgt tgcagaacgg aagaacaat tcaacaattg aagacctigt ccacacattt 480
 gggatccat catgtttagg agctcttata atacagatct ggatagttct ggtcaaagct 540
 atcactagta tctcagggtt aagaaaaggc tttttcacc gattggaagc ttccagacaa 600
 gatggaacag tgcaggcagg gcttggattg agcggtgaca cagtggatca gattgggtca 660
 attatgcggc ctcaacagag ctttggtaact cttatggttg aaacattaat aacaatgaat 720
 actagcagaa atgacctcac aacctagaaa aagaatatac aaattgttgg taactatata 780
 agatggtcag gtctcggctt attcttcaat acaatcagat atggaattga gactagaatg 840
 gcagcttga ctctatccac tctcagacca gacatcaata gattaaaagc tttgatggaa 900
 ctgtatttat caaagggacc cgcgctctct ttcactgta tctcagaga tcccatatcat 960
 ggtgagttcg caccaggcaa ctatcctgcc atatggagct atgcaatggg agtggcagtt 1020
 gtacaaaata gagccatgca acagtatgtg acgggaagat catatctgga tattgatatg 1080
 ttccagctag gacaagcagt agcacgtgat gctgaagctc agatgagctc aacactagaa 1140
 gatgaacttg gagtgcaca cgaagctaaa gaaagcttga agagacatag aaggaacata 1200
 aatagttcag agacatcirt ccacaaaacca acagttggat cagccataga gatggcaata 1260
 gatgaagagc cagaacaatt cgaacataga tcagatcaag aacagatgg agaacctcaa 1320
 tcatctataa ttcaatatgc ttgggcagaa ggaacagaaa gcgatgatcg gactgagcaa 1380
 gatacagaat ctgacaatat caagactgaa caacaaaaca tcagagacag actaaaacaag 1440
 agactcaacg aaaagaagaa acaaggcagt caaccacctt ccaatccac aaacagaacg 1500
 aatcaggacg aatatagatga tctgtttaat gcatttggaa gcaactaa 1548

<210> 136
 <211> 2910
 <212> DNA
 <213> human Adenovirus

<220>
 <221> gene
 <222> (1)...(2910)
 <223> human Adenovirus
 strain 105
 accession number aj293903

<400> 136
 atggctacc cttcgatgat gccgcagtg tcttacatgc acatctcggg ccaggacgcc 60
 tggagtagc tgagccccgg gctgggtgca tttgcccgg ccaccgagac gtacttcagc 120
 ctgaaataca agtttagaaa ccccacggtg ggcgctacgc acgacgtgac cacagaccgg 180
 tcccagcgtt tgacgctgcg gttcatccct gtggatcgcg aggataccgc gtactcgtac 240
 aagggcgggt tcaccctggc tgtgggtgac aaccgctgct ttgatattggc ttccacgtac 300
 tttagacatc gggcgctgct ggacaggggc cctactttca agccctactc tggcactgcc 360
 tacaacgctc tagctcccaa gggcgctccc aactcctgtg agtgggaaca aaccgaagat 420
 agcgccgggg cggttgccga ggatgaagaa gaagaggaa atgaagatga agaagaggaa 480
 gaggaagagc aaaacgctcg agatcaggct actaagaaa cacatgttta tgcccaggct 540
 cctttgtctg gagaaacaa tacaaaaagc gggctacaaa taggatcaga caatgcagaa 600
 acacaagcta aacctgtata tgcagatcct tccatcaac cagaaacctc aattggcgaa 660
 tctcagtgga acgaagctga tgctaattgca gcaggagggg gagtgtttaa aaaaaaact 720
 cccatgaaac catgctatgg atccttatgc aggcctacaa atccttttgg tggccaatcc 780
 gtccctggtc cggatgaaaa aggggtgctt ctccaaggg ttgacttgca attcttctca 840
 aatactacct ctttgaacga ccggcaaggc aatggcacta aaccaaaagt ggtgtgttac 900
 agtgaagatg taaatttgga aaccccagac acacatctgt cttacaaacc tggaaaagg 960
 gatgaaaatt ctaaagctat gttgggtcaa caatttatgc caaacagacc caattacatc 1020
 gctttcaggg actaattttat tggcctaatt tattataaca gactggcaa catgggtgtt 1080
 cttgctggtc aggcacgca gctaaatgcc gtggtagatt tgcaagacag aaacacagag 1140
 ctgtccctatc aacttttgc tgcattccata ggtgatgaa ccagatattt ttctatgtgg 1200
 aatcaggctg tagaccagat tgaccagat gttagaatca ttgaaaacca tggaaactgag 1260
 gatgaattgc caaattattg ttccctctt ggggtattg gggtaactga cacctatcaa 1320
 gctattaagg ctaatggcaa tggcgcaggt gataatggaa atactacatg gacaaaagat 1380
 gaaacttttg caacacgtaa tgaatatgga tctggtaaca actttgcat ggaattaac 1440
 ctaaattgcca acctatggag aaatttctt tactcaata ttgcactata cctggcagac 1500
 aagctaaaa acacccccac caacgtggaa atatctgaca accccaacac ctacgactac 1560

atgaacaagc	gagtgggtggc	tccctgggctt	gtagactgct	acattaacct	tggggcgcg	1620
tggctctctgg	actacatgga	caacgttaat	ccctttaacc	accaccgcaa	tgcgggcctg	1680
cgttaccgct	ccatgttgrt	gggaaacgga	cgctacgtgc	cttttcacat	tcagggtgcc	1740
caaaagtttt	ttgccattaa	aaacctcctc	ctcctgccag	gctcatacac	atatgaatgg	1800
aacttcagga	aggatgttaa	catggttctg	cagagctctc	tgggaaacga	ccttagagti	1860
gacggggcta	gcattaagtt	tgacagcatt	tgctttatg	ccaccttctt	ccccatggcc	1920
cacaacacgg	cctccacgct	ggaagccatg	ctcagaaatg	acaaccaacga	ccagtccttt	1980
aatgactacc	tttccgcccg	caacatgcta	tatcccatac	ccgccaacgc	caccaacgtg	2040
cccattctca	tcccaticg	caactgggca	gcatttcgcg	gttgggcctt	cacacgcttg	2100
aagacaaagg	aaacccttcc	cctgggatca	ggctacgacc	cttactacac	ctactctggc	2160
tccataccat	accttgacgg	aaccttctat	cttaatcaca	cctttaagaa	ggtggccatt	2220
acttttgact	cttctgttag	ctggccgggc	aacgaccgcc	tgcttactcc	caatgagttt	2280
gagattaagc	gctcagttga	cggggagggc	tataacgtag	ctcagtgcaa	catgacaaag	2340
gactggttcc	tagtgcagat	gttggccaac	tacaatatg	gctaccaggg	cttctacatt	2400
ccagaaagct	acaaagaccg	catgtactcg	ttcttcagaa	acttccagcc	catgagccgg	2460
caagtgggtg	acgatactaa	atacaaagat	tatcagcagg	ttggaattat	ccaccagcat	2520
aacaacfcag	gcttcgtagg	ctacctcgct	cccaccatgc	gcgagggaca	agcttaccct	2580
gctaattgct	cctaccctct	aataggcaaa	accgcggttg	atagttattac	ccagaaaaag	2640
tttctttg	accgcaacct	gtggcgcatc	ccattctcca	gtaactttat	gtccatgggt	2700
gcgctcacag	acttgggcca	aaaccttctc	tacgaaact	ccgcccacgc	gctagacatg	2760
acctttgagg	tggatcccat	ggacgagccc	acccttcttt	atgttttgit	tgaagtcttt	2820
cacgtggtcc	gtgtgcacca	gccgcaccgc	ggcgtcatcg	agaccgtgta	cctgcgcacg	2880
cccttctcgg	ccggcaacgc	cacaacataa				2910

<210> 137
 <211> 810
 <212> DNA
 <213> human Enterovirus

<220>
 <221> gene
 <222> (1)...(810)
 <223> human Enterovirus
 strain Coxsackievirus B1
 accession number M16560

<400> 137	cggcccttga	atgcggttaa	tcctaactgc	ggagcacata	ccctcaaacc	agggggcagt	60
	gtgtcgtaac	gggcaactct	gcagcggaac	cgactacttt	gggtgtccgt	gtttcatttt	120
	attcctatatac	tggctgctta	tggtgacaat	tgacaggttg	ttaccatata	gttattggat	180
	tggccatccg	gtgactaaca	gagcaattat	atatctcttt	gttgggttta	taccacttag	240
	cttgaagagag	gttaaaacac	tacatctcat	cattaaacta	aatacaacaa	aatgggggct	300
	caagtatcaa	cacaaaagac	tggagcacat	gagaccgggc	tgaatgcaag	cgggaaattcc	360
	atcatccatt	acacaaaacat	aaactactat	aaagatgctg	catccaactc	agccaacaga	420
	caggatttca	ctcaagacc	aggtaaatft	actgagccag	tgaaggacat	tatgatcaaa	480
	tcgatgccag	catrgaacct	ccccctctg	gaagagtgtg	ggtatagtga	cagggttcga	540
	tcaataacc	tcgggaactc	cactatcaca	acacaggagt	tgctaatgt	tgtggttggg	600
	tatggtgtgt	ggccagaata	tttgaaggac	aatgaagcca	caggcgagga	ccaaccaaca	660
	caaccgacg	tggccacatg	tcggttctac	actttagagt	ccgtgcagtg	gatgaagaat	720
	tcagcaggtt	ggtggtggaa	gttaccagat	gcactttcac	aaatgggggt	gtttggacaa	780
	aatatgcagt	accactactt	agggagaaca				810

<210> 138
 <211> 681
 <212> DNA
 <213> human Rhinovirus

<220>
 <221> gene
 <222> (1)...(681)
 <223> human Rhinovirus
 strain 14
 accession number K02121

<400> 138	taaccetaga	gccttatgcc	acgatccagt	ggttgaagg	tcgtaatgag	caattccggg	60
	acgggaccga	ctactttggg	tgctcgtggt	tctcattttt	cttcatattg	tcttatggtc	120
	acagcatata	tatacatata	ctgtgatcat	gggcgctcag	gtttctacac	agaaaagtgg	180
	atctcacgaa	aatcaaaaca	ttttgaccaa	tgatcaaat	cagactttca	cagttataaa	240
	ttactataag	gatgcagcaa	gtacatcatc	agctgggtcaa	tcactgtcaa	tggaccatc	300
	taagtttaca	gaaccagrra	aagatctcat	gcttaagggt	gcaccagcat	tgaattcacc	360
	caatgltgag	gcctgtggtt	atagtgatag	agtacaacaa	atcacactcg	ggaattcaac	420

47/52

```

aataacaaca caagaagcag ccaacgctgt tgtgtgttat gctgaatggc cagagtacct 480
tccagaigtg gacgctagtg atgtcaataa aacttcaaaa ccagacactt ctgtctgtag 540
gtttracaca ttggatagta agacatggac aacaggttct aaaggctggg gctggaaatt 600
accagatgca ctcaaggata tgggtgtggt cgggcaaaac atgtttttcc actcactagg 660
aagatcaggt tacacagtac a 681

<210> 139
<211> 21
<212> DNA
<213> human Influenza A virus

<220>
<223> primer no 12 multiplex assay

<400> 139
cttctaaccg aggtcgaaac g 21

<210> 140
<211> 24
<212> DNA
<213> human Influenza A virus

<220>
<223> primer no 13 multiplex assay

<400> 140
agggcatttt ggacaaagcg tcta 24

<210> 141
<211> 20
<212> DNA
<213> human Influenza B virus

<220>
<223> primer no 14 multiplex assay

<400> 141
ttacactggt ggttcgggtg 20

<210> 142
<211> 20
<212> DNA
<213> human Influenza B virus

<220>
<223> primer no 15 multiplex assay

<400> 142
gccagttttt ggacgtcttc 20

<210> 143
<211> 23
<212> DNA
<213> human Respiratory syncytial Virus

<220>
<223> primer no 16 multiplex assay

<400> 143
aacagttaa cattaccaag tga 23

<210> 144
<211> 23
<212> DNA
<213> human Respiratory syncytial Virus

<220>
<223> primer no 17 multiplex assay

<400> 144
tcattgactt gagatattga tgc 23
    
```

48/52

<210> 145
 <211> 26
 <212> DNA
 <213> human Parainfluenza 1 virus

 <220>
 <223> primer no 22 multiplex assay

 <400> 145
 tctggcggag gagcaattat acctgg 26

 <210> 146
 <211> 26
 <212> DNA
 <213> human Parainfluenza 1 virus

 <220>
 <223> primer no 23 multiplex assay

 <400> 146
 atctgcatca tctgtcacac tcgggc 26

 <210> 147
 <211> 22
 <212> DNA
 <213> human Parainfluenza 1 virus

 <220>
 <223> human Parainfluenza 1 virus
 primer P1

 <400> 147
 gtatggtgta gaaacgaaga tg 22

 <210> 148
 <211> 22
 <212> DNA
 <213> human Parainfluenza 1 virus

 <220>
 <223> human Parainfluenza 1 virus
 primer P2

 <400> 148
 ttgtaccaca gcaacaccca tt 22

 <210> 149
 <211> 26
 <212> DNA
 <213> human Parainfluenza 3 virus

 <220>
 <223> primer no 24 multiplex assay

 <400> 149
 aacaggaaac tatgctgcag aacggc 26

 <210> 150
 <211> 26
 <212> DNA
 <213> human Parainfluenza 3 virus

 <220>
 <223> primer no 25 multiplex assay

 <400> 150
 gatccactgt gtcaccgctc aatacc 26

 <210> 151
 <211> 25
 <212> DNA
 <213> human Parainfluenza virus

49/52

<220>
 <223> human Parainfluenza virus
 primer P3

<400> 151
 tcttgcttca ttcttcaata caatc 25

<210> 152
 <211> 23
 <212> DNA
 <213> human Parainfluenza 3 virus

<220>
 <223> human Parainfluenza 3 virus
 primer P4

<400> 152
 aattccatca gagcttttaa tct 23

<210> 153
 <211> 18
 <212> DNA
 <213> human Adenovirus

<220>
 <223> primer human Adenovirus P5

<400> 153
 actccctcga tgatgccg 18

<210> 154
 <211> 26
 <212> DNA
 <213> human Adenovirus

<220>
 <223> primer no 26 multiplex assay

<400> 154
 cctacgcacg atgtgaccac agaccg 26

<210> 155
 <211> 26
 <212> DNA
 <213> human Adenovirus

<220>
 <223> primer no 27 multiplex assay

<400> 155
 gtgttgtagg cagtgccgga gtaggg 26

<210> 156
 <211> 21
 <212> DNA
 <213> human Sars Coronavirus

<220>
 <223> primer SARS no P5

<400> 156
 ctaacatgct taggataatg g 21

<210> 157
 <211> 21
 <212> DNA
 <213> human Sars Coronavirus

<220>
 <223> human Sars Coronavirus
 primer P6

50/52

<400> 157
 caggtaagcg taaaactcat c 21
 <210> 158
 <211> 24
 <212> DNA
 <213> human Sars Coronavirus
 <220>
 <223> human Sars Coronavirus
 primer P7
 <400> 158
 atgaattacc aagtcaatgg ttac 24
 <210> 159
 <211> 22
 <212> DNA
 <213> human Sars Coronavirus
 <220>
 <223> human Sars Coronavirus
 primer P8
 <400> 159
 cataaccagt cggtagcagct ac 22
 <210> 160
 <211> 16
 <212> DNA
 <213> human Enterovirus/human Rhinovirus
 <220>
 <223> primer no 28 multiplex assay
 <400> 160
 ctactttggg tgtccg 16
 <210> 161
 <211> 19
 <212> DNA
 <213> human Enterovirus/human Rhinovirus
 <220>
 <223> primer no 29 multiplex assay
 <400> 161
 ggtaattcca ccaccancc 19
 <210> 162
 <211> 23
 <212> DNA
 <213> human Influenza A virus
 <220>
 <223> probe no 30 multiplex assay
 <400> 162
 tcttcaagtc tctgtcgat ctc 23
 <210> 163
 <211> 23
 <212> DNA
 <213> human Influenza B virus
 <220>
 <223> probe no 31 multiplex assay
 <400> 163
 agctcagcgc tactatattg tct 23

51/52

<210> 164
 <211> 23
 <212> DNA
 <213> human Respiratory syncytial virus

 <220>
 <223> probe no 32 multiplex assay

 <400> 164
 ccttccagct tgtttacata gta 23

 <210> 165
 <211> 23
 <212> DNA
 <213> human Parainfluenza 1 virus

 <220>
 <223> probe no 35 multiplex assay

 <400> 165
 aagtaccggt tctgtcttca cat 23

 <210> 166
 <211> 23
 <212> DNA
 <213> human Parainfluenza 3 virus

 <220>
 <223> probe no 36 multiplex assay

 <400> 166
 cctgcactgt tccatcttgt ctg 23

 <210> 167
 <211> 18
 <212> DNA
 <213> human Adenovirus

 <220>
 <223> probe no 37 multiplex assay

 <400> 167
 cgcgtactcg tacaaggc 18

 <210> 168
 <211> 23
 <212> DNA
 <213> human Rhinovirus

 <220>
 <223> probe no 38 multiplex assay

 <400> 168
 attcagcata acacacaaca gcg 23

 <210> 169
 <211> 23
 <212> DNA
 <213> human Enterovirus

 <220>
 <223> probe no 39 multiplex assay

 <400> 169
 cctgtggctt cattgtcctt caa 23

 <210> 170
 <211> 558
 <212> DNA
 <213> human Herpesvirus 2

 <220>

<223> modified human Herpesvirus 2
internal control
multiplex no 1

<400> 170
ttacactggt ggttcggtgg cgactttgcc agcctgtacc ccagcatcat ccaggcccac 60
aacctgtgct tcagtacgct tccctgccc cccgagccc tcgcgcacct ggaggcggac 120
cgggactacc tggagatcga ggtggggggc cgaaggctgt tcttcgtgaa ggcccacgta 180
cgcgagagcc tcttgagcat cctgctgccc gactggctgg ccattgcgaaa gcagatccgc 240
tcgcggatcc cccagagcac ccccgaggag gccgtcctcc tcgacaagca acaggcccgc 300
atcaagggtgg tgtgcaactc ggtgtacggg ttcaccgggg tgcagcacgg tcttctgccc 360
tgacctgacg tggccgccac cgtgacgacc atcggcccgc agatgctcct cgcgacgcgc 420
gcgtagctgc acgcgcgctg ggcggagttc gatcagctgc tggccgact tccggaggcg 480
gccggcatgc gcgcccccg tccgtactcc atgcatca tctacgggga cacggactga 540
agacgtccaa aaactggc 558

<210> 171
<211> 554
<212> DNA
<213> human Herpesvirus 2

<220>
<223> modified human Herpesvirus 2
internal control
multiplex no 2

<400> 171
ctactttggg tgtccgcgac tttgccagcc tgtaccccag catcatccag gcccaacaacc 60
tgtgtctcag tacgctctcc ctgcccggc aggcgctcgc gcacctggag gcggaccggg 120
actacctgga gatcgaggtg gggggccgac ggctgttctt cgtgaaggcc cacgtacgcg 180
agagcctgct gagcatcctg ctgcccgact ggctggccat gcgaaagcag atccgctcgc 240
ggatccccca gagcaccccc gaggaggccc tcttctcga caagcaacag gccgccatca 300
aggtgggtgt caactcggtg tacgggttca ccggggtgca gcacggtctt ctgcccggc 360
tgcacgtggc cgcaccgtg acgaccatcg gccgcgagat gctcctcgcg acgcgcgcgt 420
acgtgcacgc gcgctgggcg gagttcgatc agctgctggc cgactttccg gaggcggccg 480
gcatgcccgc ccccggtccg tactccatgc gcatcatca cggggacacg gactggctgg 540
tggtggaaat tacc 554

<210> 172
<211> 23
<212> DNA
<213> human Herpesvirus

<220>
<223> Internal Control probe no 42
multiplex assay

<400> 172
acaccgagtt gcacaccacc ttg 23